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INVESTIGATING GENETIC DETERMINANTS OF ANKYLOSING 
SPONDYLITIS 
Ankylosing spondylitis (AS) is a common form of inflammatory arthritis, occurring in 
approximately 0.1 % of the British and Finnish populations. The genetic contribution to 
the disease susceptibility accounts for >90% of the population variance, and the disease 
severity is also predominantly genetically determined. HLA-B27 has been strongly 
associated with the disease world-wide, but although it is almost essential for the 
inheritance of AS, the attributable risk of HLA-B27 has been estimated to be 16-50%, 
leaving a large component of the genetic variance to be discovered. 
The influence of a positional and biological candidate gene, transforming growth factor 
fJl (TGFBl), was investigated in a Finnish and British population. A weak association 
between the rare TGFBl 1627 T allele and susceptibility to, and age of symptom onset 
of, AS was noted. However the lack of association of TGFBl promoter 
polymorphisms, which are in LD with the TGFBl1627 alleles, with AS in families with 
positive non-parametric linkage scores at the locus indicates that these polymorphisms 
do not explain the observed linkage of disease susceptibility to chromosome 19. 
A novel high throughput HLA-DRBl genotyping method based on multiplex primer 
extension reactions was developed. This method allows rapid and cost-effective 
screening of a large number of samples. 
The effect of HLA genes and haplotypes in susceptibility to, and severity of, AS was 
investigated in the Finnish population. An overrepresentation of HLA-B27 
homozygotes was noted in cases with AS compared with the expected number of HLA-
B27 homozygotes under Hardy-Weinberg equilibrium. Significant associations 
between both HLA-B27 and HLA-DRBl *08 and a younger age of symptom onset was 
noted suggesting that genes within the MHC are involved in determining the age of 
symptom onset. A haplotype-based case-control study noted no association between 
HLA-DRB1-B27 haplotypes and AS susceptibility, but this study was underpowered. 
The effect of CYP2D6*4 poor metaboliser allele was investigated in the Finnish AS 
families. No association was noted, but due to lack of power this study could not 
exclude a true positive association with the disease. 
In summary, a novel HLA-DRBl genotyping technique was developed to enable the 
assessment of the contribution of HLA-DRBl genes in a large number of AS samples. 
HLA-B27 homozygosity was increased in cases with AS compared with the expected 
number of HLA-B27 homozygotes. HLA-B27 and HLA-DRBl *08 alleles were 
significantly associated with a younger age of symptom onset in AS. TGFBl gene 
polymorphisms do not appear to have a major impact in AS. 
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CHAPTER 1 - INTRODUCTION 
1.1 ANKYLOSING SPONDYLITIS 
1.1.1 Clinical characteristics 
Ankylosing spondylitis (AS) (OMIM reference number 106300) is a chronic, systemic, 
inflammatory rheumatic disease that predominantly involves the axial skeleton 
including the sacroiliac joints and the spine. The presence of sacroiliitis is its hallmark. 
The other axial sites commonly affected include apophyseal, discovertebral, 
costovertebral and costotransverse joints of the spine, and the paravertebral ligamentous 
structures. Hip and shoulder joints and less commonly peripheral joints may be 
involved. The presence of hip involvement correlates positively with a young age of 
onset and disease severity (Brophy and Calin 2001). Peripheral arthritis typically 
affects large synovial joints and occurs in approximately 30% of patients. Extra-
articular manifestations include acute anterior uveitis (AAU), aortic valve disease and 
enteric mucosal inflammatory lesions (Calin and Taurog 1998). 
AS belongs to the group of related inflammatory joint diseases termed 
spondyloarthropathies (SpA). They share characteristic clinical features and an 
association with the human MHC class I molecule HLA-B27. Other SpA include 
reactive arthritis, psoriatic arthritis, arthritis associated with inflammatory bowel disease 
(IBD) and undifferentiated SpA (Dougados et a1. 1991). In most cases, primary AS is 
not associated with any other disorder, but secondary AS occurs in association with 
1.+ 
reactive arthritis, psoriasis, ulcerative colitis or Crohn's disease. The strength of 
association with HLA-B27 varies among different SpA, ranging from 50-60% in 
psoriatic and enteropathic spondylitis, to 60-80% in undifferentiated SpA and reactive 
arthritis, and to over 90% in primary AS. Reactive arthritis is triggered by bacteria 
infecting the urogenital tract (Chlamydia trachomatis), the gut (Yersinia, Salmonella, 
Shigella and Campylobacter) and possibly also the upper respiratory tract (Chlamydia 
pneumoniae) (Ramos and De Castro 2002). The involvement of microbes has often 
been suggested in AS, but no triggering pathogenic agents have been identified. 
AAU is the most frequent extra-articular manifestation in patients with AS. Up to 30% 
of AS patients manifest AAU and it is more common in HLA-B27 positive than 
negative patients. The uveitis associated with AS is typically acute in onset, unilateral, 
frequently recurrent and spares the choroid and the retina (Rosenbaum 1989). This 
recurrent unilateral AAU can also occur as an isolated disease entity without joint 
involvement but with a strong association with HLA-B27 antigen (Brewerton et al. 
1973a). 
AS and IBD are clinically associated diseases, with studies indicating that 10% of cases 
ofIBD are complicated by AS (de Vlam et al. 2000). Clinically proven IBD is present 
in 4% of AS patients (Edmunds et al. 1991). Clinically silent enteric mucosal 
inflammatory lesions in the terminal ileum and colon have been detected by endoscopy 
in 44-69% of patients with AS (Leirisalo-Repo et al. 1994; Mielants et al. 1995). The 
role of these mucosal changes in the pathogenesis of AS is unknown, but it has been 
suggested that abnormal mucosal permeability in the ileum may allow pathogenic 
antigens to enter the circulation and trigger AS. Clinical remission of SpA is associated 
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with normal gut histology, whereas active locomotor inflammation was usually 
associated with the presence of gut inflammation (Mielants et al. 1995). The gut 
inflammation is clinically and histologically closely related with gut inflammation seen 
in Crohn's disease (Baeten et al. 2002). Anti-Saccharomyces cerevisiae IgA antibodies 
are considered to be important marker for Crohn's disease. A recent study noted 
significantly higher levels of anti-Saccharomyces cerevisiae IgA antibodies in patients 
with AS than in healthy controls (Hoffman et al. 2003). This may indicate a possible 
common pathogenic mechanism underlying these two diseases, or IgA antibodies may 
be a marker of small bowel ulceration. Bowel inflammation is clinically associated with 
peripheral joint inflammation (Baeten et al. 2002). 
Other nonarticular structures, such as the aortic valve, lungs and kidneys can be 
affected, but these complications are rare. Three types of heart involvement in AS have 
been noted: aortitis and aortic insufficiency, conduction disturbances of the 
atrioventricular node and myocardial involvement with a possible compromise of left 
ventricular function (Lautermann and Braun 2002). Aortitis of ascending aorta can 
result in the dilatation of the aortic ring and aortic valve incompetence. A slowly 
progressive apical pulmonary fibrosis is a rare complication of AS (Rosenow et al. 
1977), as are amyloidosis and uraemia. IgA nephropathy is also a reported 
complication of AS, which is associated with raised serum IgA levels. 
16 
1.1.2 Diagnostic criteria of AS 
AS patients in our studies were diagnosed using the Modified New York Criteria (1984) 
(van der Linden et al. 1984a) as follows. 
1. Clinical criteria 
a) Low back pain of at least 3 months' duration improved by exercise and 
not relieved by rest 
b) Limitation of lumbar spine in sagittal and frontal planes 
c) Decreased chest expansion relative to normal values for age and sex 
2. Radiologic criterion 
Bilateral sacroiliitis grade 2 to 4 or unilateral sacroiliitis grade 3 to 4 on X-ray. 
The following scoring of the radiographs was used: grade 0 = normal; grade 1 = 
suspicious changes; grade 2 = minimum abnormality (small localised areas with 
erosion or sclerosis, without alteration in the joint width); grade 3 = unequivocal 
abnormality (moderate or advanced sacroiliitis with erosions, evidence of 
sclerosis, widening, narrowing or partial ankylosis); grade 4 = severe 
abnormality (total ankylosis). 
Definite AS if the radiologic criterion is associated with at least 1 clinical criterion. 
Imaging in AS. The onset of AS is insidious, progressing to radiological sacroiliitis 
over several years. The development of radiographic bone damage may be slow, taking 
up to at least a decade to manifest (Mau et al. 1988). Radiography lacks the sensitivity 
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to show small focal changes in skeletal calcium content in large joints. Figure 1.1 
illustrates typical radiological features of AS. 
Recent data suggest that magnetic resonance imaging (MR1) of the sacroiliac (S1) joints 
can be used to identify sacroiliitis earlier than plain radiography (Oostveen et al. 1999). 
Early sacroiliitis can be demonstrated by dynamic MR1 in SpA patients in whom 
abnormalities are not revealed by conventional radiography (Braun et al. 1994). 
However, the specificity of the MR1 is unknown and therefore it has not yet been 
included in diagnostic criteria. 
18 
Figure 1.1 Clinical and radiological features of AS. 
a) Early sacroiliitis . The arrows point to the sacroiliac jo ints, whi ch are shown in Ferguson 
projection, with the patient supine and the tube angled caudocephalad approximatel y 30°. Th is a ll ows a 
view of the entire length of the sacroiliac joints symmetrically. Subchondral bone resorpti on and 
irregularity of the sacroiliac joint spaces give rise to the apparent pseudowidening. I ncreased sc leros is is 
present around the sacroiliac joints. 
b) Advanced sacroiliitis. The sacroiliac joints are nearly completely obliterated. Bony 
trabeculae cross the residual sacroiliac joint space. Bony ankylosis results from endochondral 
ossification. No gross sclerosis is seen in this radiograph . A moderate degree of osteopenia is present. 
c) Thoracic (left) and lumbar (right) spine show squaring of the vertebral bodies, osteopenia 
and ossification of the anterior longitudinal ligaments. 
Left: A lateral projection of the lower thoracic spine shows osteopenia. The intervertebral 
spaces are preserved. There are loss of the anterior concavity of the vertebral bodies and straightening of 
the anterior margins. The squaring of the vertebral bodies is caused by anterior spondylitis with 
resorption at the enthesis. Squaring is pathologic when seen in the lumbar spine, but it may be normal in 
the thoracic spine. 
Right: A lateral view of the lumbar spine shows moderate osteopenia and ossification of the 
anterior longitudinal ligaments. The intervertebral spaces are preserved, and the configuration of the 
vertebral bodies is relatively normal. In this case, the lumbar lordosis is maintained. 
d) The progression of deformities of a patient with AS over a period of 26 years. The clinical 
changes include thoracic kyphosis and the loss of lumbar lordosis and subsequent development of 
increasing flexion contractures of the hips and knees along with progressive ankylosis of the spine. In 
1973, bilateral total hip arthroplasties were performed, which improved the patient's posture. 
The figures were obtained from a CD-ROM compiled by the American College of Rheumatology. 
a) b) 
c) 
JL) 
1.1.3 Epidemiology 
A Finnish study has reported an AS prevalence of 0.13% (Kaipiainen-Seppanen et al. 
1997), similarly a Dutch study reported an AS prevalence of 0.1-0.2% (van der Linden 
et al. 1 984b ). In contrast studies from Norway and Germany reported AS prevalences 
of 1.1-1.4% and 0.9%, respectively (Gran et al. 1985; Braun et al. 1998). The 
differences between these studies are likely to be attributable to the diagnostic criteria 
used, differences in the population frequency of HLA-B27, response rate of the study or 
other factors related to study methodology. 
The symptoms usually begin in late adolescence or early adulthood and the average age 
of symptom onset is 25 years (Fe1dtkeller et al. 2003). The disease is more common in 
males, with the male to female ratio about 2.5: 1 to 5: 1. Clinical manifestations appear 
to be similar in men and women, whereas radiological features appear to be more 
frequent and severe in males (Gran and Ostensen 1998). 
1.lA Pathology of AS 
Classically, AS begins at the sacroiliac joints and then ascends the spinal column by 
involving the small joints of the posterior elements of the spine. Sacroiliitis, enthesitis 
and osteitis are characteristic primary spinal lesions in AS. The inflammation affects 
the synovium, articular cartilage and subchondral bones of involved joints and can also 
involve juxta-articular ligamentous structures. Plasma cells, lymphocytes and 
polymorphonuclear cells infiltrate the sites of enthesitis. Inflammatory infiltrates and 
oedema may be present at the adjacent bone-marrow space. The inflammatory process 
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results in initial bone and joint erosion. The inflammation frequently results in gradual 
fibrosis and ossification, leading to subsequent syndesmophyte formation (with eventual 
bony bridging) and ankylosis (Calin and Taurog 1998) (see Figure l.1). 
Enthesitis is an important but not the sole pathologic lesion in AS (McGonagle et al. 
1998a; Francois et al. 2001). An enthesis is the region where a tendon, ligament or joint 
capsule attaches to bone. Tendon enthesis can be classed as fibrous or 
fibrocartilaginous according to the tissue present at the skeletal attachment site. 
Fibrocartilaginous entheses consist of un calcified fibrocartilage, a proteoglycan-rich 
matrix and calcified fibrocartilage. Fibrous entheses have no cartilage matrix and 
consist purely of dense fibrous connective tissue, where the characteristic cell type is the 
fibroblast (McGonagle et al. 2003). It has been suggested that AS mainly affects the 
fibrocartilaginous enthesis (Maksymowych 2000). Fat-suppressed MRI scans of knee 
joints of SpA patients demonstrated prominent entheseal abnormalities which were not 
present in knee joints of patients with rheumatoid arthritis (RA). This supports the 
central role of enthesis in the pathology of SpA (McGonagle et al. 1998b). 
Enthesitis is closely associated with adjacent osteitis. The pathogenesis of osteitis 
relates to bone microfractures or an abnormal response to bone stress adjacent to the 
insertions. The mechanism of osteitis is poorly understood, but tumor necrosis factor a 
(TNF -a) and interleukin (IL) 1 contribute to osteoclast activation and may play 
important roles (Braun et al. 1995; McGonagle et al. 2003). A recent study 
investigating tissue specimens of enthesis of SpA patients noted that oedema and an 
inflammatory infiltrate were predominant in the bone marrow component of the 
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enthesis. The predominant T cells were CD8+ which suggests that these cells may have 
a key role in local inflammation in chronic SpA (Laloux et al. 2001). 
Sacroiliitis is a hallmark of AS and the presence of radiologically confirmed sacroiliitis 
is included in the diagnostic criteria of the disease (van der Linden et al. 1984a). A 
recent systematic histopathological study of sacroiliitis which included 12 cases of AS 
and 22 control cases demonstrated that AS pathology represents more than enthesitis. 
In AS synovitis, myxoid bone marrow, cartilage destruction, enthesitis, new bone 
formation and bony ankylosis were significantly more frequent than in control cases. 
Mild but destructive synovitis and myxoid subchondral bone marrow were the earliest 
changes identified in AS. These changes gave rise to granulation tissue, which may be 
more important than enthesitis to explain the widespread destruction of cartilage and 
bone. A proliferative process of cartilage metaplasia and endochondral ossification 
contributes to the final ankylosis (Francois et al. 2000). Another study investigated 
computed tomography (CT)-assisted biopsy specimens of sacroiliac joints using 
immunohistology and in situ hydridisation. T cells, macrophages and various 
cytokines, especially TNF -u and transforming growth factor ~2 (TGF -~2) were 
observed in infiltrates (Braun et al. 1995). 
Bone sclerosis, new bone formation and syndesmophyte formation in addition to bone 
destruction are characteristic in AS. These bone changes result in joint ankylosis and 
cause disability in these patients. At the end stage of disease, the spine may become 
fused anteriorly resulting in the characteristic bamboo spine appearance in the 
radiograph. The unburdened vertebral bodies become' square' and osteoporotic. 
Radiographs of the spine often reveal some degree of osteopenia and the risk of 
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fracturing is increased. Radiographic and MRI studies in early AS suggest that MRI 
bone changes predate radiographic abnormalities suggesting that enthesitis and osteitis 
are primary and bone changes such as sclerosis or the formation of syndesmophytes are 
secondary (Oostveen et al. 1999). 
Osteoporosis may also be a primary pathological event. Several studies have reported 
that patients with early AS demonstrate a significantly lower bone mineral density both 
in the lumbar spine and in the femoral neck than controls (Will et al. 1989; EI 
Maghraoui et al. 1999). Possible mechanisms explaining the early osteoporosis in AS 
include genetic predisposition, the production of cytokines, such as transforming growth 
factor ~1 (TGF-~I), IL-l and TNF-a, involved in bone remodelling (Centrella et al. 
1991), and impaired calcium and vitamin D absorption related to chronic inflammatory 
intestinal lesions (Mielants et al. 1995). Serum levels of vitamin D have been reported 
to correlate negatively with disease activity in AS (Lange et al. 2001). Decreased 
vitamin D may contribute to a negative calcium balance and inhibition of bone 
formation. In the late stage of the disease, bony ankylosis is responsible for the 
osteoporosis. 
The mechanisms leading to immune activation in AS are poorly defined. A multi-hit 
model, in which biomechanical stressing, tissue microtrauma and microbial factors at 
the entheses induce the expression of pro-inflammatory cytokines and incite immune 
activation, has been proposed (McGonagle et al. 2001). Extra-articular involvement in 
the eye, heart and lung may be related to repeated cyclical biomechanical stressing at 
these sites. According to this model, two signals are required for the activation of the 
immune response in AS. The first signal comes from an antigen presenting cell 
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displaying arthritrogenic peptides via HLA-B27 to an appropriate T cell. The second 
co-stimulatory signal comes from the local diseased microenvironment (McGonagle and 
Emery 2000). It has been proposed that the costimulatory signal in AS involves the 
activation ofNF-KB, which is a pivotal transcription factor in chronic inflammatory 
disease (Barnes and Karin 1997). NF-KB can be activated by cytokines, such as TNF-a 
and IL-1~, protein kinase activators, oxidants, viruses, immune stimuli, antigens, 
bacterial heat shock proteins, bacterial epG motifs and lipopolysaccharides (Barnes and 
Karin 1997; Yi et al. 1998; Kol et al. 1999). This activation in turn leads to the 
coordinated expression of many genes encoding cytokines, enzymes, adhesion 
molecules and chemokines, which can further amplify and perpetuate the inflammatory 
process (Barnes and Karin 1997). 
Maksymowych has suggested that immunity to a component of fibrocartilage rather 
than enthesis is a more likely hypothesis in SpA pathology (Maksymowych 2000). The 
reason is that in AS pathologic changes frequently involve the fibrocartilaginous 
enthesis and cartilaginous joints, including the intervertebral discs, the manubriosternal 
joints and the symphysis pubis. The involvement of the hyaline cartilage of sacrum, 
vertebral endplate and hip has also been observed. An alternative explanation is that 
osteitis is primary and cartilage autoimmunity secondary (McGonagle and Emery 
2000). Poole has suggested that commonly expressed autoantigens or common epitopes 
from structurally related cartilage proteins are responsible and cross-reactive immunity 
may explain the involvement of other tissues (the eye and arterial vessels) (Poole 1998). 
The G 1 domain of aggrecan, the major cartilage proteoglycan has been suggested as an 
autoantigen and in vitro studies have demonstrated that a cellular immune response to 
G 1 is present in most AS patients (Zou et al. 2003). 
Recently, it has been proven that TNF -u antagonists such as infliximab or etanercept are 
efficacious in controlling signs and symptoms in patients with chronic AS (Brandt et al. 
2000). Etanercept is associated with marked improvement of enthesitis and associated 
osteitis pathology as detennined by MRI (Marzo-Ortega et al. 2001). Preliminary 
results suggest that a recombinant human IL-l receptor antagonist (IL-IRa) is also 
effective in AS (Haibel et al. 2003). This efficacy suggests a central role for 
proinflammatory cytokines such as TNF -u and IL-I in the pathogenesis of the disease. 
Altogether, immune mediated mechanisms involving HLA-B27, inflammatory cellular 
infiltrates, cytokines and genetic and environmental factors are believed to have key 
roles in AS pathogenesis. 
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1.2 GENETICS OF AS 
Twin and family studies indicate that the genetic contribution to the disease 
susceptibility accounts for >900/0 of the population variance (Brown et al. 1997b). 
Disease severity is also predominantly genetically determined (heritability 0.51-0.68) 
(Hamersma et al. 2001). The heritability as assessed by the excess sibling risk (As) has 
been calculated (As = Ks/K) at 58 (see section 1.3.1) (Carter et al. 2000). The relative 
contribution ofMHC and non-MHC genes in AS are discussed in sections 1.2.2 and 
1.2.3, respectively. 
1.2.1 HLA-B27 
The discovery of the association between HLA-B27 and AS dates from 1973 (Brewerton 
et al. 1973b; Schlosstein et al. 1973), it remains one of the strongest associations 
between an HLA antigen and a disease. Substantial evidence from HLA-B27 transgenic 
animal and population studies strongly favours a direct role for HLA-B27 in genetic 
susceptibility to AS. However, it remains an unproven hypothesis that HLA-B27 itself 
is involved rather than a nearby gene. 
HLA-B27 transgenic animal studies. HLA-B27 transgenic rats with the appropriate 
genetic background develop a multisystem inflammatory disorder with many 
similarities to human SpA including gut, joint and skin lesions (Hammer et al. 1990). 
The disease is dependent on the presence of bacterial flora suggesting a critical 
involvement of microbes in the disease pathogenesis (Taurog et al. 1994). However, 
this model has significant differences to the human disease. Susceptibility to disease is 
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related to the gene copy number and level of expression ofHLA-B27, with disease 
developing only in those lines having supraphysiologicallevels of trans gene expression 
(Taurog et al. 1993). In contrast to humans who develop axial disease, the rats develop 
a more prominent peripheral disease. HLA-B27 transgenic rats develop orchitis and 
severe colitis, whereas human AS has no association with orchitis and severe colitis is 
uncommon (Hammer et al. 1990). Mice transgenic for HLA-B27, with or without 
human ~2-microglobulin, have been described (Krimpenfort et al. 1987; Taurog et al. 
1988; Khare et al. 1995). Unlike humans, these mice develop predominantly peripheral 
arthritis and enthesopathy. 
Population studies. HLA-B27 is strongly associated with AS world-wide, although the 
strength of the association varies between various ethnic groups (Calin and Taurog 
1998). In Caucasians more than 900/0 of the AS patients have HLA-B27 compared with 
only 4-14% of unaffected individuals. HLA-B27 is virtually absent in most of the sub-
Saharan Africa where AS is rare. In some of these areas HLA-B27 negative AS is 
increased, the disease shows clinical features that are similar to those observed in 
Caucasian HLA-B27 negative patients with AS. In these patients the disease onset is 
later compared with HLA-B27 positive patients, the patients rarely get AAU and 
familial occurrence of AS is rarely observed (Mijiyawa et al. 2000). The epidemic of 
HIV infection in sub-Saharan Africa has been associated with a dramatic increase in the 
prevalence of SpA other than AS despite the low prevalence of HLA-B27 (Mijiyawa et 
al. 2000). AS is virtually absent in West Africa where HLA-B27 is more common in the 
general population (Brown et al. 1997a). The risk conferred by HLA-B27 for AS is 
lower for Africans than that for black Americans (Mijiyawa et al. 2000). 
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Predictive value of RLA-B27 testing in the clinical practice. The penetrance of RLA-
B27 in AS is low, approximately 1-2% of RLA-B27 positive adults in the general 
population are likely to develop AS (van der Linden et al. 1984b). Thus, when used in 
general population screening RLA-B27 testing has a low positive predictive value - that 
is, the likelihood of disease is low when the test is positive. Bayesian modelling has 
demonstrated that the diagnostic value of RLA-B27 testing in AS depends on the pre-
test likelihood of the disease based on a clinical estimate. RLA-B27 testing is useful if 
the pre-test probability is intermediate. For example, if the pre-test probability of AS in 
a Caucasian patient was 500/0, a positive RLA-B27 result would increase the likelihood 
that the patient has the disease to 92% and a negative result would decrease the 
likelihood that the patient has the disease to 8% (Khan and Khan 1982). These data are 
in accordance with a German study demonstrating that RLA-B27-positive blood donors 
with inflammatory back pain were 10 times more likely to have sacroiliitis and SpA 
than RLA-B27-negative donors (Braun et al. 1998). However, the clinical usefulness of 
RLA-B27 typing as an aid to diagnosis of AS is much less in the black population due to 
weaker association between RLA-B27 and disease. 
Structure ofRLA-B27. HLA-B27, in common with other MHC class I molecules, is a 
transmembrane glycoprotein expressed on the surface of most nucleated cells. The 
amino acid sequence of RLA-B27 has been known since 1985 (Ezquerra et al. 1985). 
The HLA-B27 molecule has been crystallised and its structure determined (Figure 1.2) 
(Madden et al. 1991). HLA-B27 is associated with ~2-microglobulin through its a3 
domain and crystallographic studies indicate that the a 1 and a2 domains constitute the 
peptide-binding site. The most distinctive structural feature is ofHLA-B27 is its deep B 
pocket. Dissection of the peptide-binding grooves of the HLA-B27 subtypes shows that 
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Figure 1.2 Schematic diagram of the three-dimensional structure of HLA-B27 molecule. 
a) HLA-B27 heterodimer comprises of a heavy chain membrane glycoprotein of - 44 kDa 
noncovalently bound to a light chain of 12 kDa, termed ~2-microglobulin . 
b) Three-dimensional structure of the al and a2 domains of the B*2705. Numbers indicate 
polymorphic residues among HLA-B27 subtypes. Letters indicate the pockets of the peptide-binding 
groove. The peptide is shown in green and it interacts with the groove through hydrogen bonds. 
c) Pocket F ofHLA-B27. The residues ofHLA-B27 that interact with position 9 of the binding 
peptide are shown. 
Figure obtained from (Lopez-Larrea et al. 1998) with permission from Dr Carlos Lopez-Larrea. 
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B pocket is conserved among all the common HLA-B27 subtypes (Buxton et al. 1992). 
HLA-B27 is highly selective for peptides of9 amino acids with an arginine at the 
second position of the B pocket (Madden et al. 1991; Guo et al. 1993). 
HLA-B27 subtype polymorph isms and association with disease. HLA-B27 itself is a 
serologic specificity, which encompasses a family of24 different subtypes, denoted 
HLA-B*2701 to B*2725. (HLA-B*2722 subtype has been eliminated as it turned out to 
have the same sequence as HLA-B*2706). The distribution of the subtypes varies 
strongly among different ethnic groups. B*2705 is present in almost all populations of 
the world, but is most common in Circumpolar and Subartic regions from Eurasia and 
North America. B*2702 has been described in Caucasians. B*2704 and B*2706 have 
been found mainly in Asians. B*2703 is most common in West African populations. 
The structural pattern and ethnic distribution of the subtypes suggests that B*2705 is the 
ancestral allele. Occurrence of at least one case of AS or related SpA has been reported 
in subjects possessing any of the first 10 subtypes, B*2701 to B*2710 (Gonzalez-Roces 
et al. 1997; Armas et al. 1999; Olivieri et al. 2002) as well as B*2714 (Shankarkumar et 
al. 2002), B*2715 (Garcia-Fernandez et al. 2001) and B*2719 (Tamouza et al. 2001). 
However, only the relatively common subtypes, B*2705, B*2702, B*2704 and B*2707, 
are proven to be disease associated by epidemiological case-control studies. Two 
subtypes, B*2706 in Southeast Asia and B*2709 in Sardinia lack a strong association 
with AS (Lopez-Larrea et al. 1995; N asution et al. 1997). The differential disease 
associations between patients and healthy controls may provide clues to the effects of 
the sequence variations on the peptide binding specificity of the molecule. 
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The pathogenic link between HLA-B27 and AS remains enigmatic. Different 
hypotheses have been formulated in the attempt to explain the association. A detailed 
evaluation of these theories is outside the scope of this thesis. The molecular mimicry 
theory was proposed in 1976, when it was shown that several gram-negative micro-
organisms, such as Klebsiella pneumoniae, carry antigens that cross-react with HLA-
B27 (Ebringer and Wilson 2000). This theory postulates that an autoimmune response 
initially mounted against an antigenic component of a micro-organism is directed 
against HLA-B27 itself. However, at least one controlled study failed to find a 
convincing association between microbial antigens and HLA-B27 (Lahesmaa et al. 
1992), and human studies remain inconclusive (Ringrose 1999). Additionally, this 
theory cannot explain the differential HLA-B27 subtype associations. 
A related hypothesis, the arthritogenic peptide model predicts that HLA-B27, as a result 
of its particular peptide binding specificity, presents self-peptides mimicking pathogen-
derived epitopes that then become the target of autoreactive cytotoxic T lymphocytes 
(CTL) (Benjamin and Parham 1990). In support of this hypothesis, it has been 
demonstrated that HLA-B27 is capable of presenting potentially arthritogenic peptides 
to CTL. Hermann et al. isolated HLA-B27-restricted autoreactive CD8+ T cells from 
synovial fluids of patients with reactive arthritis and AS (Hermann et al. 1993). It has 
also been suggested that amino acid differences in B*2706 and B*2709, which limit 
their peptide repertoire compared with B*2705, also prevent the presentation of putative 
arthritogenic peptides. Recently HLA-B27 reactive CD4+ T cells have been identified 
in the HLA-B27-positive AS patients (Boyle and Hill Gaston 2003). These cells may 
playa role in the pathogenesis of SpA. 
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New ideas have focussed on abnormal characteristics ofHLA-B27 resulting from 
disulfide bond formation, aberrant folding or both. It has been recently demonstrated 
that HLA-B27 has an unusual ability to form heavy chain homodimers in vitro and in 
certain cell lines in vivo (Allen et al. 1999). Dimerization in vitro is dependent upon the 
formation of a disulphide bond through unpaired cysteines at position 67 in the al helix 
of the HLA-B27 heavy chain. These homodimers lack ~2-microglobulin. HLA-B27 
heavy chain homodimers and receptors for HLA-B27 homodimers are expressed on 
populations of peripheral blood and synovial monocytes and Band T lymphocytes from 
patients with SpA (Kollnberger et al. 2002). Control subjects also express receptors for 
HLA-B27 heavy chain homodimers. One possible mechanism by which expression of 
HLA-B27 heavy chain homodimers could lead to joint inflammation is presentation of 
peptides to either CD4+ or CD8+ T cells, or more likely interaction with natural killer 
(NK) family receptors (Kollnberger et al. 2002). 
An alternative hypothesis relates to the observation that B*2705 heavy chain folded 
much more slowly than a mutant in which six B pocket residues had been replaced by 
those in HLA-A *0201, resulting in misfolding of a portion of HLA-B27 pool (Mear et 
al. 1999). These results indicate that in addition to its role in peptide selection, the B 
pocket is also involved in misfolding a portion ofHLA-B27 heavy chains in the 
endoplasmic reticulum (ER), resulting in their degradation in the cytosol. On the basis 
of these observations, it was suggested that an accumulation ofmisfolded B*2705 in the 
ER might elicit an ER stress response. This could lead to the activation ofNF-KB, 
which in appropriate cell types might increase the production of proinflammatory 
cytokines. Colbert proposed that even if the degree of misfolding is insufficient to 
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stimulate cytokine production, it could lower the threshold of activation by other 
stimuli, such as bacterial infection (Colbert 2000). 
1.2.2 MHC genes and AS 
Genes of the human MHC, in particular HLA-B27, are major genetic factors in 
determining the familial clustering of AS, as evidenced by linkage and association 
studies (Brewerton et al. 1973b; Schlosstein et al. 1973; Rubin et al. 1994; Laval et al. 
2001). A recent whole genome screen yielded a maximum LOD score of 15.6 for the 
MHC region indicating that it is the major susceptibility locus in AS (Laval et al. 2001). 
HLA-B27, although almost essential for the inheritance of AS, is estimated to contribute 
only 16-50% to the overall genetic component (Brown et al. 1997b; Carter et al. 2000). 
HLA-B27 positive relatives of AS patients have a recurrence risk of the disease that is 
5.6-16 times higher than that for HLA-B27 positive individuals in the general 
population, implying the presence ofnon-HLA-B27 shared familial risk factors (Calin et 
al. 1983; van der Linden et al. 1984b). Several haplotypic and association studies 
suggest that more than one gene within the MHC may influence the disease 
susceptibility (Brown et al. 1998a; Hohler et al. 1998). 
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Figure 1.3 Graphical representation of the MHC region. 
Picture obtained from the Anthony Nolan database (www.anthonynolan. org.ukHI Gi ndex. htm l). 
The numbers underneath refer to the kilobases. 
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Other HLA class I antigen associations have been studied extensively but only HLA-
B60 association has been confirmed by several independent groups. HLA-B60 is 
associated with 2-4 times increased risk of AS in Caucasian populations (Robinson et al. 
1989; Brown et a1. 1996b). An association between AS and HLA-B* 1403 has been 
noted in a West African population (Lopez-Larrea et a1. 2002). A recent Mexican study 
reported a moderate increase of HLA-B15 among patients with SpA (Vargas-Alarcon et 
a1. 2002b). HLA-B39 has been reported to be associated with AS in an HLA-B27 
negative Japanese population (Yamaguchi et a1. 1995), although not in other 
populations (Brown et al. 1996a). A small Spanish study demonstrated a significant 
increase in the HLA -A9 allele frequency in AS patients compared to an HLA-B27 
positive control group (de Juan et a1. 1999) . 
The A1lCA gene is located 47 kb centromeric from the HLA-B gene and is expressed in 
gastrointestinal epithelium, fibroblasts and endothelial cells (Groh et al. 1996; Zwirner 
et al. 1999). It has been suggested that MICA is recognised by diverse V81 y8 T cells in 
the epithelium of intestinal tract (Groh et al. 1998). A Sardinian study demonstrated an 
association between A1lCA-A4 allele and HLA-B27 negative AS patients (Ricci-Vitiani 
et al. 2000), but the sample size for this analysis was small. However, several studies 
have observed no association between polymorphisms of the A1lCA gene and AS 
independent of HLA-B27 (Tsuchiya et al. 1998; Yabuki et al. 1999; Martinez-Borra et 
al. 2000), suggesting that at least in HLA-B27 positive individuals A1lCA alleles are not 
likely to playa role. 
Several previously published studies have demonstrated weak associations between 
HLA-DRB1 alleles and both disease susceptibility and clinical manifestations of the 
disease. These studies are discussed in chapter 5. Other MHC class II genes encoding 
products involved in class I antigen processing pathway have been investigated in AS. 
These include the transporter associated with antigen processing (TAP) genes, TAP 1 and 
TAP2, and the large-molecular-weight proteasome (LMP) genes, LMP2 and LMP7. 
Iritis and extraspinal disease in AS have been reported to be associated with 
polymorphisms in LMP2 gene (Maksymowych et al. 1997c; Maksymowych et al. 
2000), but other studies have not confirmed this (Burney et al. 1994). A Spanish study 
noted an association between an LMP7 gene polymorphism and susceptibility to AS 
(Fraile et al. 1998b). No significant association has been reported between TAP1 and 
TAP2 gene variants and SpA (Burney et al. 1994; Westman et al. 1995; Fraile et al. 
2000). 
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HLA class III. TNF-a gene is located 250 kb centromeric of HLA-B. TNF-a mediates 
inflammation and has immunoregulatory activities. The production ofTNF-a is highly 
heritable (Westendorp et al. 1997), and several studies have shown that TNF -a levels 
are raised at baseline in patients with SpA. Gratacos et al. analysed the cytokine 
profiles in the serum from 69 patients with AS and 36 controls with non-inflammatory 
back pain using an enzyme linked immunosorbent assay (ELISA) (Gratacos et al. 1994). 
TNF-a levels were raised in patients with AS compared with patients with non-
inflammatory back pain (p=O.O 16). Sonel et al. compared cytokine levels between 22 
healthy controls and 42 patients with SpA having either active or inactive disease (Sonel 
et al. 2002). Both SpA groups with active and inactive disease had higher serum TNF-a 
levels than controls (p<0.05). High amounts ofTNF-a mRNA were observed in biopsy 
specimens of sacroiliac joints in patients with AS (Braun et al. 1995), demonstrating 
that TNF-a acts at the primary site of inflammation. AS patients from Germany and 
western Scotland have a decreased frequency of the TNF-a -308.2 allele (Hohler et al. 
1998; McGarry et al. 1999), although this association has not been demonstrated in 
British or Dutch patients (Kaijzel et al. 1999; Milicic et al. 2000). The discrepant 
association between different ethnic populations possibly suggests that this TNF-a 
polymorphism may merely be in LD with another disease-causing gene rather than 
being the true disease causing variant itself, as suggested by the different HLA-DRB1-
B27 LD patterns in British Caucasians and Germans (Milicic et al. 2000). 
Heat shock protein 70 (HSP70) loci are located between the complement and tumour 
necrosis factor genes and include three immediately adjacent genes, HSP70-1, HSP70-2 
and HSP70-hom. HSP70 proteins have been linked with a protective role during and 
after cellular stress (Sargent et al. 1989). Finnish and Spanish studies demonstrated no 
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independent association between HSP70 gene polymorphisms and AS (Westman et al. 
1994b; Fraile et al. 1998a). A recent Mexican study noted a significant association 
between HSP70-hom A allele and AlA genotype between HLA-B27 negative SpA 
patients and healthy controls (Vargas-Alarcon et al. 2002a), but the control genotypes in 
this study were not in Hardy-Weinberg equilibrium (HWE), suggesting either a 
sampling bias or a genotyping error. 
1.2.3 Non-MHC genes and AS 
The genetic contribution of genes lying outside the MHC region has been investigated 
by a systematic genome-wide approach and by functional and positional candidate gene 
analysis. A large non-MHC component of the genetic risk for the disease is suggested 
by the significant difference in concordance rates for monozygotic (MZ) twins (63%) 
and HLA-B27-positive dizygotic (DZ) twins (23%) (Brown et al. 1997b). Whole-
genome screening of AS showed suggestive or stronger linkage with the disease on 
chromosomes 1 p, 2q, 9q, 10q, l6q and 19q (Laval et al. 2001). Recurrence risk 
modelling suggests that the best fitting model of genetic susceptibility to AS is a five-
locus model with multiplicative interaction between loci (Brown et al. 2000b). The 
susceptibility of AS is likely to arise from the combined impact of multiple contributing 
genes, each potentially interacting with environmental and stochastic factors. 
Recent studies have added to the evidence that cytokines play an important role in AS 
pathogenesis. Several candidate gene studies have investigated the effect of cytokine 
gene polymorphisms in AS. Recently intracellular cytokine staining demonstrated that 
patients with AS and healthy HLA-B27 positive controls produced significantly less 
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TNF-u and interferon y (IFNy) than HLA-B27 negative controls (Rudwaleit et al. 2001). 
In contrast, production of IL-1 0 by CD8+ T cells was higher in patients with AS than in 
HLA-B27 positive and negative controls. IL-10 is a potent inhibitor of many 
pro inflammatory cytokines, it attenuates the elimination of a variety of pathogens thus 
influencing the outcome of disease (Redpath et al. 2001). It has been estimated that 
75% of the variation in IL-10 production is genetically determined (Westendorp et al. 
1997). Haplotypes defined by the micro satellites IL10.G12 and G10 in the IL-lO 
promoter associated with a protective effect against the development of reactive arthritis 
in Finnish patients (Kaluza et al. 2001), suggesting that IL-l 0 promoter region variants 
may playa role in SpA. However, no association between IL-l 0 promoter variants and 
susceptibility to disease was noted in Finnish families with AS (Goedecke et al. 2003). 
TGFBl is another immunosuppressive cytokine, and TGFBl polymorphisms in AS are 
discussed in chapter 3. 
The IL-l gene cluster is located on chromosome 2q13-14. It encodes for three proteins, 
IL-1 u, IL-1 ~ and interleukin-1 receptor antagonist IL-1 Ra. The first two are strong 
inducers of inflammation, while IL-1 Ra binds to the IL-1 receptors with high affinity 
without activating the cell and is thus an effective antagonist (Hurme and Santtila 1998). 
This cluster is an interesting positional and functional candidate region for AS, as this 
locus is approximately 0.3 cM centromeric to the marker D2S 160 which is strongly 
linked to AS (p=0.007) (Laval et al. 2001). Polymorphisms in these cytokine genes 
have been implicated in several other inflammatory and autoimmune diseases 
(Blakemore et al. 1995; Heresbach et al. 1997; Schrijver et al. 1999). Allele 2 in the IL-
l Ra has been associated with susceptibility to AS by a Scottish and a Dutch group 
(McGarry et al. 2001 b; van der Paardt et al. 2002a), but this was not confirmed by a 
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small French study (Djouadi et al. 2001). Allele 2 of the IL-1Ra is associated with 
increased production ofIL-1Ra protein (Danis et al. 1995; Hurme et al. 1998), 
suggesting a functional role of this variant. Recently, an association between AS and 
single nucleotide polymorphisms (SNPs) in the 3' region of the IL-l Ra gene was 
reported in a large case-control and family-based study (Maksymowych et al. 2003). 
Given these three independent reports of positive association between variants in this 
gene and AS, it is very likely that either IL-Ra gene itself or another tightly linked gene 
is a true susceptibility gene in AS. Further studies are required to pinpoint the causative 
variant/s at this locus. 
IL-6 is a pro inflammatory cytokine involved in local inflammatory reactions by 
amplifying leukocyte recruitment (Romano et al. 1997). IL-6 gene is located on 
chromosome 7p21. IL-6 levels are increased in patients with AS and a close correlation 
between serum IL-6 and disease activity and severity has been noted (Gratacos et al. 
1994). A relatively small Spanish study noted no association between IL-6 -174 
polymorphism and susceptibility to AS (Collado-Escobar et al. 2000). 
The NOD21CARD15 gene is located on 16q12. Recently an association between the 
variants of the NOD2 gene and Crohn's disease has been discovered (Hugot et al. 2001; 
Ogura et al. 2001). NOD2 is involved in the inflammatory response to bacteria via the 
activation ofNF -KB pathway, following its interaction with bacterial components. 
Several studies have concluded that polymorphisms in the NOD2 gene are not involved 
in susceptibility to AS (Crane et al. 2002; D'Amato 2002; Miceli-Richard et al. 2002; 
Ferreiros-Vidal et al. 2003). A British study reported an association between the 
carriage of NOD2 Pr0268Ser polymorphism and greater disease activity as measured by 
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the BASDAI (p=0.002) (Crane et al. 2002), indicating that this locus may act as a 
severity factor. 
The human analogue of the mouse progressive ankylosis (ank) gene, ANKH is a 
candidate gene for AS based on the mouse model. Mice homozygous for the Glu440X 
mutation in the ank gene develop a generalised progressive form of arthritis 
accompanied by mineral deposition, aberrant new bone formation resulting in ankylosis 
and eventual joint fusion (Ro et al. 2000). The ANKH gene has been mapped to 5p 14.1-
P 15 .2. Mutations in ANKH have been implicated in autosomal dominant 
craniometaphyseal dysplasia and in familial calcium pyrophosphate deposition disease 
(Numberg et al. 2001; Reichenberger et al. 2001; Pendleton et al. 2002; Williams et al. 
2002). A recent study reported significant associations between the promoter 
polymorphisms of the ANKH gene and AS (Tsui et al. 2003), but this was not confirmed 
by a large British study (Timms et al. 2003). 
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1.3 GENETICS OF COMPLEX DISEASES 
1.3.1 Estimating genetic risk 
Risk ratio of the disease. Calculating risk ratios between affected individuals and their 
relatives (e.g. siblings) is a powerful way of estimating the strength of an underlying 
genetic effect of the disease. Sibling relative risk ratio AS is commonly used and is 
calculated as follows: 
AS = Ks/K 
in which Ks is the probability that a sibling of an affected individual is also affected and 
K is the population frequency of a disease. AS defines the ratio of increase in risk of 
disease given the sibling has the disease. AS may substantially overestimate the genetic 
contribution, because siblings are likely to share the same environment. Because A is a 
ratio, the prevalence of the disease among the relatives and the prevalence of the disease 
in the general population affect its size. The risk ratio A decreases with the degree of 
relationship between proband and relatives, and the rate of decrease depends on the 
mode of inheritance underlying the trait (Risch 1990a). 
Heritability. Heritability refers to the proportion of phenotypic variation that can be 
ascribed to genotypic variation. Heritability can be determined using family and twin 
studies. Since MZ twins share all their genes whereas DZ twins are assumed to share 
on average 50% of their genome, the ratio of their concordances for a condition gives a 
rough indication of the relative importance of genotype in its causation. Both groups 
are assumed to share environmental factors to a similar extent. A disadvantage is that 
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twins are difficult to recruit especially for relatively rare diseases. Also, twin studies are 
a statistically weak method for investigating genetic dominance. 
Risk ratio of the disease locus. Once genetic susceptibility loci are identified, locus 
specific AS can be determined by calculating the ratio of expected proportion of affected 
sibling pairs sharing zero alleles identical by descent (0.25) by the actual observed 
fraction. Locus specific AS facilitates estimation of the number of major genes 
remaining to be found, although the interaction between these genes may be 
multiplicative. Another measure of the effect of a locus is the parameter y, the genotype 
relative risk (GRR) associated with heterozygosity or homozygosity for a disease 
susceptibility allele (Risch 2000). 
1.3.2 Linkage analysis 
Definition. Linkage analysis relies on the fact that loci which are physically adjacent to 
each other in the same chromosome are likely to be inherited together, the closer the 
loci are the more rarely they are separated by genetic recombination. It aims to identify 
regions of the genome that co-segregate with the disease in many independent families 
or over many generations in an extended pedigree. Genes can usually be localised to a 
large physical interval by this approach as the size of the co-segregating segment of 
DNA is only delimited by the observation of a crossover between a marker and the 
disease locus itself. The probability that recombination will occur between two loci is, 
in part, a function of the physical distance separating them. However, this relationship 
is not linear for several reasons: (1) recombination results from an odd number of 
crossovers, which are not directly observed; (2) the density of occurrence of crossover 
appears to be variable along the chromosomes; (3) multiple crossovers do not appear to 
occur independently (Lalouel and White 1997). A crossover event tends to inhibit the 
occurrence of another in its vicinity, a phenomenon called positive interference. 
Map functions. A mathematical relationship that converts recombination fraction to 
genetic map distance is called a map function. Haldane's function assumes that 
crossovers occur at random along a chromosome and they do not influence on one 
another. Haldane's function is expressed as: 
m = -0.5 In (1-28), 
in which m is the map distance and 8 is the recombination fraction (Haldane 1919). 
Kosambi's mapping function takes into account interference and is described by: 
m = 0.25 In [(1 +28)/ (1-28)] (Kosambi 1944). 
For small values of8 «0.1) the Haldane and Kosambi mapping functions provide a 
similar estimate of genetic distance, which is equivalent to the recombination fraction 
expressed as a percentage. For greater recombination values, interference becomes 
more relevant and the estimates of genetic distance provided by these functions can 
differ. 
Genetic distance vs. physical distance. Genetic distance between loci is measured in 
centiMorgans (cM) and 1 cM represents the distance associated with a 1% 
recombination fraction (8=0.01) between two loci. The relationship between genetic 
and physical distance is not constant. On average, a genetic distance of I cM equates to 
a physical distance of I Mb of DNA sequence, but this varies markedly between 
different genetic regions. The genetic distance/physical distance differs considerably 
between genders, as recombination frequencies are higher in females than in males 
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(Broman et al. 1998). To overcome these differences, genetic maps typically report 
distances for each sex and a sex-averaged distance that integrates male and female 
recombination frequencies. In females, the crossover rates are much higher around the 
centromeres, whereas those in males tend to be higher towards the telomeres (Broman et 
al. 1998). 
Linkage maps. Genetic linkage maps measure the underlying genetic recombination 
that occurs in a particular chromosomal region. They can also serve as frameworks for 
building physical maps. Construction of precise genetic linkage maps is important as 
the precise estimates of genetic distance improve the statistical power of linkage 
analysis. With actual linkage, any map misspecification causes negative bias in 
multipoint (analysis of several markers at once) LOD scores, resulting in loss of power 
to detect linkage. In the absence of linkage, map misspecification can cause positive or 
negative bias: using too large a distance gives a positive bias; using too small a distance 
gives a negative bias; falsely assuming a 1: 1 female:male ratio always causes positive 
bias (Daw et al. 2000). A range of genome-wide human genetic maps has been 
published to date. The most recent genetic map based on micro satellite markers has 
been developed by the deCode genetics (Kong et al. 2002), and it provides higher 
resolution compared to the Marshfield map (Broman et al. 1998). Recently, a genome-
wide SNP linkage map has been published based on 2679 SNP markers (Matise et al. 
2003). The disadvantage of using SNP based linkage maps is the lower information 
content of a single SNP compared to a polymorphic microsatellite, but this can be 
overcome by increasing the marker density 3-8-fold (Kruglyak 1997), or using multiple 
clusters of two or three SNPs in linkage analysis at a similar density to micro satellites 
(Goddard and Wijsman 2002). 
LOD scores. Linkage is statistically calculated by the LOD score method (Morton 
1955). It gives the statistical likelihood that the loci are linked with recombination 
fraction 8 compared with the likelihood that they are inherited independently, when 
recombination is observed in 50% of the meioses, corresponding to 8=0.5. The ratio of 
these likelihoods indicates the odds for or against linkage and is presented as a LOD 
score estimate as follows: LOD(8) =IOglO (L(8)1 L(1/2)). 
For a Mendelian character, a LOD score greater than 3 has been deemed to indicate 
significant linkage. However, it is of note that even a LOD score of 3 will prove to be 
spurious in approximately 1120 instances (p=0.05) (Nyholt 2000). A LOD score of -2 
or less is considered to exclude linkage. Lander and Kruglyak proposed the following 
criteria for interpretation of linkage findings of complex traits (Lander and Kruglyak 
1995): 
1. Suggestive linkage - statistical evidence expected to occur one time at random in 
a genome scan 
2. Significant linkage - statistical evidence expected to occur 0.05 times in a 
genome scan (ie. with the probability 5%) 
3. Highly significant linkage - statistical evidence expected to occur 0.001 times in 
a genome scan 
4. Confirmed linkage - significant linkage from one or a combination of initial 
studies that has subsequently been confirmed in a further sample, preferably by an 
independent group of investigators. A nominal p-value of 0.01 should be required for 
confirmation. In case of sib pair studies, the first three categories would correspond to 
pointwise significance levels of7 x 10-4,2 X 10-5 and 3 x 10-7, and LOD scores of2.2, 
3.6 and 5.4. Nevertheless, LOD scores may vary greatly in their statistical properties 
and, consequently, in their level of significance depending on the statistical test 
employed (Nyholt 2000). 
Parametric linkage analysis. Parametric linkage analysis has proved a powerful way to 
map the genes underlying monogenic disorders. The basis of the parametric linkage 
approach is to search for recombinants and non-recombinants between the phenotype 
and the marker being tested. If a marker is unlinked to a disease, each child will have 
an equal chance of receiving each of the parental alleles. If the marker is linked to the 
disease, offspring will be more likely to inherit one allele over the other, depending on 
whether or not they are affected. Parametric linkage analysis requires the specification 
of an inheritance model, including gene frequencies and penetrance. The power to 
detect linkage by parametric LOD score analysis is sensitive to misspecification of the 
genetic model: the false negative (but not false positive) rate increases with model 
misspecification. If the mode of inheritance is known, traditional parametric methods 
are more powerful than non-parametric linkage (NPL) methods. 
NPL analysis. NPL analysis does not require the specification of values for the 
parameters defining the transmission model and allele frequencies; thus it is suitable to 
disease gene mapping of complex disease. The commonly employed study design of 
NPL mapping requires affected sibling pairs and their parents (figure 1.4). This 
affected-sib-pair test compares the observed number of affected sibling pairs sharing 
zero, one or two alleles identical by descent (ibd) with that which is expected with no 
linkage (proportioned 25%, 50%, 250/0) (Nyholt 2000). If the marker is linked to the 
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disease locus, the affected sibling pairs will share the disease allele ibd more often than 
they would a marker unlinked to the disease locus. 
Figure 1.4 Affected-sib-pair test. 
The probabilities of two siblings sharing 0, 1 or 2 alleles ibd are 0.25 , 0.5 and 0.25 , respectivel y. Ibd 
sharing may be equivocal, ifboth parents are not heterozygous with different genotypes. 
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Power of linkage analysis. The critical parameters in determining power to detect 
linkage by using affected pairs of relatives are the magnitude of underlying genetic 
effect, and recombination fraction between the trait and the marker loci (Risch 1990b). 
Reduced marker polymorphism results in decreased power (Risch 1990c). For a 
partially penetrant recessive trait , affected sib pairs are the most informative type of 
relative pair. For a dominant trait, other relationships may be considerably more 
informative, depending on allele frequency of the trait and marker polymorphism. 
Risch and Merikangas demonstrated that linkage analysis is likely to be successfu l onl y 
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for loci with y (GRR) values in the range of four or larger, provided the allele frequency 
is between 5 and 75%, but not for loci with y values of2 or less (Risch and Merikangas 
1996). Linkage analysis can fail even in very large studies, if misdiagnoses, 
heterogeneity, complex inheritance or frequent phenocopies are abundant (Botstein and 
Risch 2003). Genome-wide linkage scans designed to localise disease genes for 
complex diseases have yielded few significant findings. Failure to reproduce linkage 
results in subsequent studies is frequent. 
1.3.3 Association analysis 
Definition. Association analysis looks for a statistical correlation or dependence 
between genetic variants and a disease on a population scale. Distantly related 
individuals are separated by numerous random recombination events. Association 
studies draw from historic recombination so disease-associated regions are very small in 
random mating populations, usually encompassing only one gene or gene fragment 
(Cardon and Bell 2001). As the disease mutation is transmitted through generations, 
recombination will separate it from the specific alleles of its original haplotype. 
Particular DNA variants can remain together on ancestral haplotypes for many 
generations; this creates the non-random association of alleles. Association studies can 
be especially useful for narrowing a complex trait candidate interval identified by 
linkage analysis and are commonly used for fine mapping of the disease causing gene. 
Statistical evidence for an association between an allele and a phenotype arises in one of 
three situations. First, causal variants may be associated with the disease phenotype. 
Second, linked neutral variants may be associated with the disease phenotype through 
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LD between the marker allele and the causal variant. Third, the association can be 
simply attributable to artefacts such as population stratification. 
Power of association studies. Association studies are likely to be more effective than 
linkage studies for studying complex traits because they can have greater statistical 
power to detect several genes of small effect. Risch and Merikangas showed that even 
if one tests 1,000,000 polymorphic alleles genome-wide and allows for a conservative 
significance level of 5 x 10-8, gene effects with 'Y values of as low as 1.5 could be 
detected in realistically sized « 1 000 families) association studies (Risch and 
Merikangas 1996). They assumed that the polymorphisms tested are disease 
predisposing or in complete LD with the disease causing variant. 
In case-control analysis the critical factor influencing test power is simply the 
difference in allele frequency between the cases and controls. This depends on LD 
between the marker alleles and the disease locus alleles and the strength of association 
between the disease mutation and the disease phenotype. The precise magnitude of the 
detectable effect at the particular locus will depend importantly on the sample size. 
With increasing sample size, alleles of increasingly minor effects can be identified 
(Ardlie et al. 2002a). The statistical power is also influenced by the frequency of the 
alleles of interest. Association studies have more power when the predisposing variant 
is frequent (Botstein and Risch 2003). This observation has fuelled much speculation 
on the likely frequency of the allelic variants for common disease (Pritchard 2001; 
Pritchard and Cox 2002; Lohmueller et al. 2003). SNPs with very low allele 
frequencies would need to have very large relative risks associated with them to be 
detected in an association study. 
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The power to detect a disease susceptibility locus decrease with diminishing LD 
between a tested marker and the disease locus (Muller-Myhsok and Abel 1997). When 
the marker allele is in LD with the disease locus, the power is determined by the extent 
of LD between the marker and the disease locus and the potential discrepancy between 
the frequency of the disease allele and the associated haplotype. 
The LD measure r2 represents the statistical correlation between two sites, and it is 
calculated as follows: r2 = (DAB)2 / fA(l-fA)fB(l-fB) (Hill and Robertson 1968), 
in which DAB = fAB - fAX fB 
and fAB represents the observed frequency of gamete AB, and fA and fB represent the 
frequencies of alleles A and B. r2 is considered to be the most relevant measure for 
association mapping, because there is a simple inverse relationship between r2 and the 
sample size required to detect association between susceptibility loci and SNPs. In 
order to have the same power to detect the association between the disease locus and 
the marker locus, the sample size must be increased by roughly 1/r2 times when 
compared with the sample size for detecting association with the susceptibility locus 
itself(Kruglyak 1999; Pritchard and Przeworski 2001). As a rough rule of thumb, r2_ 
values of above 1/3 might indicate sufficiently strong LD to be useful for mapping 
(Ardlie et al. 2002a). 
The power of association studies is high when the allele frequency of the marker allele 
and the disease allele are equal or similar. In case of discrepant allele frequencies, the 
sample size must be increased by a factor of r, which is the ratio of the associated 
haplotype frequency to the disease allele frequency (Botstein and Risch 2003). For 
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example, if the disease allele had a frequency of 5% and the associated haplotype had a 
frequency of 25%, a sample size 5 times larger would be required for the haplotype 
approach. 
Case-control studies. The traditional case-control approach is the simplest study design 
for assessment of genotype-phenotype correlation. The case-control design employs 
simple statistics, and the recruitment of unrelated patients is easier than families 
especially in the case of late-onset diseases. Case-control studies are more powerful 
than family-based linkage analysis for detection of weak genetic effects and are more 
cost-efficient in terms of recruitment and genotyping effort (Risch and Teng 1998). 
However, when using this approach the association may be due to errors introduced by 
selection bias, recall bias, misclassification or confounding. Selection bias is the result 
of systematic differences between those who are selected for study and those who are 
not. Recall bias results from systematic differences in the accuracy or completeness of 
recall of past exposes or family history. Misclassification results from errors in the 
classification of individuals by phenotype, exposures or genotype. Confounding refers 
to the distortion of the measure of association because of the association of other non-
intermediate factors with both the variable of interest and the outcome of interest (Tabor 
et al. 2002). 
Family-based association studies. The most widely employed approach to improve the 
genetic matching of cases and controls includes use of relatives as controls. Several 
statistics have been formulated to analyse association within families. Falk and 
Rubinstein proposed a method called haplotype relative risk (HRR), which compares 
the genotype frequencies in the affected children with the non-transmitted parental 
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genotypes frequencies (Falk and Rubinstein 1987). Terwilliger and Ott further 
developed this statistic to consider allele frequencies, rather than genotype frequencies, 
observed in the affected children versus the non-transmitted parental alleles (Terwilliger 
and Ott 1992). They referred to this statistic as haplotype-based relative risk (HHRR). 
Another statistic, the transmission disequilibrium test (TDT) is based on the fact that 
heterozygote parents have a 50% probability of transmitting an allele to their offspring 
in the absence of linkage and association (Spielman et al. 1993). In the presence of an 
association between a genetic marker and disease susceptibility locus, significant over-
transmission of the associated allele can be noted. TDT can be extended to families 
with more than one affected child, because under the null hypothesis of no LD, every 
child in a family has an independent probability of 50% of inheriting either of the two 
alleles from a heterozygous parent. However, when families with more than one 
affected child are used, TDT is affected by the strength of linkage and the statistic is no 
longer a measure of association. Several modifications of the original TDT test have 
been developed, including sib-TDT test (Spielman and Ewens 1998) and methods 
suitable for situations where transmission is uncertain (Clayton 1999). Affected family 
based controls (AFBAC) test compares the frequency of alleles transmitted to affected 
children versus alleles never transmitted to an affected child (Thomson 1995). The 
relative power of these test statistics depends on the precise genetic model and 
population mating pattern. The advantages of family-based designs are the potential to 
conduct linkage analysis, assessment of parent-of-origin differences, and genotype-
phase inference for haplotyping and assessment of genotyping errors. The disadvantage 
of a family-based approach is the relatively high cost of genotyping and low efficiency 
of recruitment. 
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Controlling for stratification with anonymous genetic markers. In case-control studies 
of association, population subdivision or recent admixture of populations can lead to 
spurious associations between a phenotype and candidate loci. Such associations arise 
because population subdivision permits marker allele frequencies to vary between 
segments of the population as the result of genetic drift or founder effects. Several 
methods have been designed to recognise the situation when structure may affect a case-
control study and to correct for it when it is present. Pritchard and Rosenberg propose 
that anonymous genetic markers scattered throughout the genome indicate the amount 
of background diversity in cases and controls (Pritchard and Rosenberg 1999). They 
proposed using markers that do not correlate with each other and are independent of 
those affecting the disease of interest. As few as 30 SNPs are sufficient to detect 
population substructure. Once significant population stratification is detected, other 
statistical methods are required to control for its effect. Genomic control-method uses 
independent marker loci to adjust the distribution of the standard chi-squared statistic by 
a multiplicative factor that is proportional to the degree of stratification (Devlin et al. 
2001). Another approach, called structure assessment, defines underlying subgroups in 
stratified samples, measures association in each stratum and combines the results of 
each subgroup (Pritchard et al. 2000; Pritchard and Donnelly 2001). 
Forward genetics - Candidate gene approach. Candidate gene studies identify 
biologically meaningful genes for the disease of interest (Tabor et al. 2002). Generally 
candidate genes are prioritised on the basis of probable functional significance and 
appropriate expression profile. Polymorphic variants within and nearby the candidate 
genes are identified and genotyped in a set of cases and controls, and association 
between the disease phenotype and the markers are assessed. The candidate gene 
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approach is commonly used. Disadvantages of this approach are the multitude of 
possible candidates genome-wide and the paucity of functional data available for most 
genes. Candidate gene numbers can be limited to those found in genomic regions 
identified by prior linkage studies, this is 'the positional candidate' approach. 
Reverse genetics - Positional disease gene mapping using LD approach. The principle 
behind LD mapping is that variants that are not present in the initial screen can be 
investigated indirectly through LD with adjacent markers. LD mapping has been 
successful in identifying several genes for monogenic disorders inherited in Mendelian 
pattern (Hastbacka et al. 1992; Hastbacka et al. 1994) and recent success of identifying 
a Crohn's disease associated gene, NOD2ICARD15, demonstrates the utility ofLD 
mapping in complex disease (Hugot et al. 2001; Ogura et al. 2001). 
Population specific LD pattern and interethnic differences. The strength of the disease 
association may vary depending on gender, age and ethnicity (Farrer et al. 1997). 
Modifier genes and environmental triggers may contribute to the variations in 
phenotypic expression of the disease. A causal association between a candidate SNP 
and a disease should be reproducible in many ethnically diverse populations. Consistent 
replication in different populations is strong evidence of causality. However, the 
frequency of genetic disorders varies remarkably across populations, and not all SNP 
associations are universal. The absence of pan-ethnic replicability of association does 
not necessarily negate a causal relationship (Risch 2000). It may indicate that further 
studies in certain populations are required or for more detailed study of the function of 
the implicated gene. Patterns of LD may differ ethnically, helping to resolve causal 
from non-causal relationship. European populations typically show greater LD than 
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African populations (Reich et al. 2001) and it has been suggested that Caucasians would 
be more suitable for initial LD mapping of a disease gene. African populations exhibit 
much shorter range of LD and may be suitable for fine-mapping the disease causing 
variant. 
Genetic mapping in isolated populations. Isolated populations established by a limited 
number of founders have proven extremely useful for mapping genes for rare 
monogenic disorders. Hastbacka et al. adapted Luria and Delbruck's methods of 
analysing bacterial cultures to the study of a Finnish founder population to estimate the 
recombination fraction between a diastrophic dysplasia locus and a marker (Hastbacka 
et al. 1992). This led to the identification of a defect in the causative gene encoding a 
sulphate transporter (Hastbacka et al. 1994). Following this success, it was thought that 
the same would hold for common diseases. Simulation studies have suggested that the 
value of isolates for common diseases may have been overrated (Kruglyak 1999). 
Empirical evidence suggests that several populations, such as the Finnish and Sardinians 
that were assumed to have high LD due to their founder history and relatively small 
size, do not appear to have greatly increased LD (Eaves et al. 2000; Taillon-Miller et al. 
2000). Very small, isolated populations, exemplified by the Saami, have high levels of 
LD (Laan and Paabo 1997), but due to their small population size it is difficult to recruit 
a large enough patient cohort for genetic studies of a complex disease. In populations 
with relatively few founders, the genetic basis of disease susceptibility is likely to be 
less heterogenous than in large populations. Genetic isolates exhibit reduced number of 
polymorphic SNPs, for example 13% and 56% of SNPs are nonpolymorphic in Finns 
and Sardinians respectively (Taillon-Miller et al. 2000). The anticipated absence of 
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polymorphisms in a subset of the relevant loci may reduce genetic variation and 
increase statistical power for the identification of genes (Shifman and Darvasi 2001). 
Reproducibility of association studies. Many studies of common complex disorders 
have failed to replicate previously reported positive linkage and association findings. A 
meta-analysis of 370 association studies showed that significant between-study 
heterogeneity is frequent, and that the results of the first study correlate only modestly 
with subsequent research on the same association (Ioannidis et al. 2001). Both bias and 
genuine population diversity may explain why early association studies tend to over-
estimate the disease predisposition conferred by a polymorphism. Discrepant 
associations may reflect different sets of genes acting in different samples or differences 
in the LD pattern between the populations studied. Alternatively, it may suggest that 
positive results may be artefactual, possibly due to the large number of markers tested 
or population stratification between cases and controls in an association study 
(Conneally 2003). Different studies may not have the same power to detect an 
underlying genetic effect due to differences in study design and in sample sizes used. 
The TDT design is robust with respect to population stratification, but it requires more 
individuals to be genotyped compared with the case-control study. Common errors in 
association studies include small sample sizes, subgroup analysis and multiple testing, 
random error, poorly matched control group, failure to attempt study replication, failure 
to detect LD with adjacent loci, over-interpreting results, positive publication bias and 
unwarranted candidate gene declaration after identifying association in arbitrary genetic 
region (Cardon and Bell 2001). 
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Parameters for reliable results in genetic association studies. Features of a reliable 
genetic association study include large sample sizes, small p-values, biologically 
meaningful associations and associations with alleles that affect the gene product in a 
physiologically meaningful way (Dahlman et al. 2002). Independent replication 
increases the confidence in an association finding. True association can be 
demonstrated both in family-based and population-based studies. It is essential to carry 
out power calculations, as a study with high statistical power is more reliable. A 
nominal p-value of 10-5 or 10-8 is recommended depending upon the nature of the study. 
For example, a genome-wide association study including 1000 000 tests requires a p-
value in the range of 10-7 to 10-8 to provide a false positive rate of 0.05 (Risch and 
Merikangas 1996). 
1.3.4 Genetic studies of Mendelian disorders 
The last two decades have experienced a rapid achievement in mapping and cloning the 
genes involved in Mendelian disorders such as the X-linked muscular dystrophies 
(Koenig et al. 1987), cystic fibrosis (Kerem et al. 1989; Riordan et al. 1989; Rommens 
et al. 1989) and Huntington's disease (1993). These successes reflect the enormous 
power of linkage analysis when applied to Mendelian phenotypes (Risch 2000). 
Mendelian diseases are characterised by a one-to-one or near one-to-one 
correspondence between genotypes at a single locus and the observed phenotype. For 
Mendelian diseases, the total frequency of susceptibility mutations is generally very low 
(usually <1 %). Mendelian disorders often have extremely high levels of allelic 
heterogeneity, which means that there are multiple different mutations (or alleles) in the 
same gene, all of which may lead to disease. For example, a British study of 424 
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families with haemophilia B identified 302 independent mutations in the factor IX gene 
(Green et al. 1999). The latter does not cause a problem in linkage analysis because all 
families will show linkage to the same chromosomal region. In effect, allelic 
heterogeneity provides the strongest evidence for a causal relationship between a gene 
and disease phenotype (Risch 2000). Recent evidence suggests that modifier genes and 
environmental factors contribute to some of the clinical variability observed in 
Mendelian diseases (Badano and Katsanis 2002). Modifier genes alter the form of the 
trait or its incidence in the presence of a major gene. 
Finnish disease heritage. The term Finnish disease heritage is used to refer to the 
recessive diseases occurring in Finland at higher than usual frequencies compared with 
other European countries. At present, 35 diseases have been listed for Finnish disease 
heritage and the disease causing variant(s) have been identified in most of these 
disorders (Kere 2001). 
1.3.5 Genetic studies of complex diseases 
Encouraged by the success achieved in elucidation of the genetic aetiology of 
Mendelian traits, scientists began to turn their attention to common disorders, many of 
which have a major genetic component. The cause of common complex diseases is 
multifactorial with both genetic variation at multiple loci and environmental factors 
contributing to their development. Complex diseases may be very common, they have 
important consequences for the economics of medical provision. 
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The common disease / common variant hypothesis states that alleles at relatively high 
frequencies (> 1 %) represent a significant proportion of susceptibility alleles for 
common complex disease (Cardon and Bell 2001). Their high frequency implies that 
association studies in large population cohorts will be fruitful for identifying risk alleles. 
The key assumption of this model is that disease susceptibility is influenced by a few 
loci, each of which has a single major allele contributing to the phenotype. While the 
biological reality of these assumptions is unknown, they are critical to the success of 
association mapping experiments. A recent meta-analysis supports a contribution of 
common variants to susceptibility to common disease (Lohmueller et al. 2003), 
although this analysis may be biased due to the fact that associations with common 
alleles are easier to detect than associations with rare alleles. Conversely, it has been 
argued that rare alleles may equally contribute to the genetics of complex diseases even 
if their identification using the currently available techniques is difficult. The common 
disease / rare allele hypothesis states that there is no reason to expect that most genetic 
diseases results from common alleles. Population modelling predicts that disease loci 
exhibit extensive allelic heterogeneity in terms of the frequencies of the causative 
mutation (Pritchard 2001). The power of LD mapping of disease causing gene is 
greatly reduced if the causative mutation is rare. Simulation studies suggest that when 
the causative mutation is rare, most rare SNPs show no allelic association, but a small 
fraction show very strong association. In contrast, when the causative mutation is 
common, most rare SNPs show no allelic association, and a few show weak association, 
but almost all common SNPs show appreciable association. 
Gene mapping of common complex disorders has been hampered by locus 
heterogeneity, epigenetic mechanisms, gene-environment and gene-gene interactions 
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(epistasis). Locus heterogeneity denotes that mutations at multiple loci are involved in 
leading to the same phenotype. These mutations may act together or with 
environmental factors in additive or multiplicative way. Alternatively, a susceptibility 
locus of a major effect may act over a polygenic background of susceptibility genes. 
Other levels of genetic complexity include variable expressivity of the genes and 
pleiotropy, where the genes involved may have multiple effects. Epigenetic 
mechanisms include differential methylation pattern of GpC islands. In addition, there 
may be phenocopies, where the same clinical phenotype arises on the basis of 
environmental or random causes. 
Penetrance refers to the proportion of people with the mutation who will manifest the 
disease. The power to detect association is drastically reduced by incomplete 
penetrance. A large number of subjects, whether as case-controls, families or affected 
sibling pairs, are needed for adequate power to detect linkage to a gene with only a 
partial effect on the phenotype. Especially in case of relatively rare complex diseases, 
international collaborations may be crucial in the recruitment of adequate number of 
affected families (Conneally 2003). Even for common complex disorders, 
collaborations can facilitate the identification of smaller gene effects. Collaborations 
among clinicians, epidemiologists, geneticists, mathematicians and bioinformatics 
experts will be needed to solve the genetic defects underlying complex disease. 
A widely used approach for disease gene mapping of complex disease is initial whole 
genome screening using microsatellite markers with an average marker spacing of 10 
cM. A two-stage approach, an initial and then a replication sample, is most commonly 
employed for mapping a complex trait. Subsequently, the broadly linked chromosomal 
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regions are usually further refined with a denser set of rnicrosatellite markers. The 
resolution of linkage studies is typically of the order of several cM, which in the human 
genome may correspond to several Mb of DNA, and 100s or 1000s of genes. Once the 
areas of interest are identified using linkage analysis, LD mapping is required to narrow 
further the region of the genome in which the disease gene must lie. Generally the 
chromosomal areas identified by the linkage studies are wide and a large number of 
SNP markers are required for fine mapping of the region. An alternative strategy is to 
identify candidate genes under the linkage peak and test the involvement of SNP 
markers in patients and healthy control individuals. 
There are various alternative approaches for identification of important genes 
contributing to the complex disease phenotype. Once association is established, it is 
relevant to investigate whether any of the variants that were examined have a functional 
consequence. There may be biological, aetiological and pathological models of the 
disease of interest. Expression studies may provide important clues to the tissues and 
cells that are involved in the disease. Animal models of the disease of interest can 
provide important information on potential candidate genes and indicate relevant human 
homologues (Tabor et al. 2002). Mouse models, with their short generation times and 
high breeding efficiency, may provide shortcuts to disease gene identification, 
unequivocal proof that a particular mutation is causative (at least in mice), and rapid 
dissection of the molecular pathways in which the mutant protein acts (Peltonen and 
McKusick 2001). 
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l.3.6 Variation in the human genome 
Initial analyses of the completed chromosomal sequences suggest that the number of 
human genes is lower than expected (about 35 000) (Lander et al. 2001). Major 
components of genetic complexity in the human genome may be variations in gene 
regulation and alternative splicing of gene transcripts explaining how one gene can have 
distinct functions in different tissues. Genome-wide analyses of alternative splicing 
indicate that 40-60% of human genes have alternatively spliced forms, and suggests that 
alternative splicing is one of the most significant components of the functional 
complexity of the human genome (Modrek and Lee 2002). Human genome is replete 
with several types of polymorphism: SNPs, repeat polymorphism and insertions and 
deletions, ranging from a single nucleotide to thousands of nucleotides in size. Most of 
the DNA sequence variation in the human genome is in the form of SNPs. 
Approximately 1 in 1,250 nucleotides is a SNP (Sachidanandam et al. 2001). They are 
present in coding and noncoding, as well as regulatory regions of the genes. SNPs are 
useful for population association studies because of their high density and mutational 
stability in the genome. The International SNP Map Working Group has provided a 
map of 1.4 million candidate SNPs across the genome (Sachidanandam et al. 2001). 
The biallelic nature of SNPs limits their informativeness. This can be overcome by 
constructing haplotypes of SNPs, which can make a region highly polymorphic. In 
some cases, determination of haplotypes or combinations of SNPs that are in LD may 
offer more power to detect associations than simply measuring individual SNPs. For 
disease mapping projects, it is desirable to study only those polymorphisms that affect 
the function of the protein or its expression, because these are most likely to result in a 
definable phenotype. As only a small proportion of the millions of sequence variations 
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in our genomes are likely to have functional impact, identifying this subset of sequence 
variants will be one of the major challenges of the next decade. 
Botstein and Risch characterised 27027 mutations underlying Mendelian diseases. 
They noted that missense mutations resulting in in-frame amino acid substitutions were 
the most frequent type of mutation (59% of the total), whereas deletions account for 
220/0 of all changes, insertions/duplications account for 7%, splice-site mutations 
account for 10% and mutations in the regulatory regions account for less than 1 % of 
changes (Botstein and Risch 2003). They also noted that the severity of the disease tend 
to increase with the severity of the amino acid substitutions (Botstein and Risch 2003). 
A classic example of the correlation between severity of the phenotype and severity of 
the mutation is Duchenne (severe) and Becker (mild) muscular dystrophy: Duchenne is 
caused primarily nucleotide deletions leading to frame-shifts and Becker is caused by 
in-frame changes (Gillard et al. 1989). The clinical significance of mutation has also 
been demonstrated to correlate with the degree of cross-species evolutionary 
conservation (Botstein and Risch 2003). 
1.3.7 Linkage disequilibrium and haplotype structure in the human genome 
LD is the non-random association of alleles at adjacent loci. Factors that influence LD 
are recombination, mutation, genetic drift, population growth, admixture or migration, 
population structure, natural selection and gene conversion. Genetic drift describes the 
random fluctuation of allele and haplotype frequencies and these frequency changes are 
accentuated in small populations. Rapid population growth decreases LD by reducing 
genetic drift. Natural selection can affect the extent of disequilibrium by a hitchhiking 
63 
effect, in which an entire haplotype that flanks a favoured variant can be rapidly swept 
to high frequency or even fixation. Natural selection can also affect LD through 
epistatic selection for combinations of alleles at two or more loci on the same 
chromosome. In a gene conversion event, a short stretch of one copy of a chromosome 
is transferred to another during meiosis. Rates of gene conversion in humans are high 
and are important in LD between very tightly linked markers (Ardlie et al. 2001). 
If LD mapping strategy is to be applied successfully in disease gene mapping, it is 
essential to know how far usable levels of disequilibrium extends in the human genome 
and how much this varies from one population to another. Abecasis et al. estimated that 
physical distance could account for less than 50% of the variation in LD. The 
remaining variation was probably due to a combination of drift, demographic factors, 
selection and variable rates of mutation, recombination and gene conversion (Abecasis 
et al. 2001). Eaves et al. and Taillon-Miller et al. noted substantial variability in 
disequilibrium levels beyond that which can be explained by differences in distances 
and allele frequencies (Eaves et al. 2000; Taillon-Miller et al. 2000). 
Empirical evidence suggests that the genome is broken down into blocks of strong 
haplotype structure, characterised by low haplotype diversity, strong associations 
between alleles and rare recombination, separated by shorter regions of shattered 
haplotype structure, characterised by high haplotype diversity, weak allelic associations 
and multiple recombination events (Daly et al. 2001; Phillips et al. 2003). Within high 
LD regions, allelic dependence yields redundancy among markers and improves the 
chances of detecting association using only a fraction of all the known markers 
(Johnson et al. 2001). The Haplotype Mapping (HapMap) project is in progress to 
6.f 
identify and catalogue common haplotypes and their characteristic SNPs across the 
genome for major races. HapMap will undoubtedly benefit the mapping of regions of 
interest in complex diseases and lay a foundation for the genome-wide association 
studies (Judson et al. 2002). There is a concern that association analysis based on 
identification of common haplotype blocks will perform poorly if the allele frequency is 
as low as 0.1 (Pritchard and Cox 2002). However, rare variants are likely to be young, 
and hence may lie in conserved haplotypes that extend across several haplotype blocks. 
In conclusion, the reconstruction of accurate population specific linkage and haplotype 
maps is likely to be of key importance for the identification of causative polymorphisms 
underlying complex traits. Well-designed and large studies are likely to yield 
successful results in future gene mapping projects of complex diseases. 
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1.4 AIMS OF THIS PROJECT 
AS is a complex and highly heritable disorder exhibiting a strong association with HLA-
B27. However, HLA-B27 is estimated to account for 16-50% of the total genetic 
variation of the disease leaving a large component of the genetic variance to be 
discovered. This project aims to further define the HLA region and investigate the 
contribution of candidate genes outside the HLA region in AS. 
The specific aims are: 
1. To investigate the effect of polymorphic variants near and within the TGFBl 
gene in susceptibility to, and severity of, AS in an English and Finnish population 
2. To develop a novel HLA-DRBl genotyping method based on primer extension 
reactions 
3. To investigate the effect ofHLA genes and haplotypes in susceptibility to, and 
clinical characteristics of, AS in a Finnish population 
4. To investigate the effect of the CYP2D6 gene in susceptibility to AS in a 
Finnish population 
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CHAPTER 2 - SUBJECTS AND METHODS 
2.1 AS CASES AND CONTROLS 
2.1.1 Case definition 
Cases with AS defined by the modified New York diagnostic criteria (van der Linden et 
al. 1984a) were selected for the study. The sacroiliitis was confirmed by a qualified 
radiologist and the diagnosis of AS was confirmed by a qualified rheumatologist. 
2.1.2 Finnish families 
Finland is a northern European country covering 337 030 km2 with a total population 
size of 5.2 million people. All the Finnish AS patients were recruited from the 
Rheumatism Foundation Hospital in Heinola, which is located in southern Finland 133 
kilometres north of Helsinki (figure 2.1). It serves as a specialist unit responsible for a 
population of 200 000 people and a rheumatologic rehabilitation centre nationwide. A 
structured questionnaire was used to assess the presence of AAU, IBD, psoriasis and 
peripheral arthritis, age of symptom onset, age at diagnosis, disease duration and disease 
severity scores including the Bath AS Disease Activity Index (BASDAI) (Garrett et al. 
1994), Bath AS Functional Index (BASFI) (Calin et al. 1994) and Bath AS Global 
Score (BAS-G) (Jones et al. 1996) (see Appendix 1). The original English language 
questionnaire was translated into Finnish, and then validated by reverse translation. At 
the time of completing this thesis, sample recruitment was still continuing. At the time 
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of conducting the CYP 2D6 and TGFBI study, we had 437 individuals from 170 
families available. For the HLA studies, 673 individuals from 261 famili es were 
available . 
Figure 2.1 Map of Finland and location of Heinola. 
The figure is obtained from www.heinola.fi. 
HEINOLA 
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2.1.3 British families 
N 
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One thousand three hundred and thirty-two individuals from 212 parent-case trio 
families and 184 AS affected-sibling pair families were recruited from the UK for the 
studies reported in this thesis. AS patients were identified from several sources: the 
Royal National Hospital for Rheumatic Disease AS database ; patients attending the 
Nuffield Orthopaedic Centre, Oxford; in response to public appeals ; and by referral 
from British rheumatologists . Among the parent-case trios there were 31 parent-case 
affected pairs ; other families were simplex i.e. one affected subj ect in famil y. 
2.2 LABORATORY METHODS 
2.2.1 DNA extraction 
Thirty-six mls of blood per individual was collected in sodium EDTA anticoagulation 
tubes and stored at -20°C. DNA was extracted from the white blood cells using the 
guanidinium hydrochloride (GuHCI) DNA extraction method. 
Defrosted blood was poured into two 50 ml Falcon tubes, 25 ml of Lysis Buffer (see 
Appendix 2 for composition) was added and the solution was mixed by inversion. The 
mixture was centrifuged at 2500 rpm (1467 ref) (Heraeus Sepatech Megafuge 2.0R) for 
10 min to pellet the nuclei of the white cells. The supernatant was decanted. Twenty 
mls of Lysis buffer was added and the solution was vortexed until the pellet was 
completely dispersed. Centrifugation at 2500 rpm (1467 ref) for 10 min was performed 
and supernatant decanted. 
Three and half mls of 6 M GuHCI was added to lyse the nuclei. The solution was 
vortexed to resuspend the pellet. Two hundred and fifty}ll of7.5 M ammonium acetate 
was added. Twenty-five}ll of 20 mg/ml Proteinase K solution was added to digest the 
protein. Two hundred and fifty}ll of 10% SDS was added. Incubation at 60°C was 
performed for one hour. The tubes were shaken after ten minutes of incubation in order 
to disperse clumps of SDS. 
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Two ml ofCHCb was added and the tubes were thoroughly mixed by inversion. 
Centrifugation at 2500 rpm (1467 rcf) was performed for 5 min. The upper layer was 
collected into a new 50 ml Falcon tubes. Fifteen mls of 100% ethanol was added and 
mixed thoroughly by inversion to precipitate the DNA. The tubes were centrifuged at 
2500 rpm (1467 rcf) for 2 min to pellet the DNA. The supernatant was decanted and 10 
ml of 80% ethanol was added. The precipitated DNA was hooked out with a tip and 
removed into a clean Eppendorf tube. Eight hundred pI of 80% ethanol was added, the 
tubes were centrifuged at 13000 rpm (15115 rcf) in a microfuge (IEC Micromax) and 
the ethanol was decanted. The tubes were centrifuged again at 13000 rpm (15115 rcf) 
in a microfuge and the last visible traces of ethanol were removed with a pipette. The 
Eppendorftubes were left open for 10-20 min to dry the DNA pellets. One ml of lxTE 
buffer (see Appendix 2 for composition) was added the tubes were left overnight at 
room temperature to resuspend. Following extraction, undiluted DNA samples were 
stored at -70°C. Samples to be used in genotyping were diluted with sterile dH20 to a 
concentration of20 ng/pl and stored at -20°C until required. 
2.2.2 DNA quantification 
Nucleotides in solution absorb light in the ultraviolet (UV) region of the spectrum, with 
the maximum absorption at a wavelength of 260 nm. The maximum absorbance of 
proteins in the UV range is at 280 nm. Nucleic acids can therefore be quantified and the 
purity of a preparation can be estimated by measuring the absorption at both 260 nm 
and 280 nm. 
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The absorbance measurements at wavelengths of 260 nm and 280 nm were performed 
to determine the amount and purity of DNA using Beckman DU® 640 
spectrophotometer. The term optical density is commonly used instead of absorbance. 
An optical density (OD) of 1.0 at 260 nm is equivalent to approximately 50pg/ml so 
DNA concentration was calculated as follows: 
DNA concentration }Ig/ml = 50 x dilution x OD260 . 
The purity of DNA was assessed by measuring the ratio of OD26010D280. If protein is 
present in the solution, the OD280 increases more than the OD260, so the ratio 
OD26010D280 decreases. Pure DNA has a ratio of OD26010D280 of 1.8. Samples with the 
OD26010D280 ratio <1.5 were re-extracted with phenol and CHCh (to remove any phenol 
that has entered the aqueous DNA containing phase) and precipitated again. 
Some of the DNA concentrations were determined using the PicoGreen ™ kit 
(Molecular Probes, Leiden, Netherlands). The PicoGreen™ double-stranded DNA 
(dsDNA) quantitation reagent becomes intensely fluorescent upon binding nucleic 
acids, allowing selective detection of dsDNA in solution (Singer et al. 1997). The 
PicoGreen ™ solution and the stock DNA samples were diluted by a factor of 1 in 200 
in TE buffer. Fifty}II of the diluted DNA and 50 pI of diluted PicoGreen ™ solution 
were added in a MicroAmp Optical 96-well plate. A set of 8 standards ranging from 0 
to 1000 ng/ml were included in each plate. The fluorescence emitted by each sample 
was measured using an ABI Prism 7200 Sequence Detector. A standard curve of 
concentration against fluorescence was created using the standards and the 
concentration of each sample determined using this curve. The PicoGreen ™ dsDNA 
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quantitation reagent allows a sensitive, specific and rapid means to detect and quantitate 
DNA. 
2.2.3 Polymerase Chain Reaction (PCR) 
PCR amplifies a specific segment of DNA between two flanking oligonucleotide 
primers. Oligonucleotide primers are generally 15-30 nucleotides long and designed to 
hybridise specific sequences (5' and 3') flanking the region of interest in the target 
DNA. In a PCR reaction three steps, denaturation at 94°C, annealing at 50-60°C and 
extension at 72°C are repeated a number of times (generally about 30 times) in order to 
achieve the required amplification. DNA polymerase extends the primers after they 
anneal to the template, creating a duplicated complementary strand. Heat stable DNA 
polymerase such as Taq (derived from Thermus aquaticus) DNA polymerase is stable at 
the denaturing temperature of DNA and is suitable for PCR amplification. 
Magnesium ions are necessary to deoxynucleotide triphosphate (dNTP) incorporation 
and stabilise primer annealing. The concentration of MgCh can have a substantial 
effect on the specificity and yield of the amplification. Generally, excess magnesium 
ions will result in the accumulation of non-specific amplification products and 
insufficient magnesium ions will reduce the yield. MgCh concentration is therefore 
optimised for each primer pair. 
72 
Primer design. There are computer programs available to aid the oligonucleotide 
design. PRIMER3 [www.genome.wi.mit.edu/cgi-biniprimer/primer3 www.cgi] designs 
suitable peR primers given the stretch of nucleotide sequence. The OLIGO 
[www.oligo.net] program analyses given oligonucleotides. PCR primers were designed 
to avoid stable hairpin loop structures. The primers were designed to have a G + C 
content of 40 - 60% and not to have areas of base complimentarity either within a 
primer or between pairs of primers. In particular, overlaps at the 3' ends were avoided 
to reduce the incidence of an artifactual product, called 'primer-dimer'. 
Complementary 5' extensions may be added to primers to allow a variety of useful post-
amplification manipulations. Optimal primer concentrations were determined 
empirically for each PCR reaction. Specific concentrations and volumes used in 
individual mastermixes as well as cycling conditions used are detailed in the methods 
section of each chapter. 
2.2.4 Agarose gel electrophoresis 
DNA molecules can be separated according to their molecular weight using agarose gel 
electrophoresis. Agarose is a linear polymer composed of alternating residues of D- and 
L-galactose. Negatively charged DNA migrates toward the positively charged 
electrode. Smaller fragments of DNA migrate faster and therefore, fragments of 
different sizes can be separated. Two percent agarose gels were made using 12 g of 
agarose (Sigma Aldrich, Steinheim, Germany) and 600 ml of 1 x TBE buffer (see 
Appendix 2 for composition). 
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Nucleic acids that have been subjected to electrophoresis through agarose gels may be 
detected by staining and visualised by illumination with 300 nm UV light. Fluorescent 
dye 2,7 -diamino-l 0-ethyl-9-phenylphenanthridinium bromide (ethidium bromide) was 
used to stain the agarose gels. Ethidium bromide is a small molecule that inserts 
between the nucleotides of DNA and strongly fluoresces under UV illumination. When 
ethidium bromide binds to DNA, it is effectively concentrated and its fluorescence 
increases, so the nucleic acid shows up as a bright band on a dim background of 
unbound ethidium bromide. peR products were visualised under UV light on an 
Alphalmager (Flowgen, Staffordshire, UK). 
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2.2.5 SNP ascertainment 
2.2.5.1 Amplification Refractory Mutation System (ARMS) 
ARMS was described in 1989 as a PeR-based method to detect any known SNPs in 
genomic DNA (Newton et al. 1989) (figure 2.2). The basis of this method is that 
oligonucleotides with a mismatched 3' -residue will not function as primers in the peR 
under appropriate conditions. The 3' -mismatch principle can be used to identify 
virtually any SNP mutation within a peR reaction. Identification of the alleles is based 
on the presence or absence of amplified product observed after agarose gel 
electrophoresis. 
Figure 2.2 Agarose gel view of ARMS genotyping of TGFBI -800-509 haplotype 2/1. 
Control primers amplifying a 796 bp fragment from the third intron of HLA-DRBI gene were included in 
all the reactions . Allele specific fragment is 291 bp. From left to right: Lane I - 1 kb ladder; Lanes 2-6, 
8,10-15 - TGFBI -800-509 haplotype 211 negative; Lanes 7, 9,16 - TGFBI -800-509 haplotype 2/ 1 
positive samples. 
Lanes: 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
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2.2.5.2 PCR-Restriction Fragment Length Polymorphism (PCR-RFLP) 
PCR-RFLP method relies on the initial amplification of the fragment of interest by PCR 
and subsequent digestion of fragment with a suitable restriction endonuclease which 
cuts at specific restriction sites. Over 200 different sequence specificities of restriction 
endonucleases have been characterised which has made it possible to genotype many 
SNPs by this method. 
2.2.5.3 Primer extension method 
Primer extension reactions were performed using an ABI Prism® SNaPshot™ 
technology (Applied Biosystems, Foster City, CA, USA). The primer extension 
reaction requires a prior PCR amplification of the fragment of interest and subsequent 
purification of the PCR product. Shrimp Alkaline Phosphatase (SAP) was used to 
remove unincorporated dNTPs and Exonuclease I (Exo I) was used to remove 
unincorporated primers. Primer extension method uses a primer that anneals 
immediately adjacent to the SNP and is based on the extension of the primer using 
fluorescent dideoxynucleotide triphosphates (ddNTP) that are complimentary to the 
SNP. Unlike normal dNTPs, ddNTPs cannot be extended by DNA polymerase which 
results in termination of the reaction. The subsequent extension product is analysed on 
an ABI Prism 3700 capillary electrophoresis instrument. 
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2.2.6 DNA sequencing 
Two automated methods, dye-primer and dye-terminator, are commonly used for DNA 
sequencing. They are based on Sanger dideoxy DNA sequencing method (Sanger et al. 
1977). In sequencing with dye-labeled terminators, the dyes are attached to the 
terminating ddNTP (Lee et al. 1992; Rosenblum et al. 1997). The advantage of dye-
terminator chemistry is that four chain-extension reactions can be carried out with the 
same primer in a single reaction and only properly terminated products are detected. In 
sequencing with dye primers, the fluorescent dyes are attached to the 5' end of the 
primer oligonucleotide (Smith et al. 1985; Smith et al. 1986; Voss et al. 1989). Four 
separate reactions are carried out for each DNA sample, each reaction containing a 
different dye-labeled primer. This set of four reactions is then mixed and loaded into a 
single channel for gel electrophoresis. As the sequence undergoes electrophoresis in an 
automated sequencer, a laser beam excites the dyes. The fluorescent signal can be 
reproduced in the form of an intensity profile. Yellow, red, green and blue colour 
represents guanine (G), thymine (T), adenine (A) and cytosine (C) bases, respectively. 
The advantage of dye-primer sequencing is that the base-calling is more accurate, 
especially with heterozygote samples. The disadvantage of the dye primer method is 
the requirement of for four separate extension reactions and four dye-labeled primers for 
each template (Sambrook and Russell 2001). 
HLA-DRBl gene sequencing was performed using the dye-primer sequencing (figure 
2.3). Specific concentrations, volumes and cycling conditions used in sequencing 
reactions are presented in the methods section of chapter 5. 
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Figure 2.3 An electropherogram view of HLA-DRBl *OlOl positive sample. 
The sequence spans the codons 89-117 of the HLA-DRB 1 gene (reference sequence ID: 
OTTHUMG00006006904). The arrows point to the location of the polymorph isms which define thi s as 
an HLA-DRB1 *0101 subtype sequence. The corresponding bases found in the other HLA-DRB1 *01 
subtype sequences are denoted in the boxes. 
TG: *0 102 and *0104 
C: *0102 
T : *0102 
AT: *0104 
C: *01022 
CGA: *0103 
AG : *0103 
A: *0103 
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2.3 ANALYTICAL METHODS 
2.3.1 Genotype error checking 
The GAS program version 2.0 (Alan Young, Oxford University, 1995) was used to 
check for Mendelian inheritance of alleles. The program MERLIN was used for error 
detection (Abecasis et al. 2002) (http://bioinformatics.well.ox.ac.uklMerlin). MERLIN-
ERROR detects genotypes that cause unlikely recombination events between tightly 
linked SNP markers suggestive of genotyping errors. 
2.3.2 Testing for Hardy-Weinberg Equilibrium (HWE) 
The HWE is named after the English mathematician G. H. Hardy (1877-1947) and the 
German physiologist Wilhelm Weinberg (1862-1937), who in 1908, independently 
formulated the principle and deduced its theoretical predictions of genotype frequency. 
In the Hardy-Weinberg model, the mathematical relation between the allele frequencies 
and the genotype frequencies is defined by 
p2 + 2pq + q2 = 1 
p+q=1 
in which p2, 2pq and q2 are the frequencies of the genotypes AA, Aa and aa in zygotes 
and p and q are the allele frequencies of A and a. 
The assumptions of HWE are diploid organism, sexual reproduction, non-overlapping 
generations, identical allele frequencies in males and females, random mating, very 
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large (in theory infinite) population size, negligible migration, no mutation and no 
natural selection (Hartl and Clark 1997). Deviation from HWE can occur due to a 
major violation of one of the HWE assumptions, sampling bias or genotyping error. 
The chi-squared test was used to examine whether the genotype frequencies were in 
HWE. P-values >0.05 were accepted as nonsignificant deviation from HWE. 
2.3.3 Haplotype reconstruction 
Traditionally haplotypes are reconstructed by using the information from the available 
family members. Families are not always available and a number of approaches have 
been developed to reconstruct haplotypes without family data. Haplotypes can be 
reconstructed from the genotype data obtained from the unrelated individuals using a 
maximum parsimony method (Clark 1990), the expectation-maximization (EM) 
algorithm (Excoffier and Slatkin 1995) or a coalescent model-based method using the 
program PHASE (Stephens et al. 2001). In the TGFBl data set PHAMILY [Hans 
Ackerman thesis, Oxford University, 2001] and PHASE (version 1.0) were used for 
haplotype reconstruction for the sporadic AS cases and parent case trio families 
(Stephens et al. 2001). The HLA-DRB1-B27 haplotypes were reconstructed using a 
family based haplotyping program, SIMW ALK2 (Sobel and Lange 1996). 
PHASE reconstructs haplotypes using a Bayesian method of genetic modelling. 
Specifically, it uses Gibbs sampling, a type of Markov chain-Monte Carlo algorithm, to 
obtain an approximate sample from the posterior distribution of haplotypes (H) given 
genotypes (G), Pr (HIG). The algorithm starts with an initial guess haplotype, 
repeatedly chooses an individual at random, and estimates that individual's haplotypes 
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under the assumption that all other haplotypes are correctly reconstructed. Repeating 
this process enough times results in an approximate sample from Pr (HIG). It also 
estimates the uncertainty of each phase call to prevent overconfidence in statistically 
reconstructed haplotypes. PHASE has been demonstrated to be more accurate than the 
EM algorithm (Excoffier and Slatkin 1995) or a maximum parsimony method (Clark 
1990). The accuracy of PHASE and EM algorithm is improved with increasing sample 
size. The disadvantage with PHASE program and EM algorithm is that, without 
pedigree information, rare haplotypes are occasionally miscalled when their 
presence/absence must be inferred (Tishkoff et al. 2000). 
PHAMILY assesses family haplotype data where phase can be directly established, 
which can subsequently be incorporated into the PHASE program. PHAMIL Y reads 
data from parent-case trio families and assigns gametic phase to unambiguous positions. 
PHAMILY provides two output files: one containing the partially reconstructed 
parental haplotypes and the second indicating whether phase is ambiguous or 
unambiguous at each site. The second output file can be used as an additional input file 
for PHASE to increase the accuracy of haplotype reconstruction by using all available 
information. 
HLA haplotypes in pedigrees were reconstructed using an algorithm based on genetic 
descent graphs, implemented in the SIMW ALK2 software (Sobel and Lange 1996). 
SIMW ALK2 is based on a Markov Chain Monte Carlo procedure and inheritance 
graphs. SIMW ALK2 performs stochastic simulation on pedigrees and estimates the 
single most likely configuration ofhaplotypes. SIMWALK2 assumes that the loci are 
in linkage equilibrium. 
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2.3.4 Linkage analysis 
2.3.4.1 Nonparametric linkage analysis 
Nonparametric multipoint linkage analysis was performed using GENEHUNTER-
PLUS (Kong and Cox 1997), a modification of GENE HUNTER (Kruglyak et al. 1996). 
GENEHUNTER calculates a NPL statistic from the sharing of alleles ibd among 
affected individuals within a pedigree (Kruglyak et al. 1996). The NPL method can 
analyse the data using a pairwise approach (using the NPLpairs statistic) by measuring 
the number of alleles shared ibd by a pair of affected relatives. It has also been 
extended to provide simultaneous comparison of alleles in all affected individuals in a 
pedigree (the NPLall statistic). NPLall calculates the observed ibd probability over all 
configurations and puts extra weight on families in which three or more affected 
individuals share the same allele. NPLall statistic is most suitable for analysis of 
dominant loci, since more affected individuals per family are likely to share the same 
allele with this type of inheritance. The NPL approach is inherently multipoint, since it 
calculates the ibd probability for any given data point along the chromosome, using all 
available marker data on the chromosome. Because the true inheritance pattern is not 
always known with certainty but significance is evaluated using the null distribution 
expected in the case of complete informativeness, the NPL score will tend to be 
conservative. The level of conservativeness depends on the marker heterozygosity, the 
number of untyped individuals and marker spacing. 
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To resolve the conservativeness of the NPL method when the descent information is 
incomplete, the GENEHUNTER-PLUS software uses the modified NPL1r statistic that 
is well approximated by a normal distribution (Kong and Cox 1997). GENEHUNTER-
PLUS provides an accurate likelihood-ratio test to assess evidence of linkage and also 
allows the calculation of a nonparametric LOD score that is based on allele sharing, and 
unlike the NPL score, can be interpreted in the same way as a traditional LOD score. 
2.3.4.2 Quantitative linkage analysis 
The Haseman-Elston method consists of regressing the squared sib-pair quantitative 
trait phenotype difference on the proportion of alleles that the sibs are estimated to 
share ibd at the marker locus (Haseman and Elston 1972). A negative slope suggests 
linkage because it correlates similarity at a trait locus with similarity at a marker locus 
(i.e. as the sib-pair trait difference decreases, their genetic identity increases). A 
modified Haseman-Elston algorithm (Sham et al. 2002) that is adapted for use in 
general pedigrees was employed to perform the quantitative linkage analysis. This 
method is implemented by the program MERLIN-REGRESS (Abecasis et al. 2002). 
The basis of this approach is to test whether relatives with close phenotypic values 
share more ibd alleles than relatives with more distant values. The method takes into 
account that ibd information may be incomplete, as is often the case with the real data. 
MERLIN-REGRESS requires specification of the trait distribution parameters (mean, 
variance and heritability) in the general population. The method is limited to additive 
genetic effects on a single quantitative trait. 
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2.3.5 Association analysis 
2.3.5.1 Transmission disequilibrium test (TDT) 
The TDT test was used as a within-family association method to assess the association 
between the polymorphisms and disease susceptibility (Spielman et al. 1993). The 
concept that underlies TDT is that, in the presence of association between a genetic 
marker and disease susceptibility locus, the probability of transmission of a marker 
gene from parents to an affected offspring is increased from the 0.5 value predicted by 
Mendelian inheritance. The statistic of TDT is 
iTDT = (a - b)2 
a+b 
in which a is the number of transmitted alleles from heterozygous parents and b is the 
number of non-transmitted alleles from heterozygous parents. This has a chi-squared 
distribution with one degree of freedom. Untransmitted alleles act as an internal control 
for transmitted alleles, and therefore, TDT test is robust to population stratification, 
which may cause spurious associations in case-control studies. However, TDT only 
counts heterozygous parents in the analysis and requires more genotyping than case-
control studies. Thus, the false negative rate of TDT is higher than that of the case-
control study, which causes loss of power. 
The program TRANSMIT version 2.5 uses a new approach to transmission 
disequilibrium testing based on the score test (Clayton 1999). TRANSMIT can deal 
with situations in which transmission is uncertain. Such situations arise when 
transmission of a multi locus marker haplotype is considered, since haplotype phase is 
often unknown. For single-locus markers, transmission is uncertain if one or both 
parents are missing. By use of the robust variance estimator, more than one affected 
offspring per family may be used to assess association independent of linkage. P-values 
can be obtained by statistical simulation using 1000 replicates. 
2.3.5.2 Quantitative transmission disequilibrium test (QTDT) 
Associations of the polymorphisms and haplotypes with quantitative data such as the 
age of disease onset, BASDAI and BASFI were assessed using the QTDT program 
(Abecasis et al. 2000). QTDT incorporates variance components methodology in the 
analysis of family data and partitions association into between- and within- family 
components. The program includes a permutation framework, which allows estimation 
of p-values. This corrects for small sample sizes and deviations of quantitative traits 
from multivariate normality. One thousand simulations were performed for all the 
polymorphisms. Disease duration and gender correlated with BASDAI and BASFI in 
this data set and were used as covariates in the analysis. 
2.3.5.3 Case-control analysis 
Case-control study design provides an alternative to the TDT analysis at the population 
level. Case-control studies compare the allele frequencies at loci among disease and 
control populations. The disease susceptibility mutations will exhibit statistically 
significant differences in frequency between cases and controls. The statistical 
significance of the case-control analysis is assessed by the chi-squared test, which 
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compares the observed numbers in each of the four categories in the contingency table 
with the numbers to be expected (table 2.1). 
Table 2.1 Observed a) and expected b) number of alleles in a 2 x 2 contingency table. 
a) 
OBSERVED DISEASE + DISEASE -
b) 
MARKER + 
MARKER-
A 
B 
A+B 
C 
D 
C+D 
EXPECTED DISEASE + DISEASE -
MARKER + ((A+C)/(A+B+C+D))*(A+B) ((A+C)/(A+B+C+D))*(C+D) 
MARKER - ((B+D)/(A+B+C+D))*(A+B) ((B+D)/(A+B+C+D))*(C+D) 
A+C 
B+D 
A+B+C+D 
Chi -squared test = L (observed - expected)2 
expected 
with 1 degree of freedom. 
The relative risk (RR) of disease in marker carriers compared with non-carriers was 
calculated as follows. 
RR= AI(A+C) 
B/(B+D) 
The odds ratio (OR) was calculated by the cross-product ratio (Kirkwood 1988). 
OR=AD/BC. In the HLA case-control study, the Haldane's modification ofWoolfs 
method was used to calculate the OR as this method avoids problems when entries are 
zeros (Svejgaard and Ryder 1994). 
OR = (A + 12)(D + 12) 
(B + 12)(C + 12) 
X6 
2.3.6 Linkage disequilibrium calculation 
The pairwise LD between the SNPs was calculated using the Lewontin' s standardised 
disequilibrium coefficient D' (Lewontin 1988). D quantifies disequilibrium as the 
difference between the observed frequency of a two-locus haplotype and the frequency 
it would be expected to show if the alleles were segregating at random. If fAB 
represents the observed frequency of gamete AB, and fA and fB represent the 
frequencies of alleles A and B, the LD is calculated as follows: 
DAB = fAB - fAX fB 
This statistic is strongly influenced by the magnitude of fA and fB independently of the 
effects ofLD. To overcome this bias, normalised statistic was used D': 
D' = DAB / Dmax where 
Dmax = min [fAfB,(1-fA)(1-fB)] when Dmax<O or 
Dmax = min [fA(1-fB),(1-fA)fB] when Dmax>O 
This statistic measures the magnitude of LD on a scale from -1 to 1 and is less 
dependent on allele frequencies than the non-standardised formula. The statistical 
significance of the finding was assessed using the chi-squared test. 
Pairwise tests of LD were performed using the HAPLOXT program, which uses 
definitions that have been expanded to allow for testing of multiallelic markers 
(Abecasis and Cookson 2000). HAPLOXT program uses Hedrick's modification of 
Lewontin's standardised disequilibrium coefficient D' (Hedrick 1987), which uses the 
absolute values of LD and thus the range of LD values fluctuates between 0 and 1. A 
graphical summary of the LD was produced using the software package GOLD 
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(Abecasis and Cookson 2000), which provides graphical output of both the LD 
measured as D' and the associated p-values. 
2.3.7 Power calculation 
The power of the TDT was determined using TDT Power Calculator as described (Chen 
and Deng 2001). This program does not allow for missing parents in the data, and thus 
in this study gives an overestimate of the actual power. Risch and Merikangas 
demonstrated that TDT has much more power than linkage using affected sibling pairs 
even if much more stringent type I error is applied to TDT assuming 100% LD between 
the marker and the disease associated allele (Risch and Merikangas 1996). Factors that 
influence power of the TDT study are disease allele frequencies, family structure, 
sample size, LD between the marker allele and the disease locus, penetrance of the 
disease, mode of inheritance, disease prevalence and type I error rate. 
The power of the case-control studies was determined by the Genetic Power Calculator 
(http://statgen.iop.kcl.ac.ukigpc/)(Purcelletal.2003).Itis a website for performing 
power calculations for the design of linkage and association genetic mapping studies of 
complex traits. It implements variance components equations and others for power 
calculations. For tests of association, Genetic Power Calculator uses the variance 
components test described by Fulker (Fulker et al. 1999). 
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2.3.8 Entropy maximization 
The program Entropy was used to measure the haplotypic diversity of the SNPs used 
www.well.ox.ac.uk/~rmottlSNPS]. Entropy (E) was defined as 
K 
E = -L Pi log2 Pi 
i=l 
and Pi = fi/2n 
in which fi is the frequency of the ith haplotype, n is the number of individuals 
genotyped and K is the number of unique haplotypes in the sample. Entropy can be 
used for haplotype tagging, the process of selecting a subset of SNPs that best 
approximate the haplotypic diversity in the population. Haplotypes constructed using 
SNPs and the haplotype population frequencies are used as an input for Entropy. 
2.3.9 PipMaker program 
The program PipMaker (http://bio.cse.psu.edulpipmaker/) was used to compare the 
coding and non-coding sequences between human and mouse (Schwartz et al. 2000). 
PipMaker is a website for comparing two long DNA sequences to identify conserved 
segments. PipMaker produces a percent identity plot (Pip), which shows both the 
position in one sequence and the degree of similarity for each aligning segment 
between the two species. It also provides a plot of the position of each aligning 
segment in both species. PipMaker requires two sequence files to be compared and a 
file containing the positions of known or predicted exons so that the exons can be 
marked in the pip. RepeatMasker (Smit, AFA & Green, P, 
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http://fip.genome.washington.eduJRM/RepeatMasker.html) is used to generate the 
coordinates of interspersed repeats in the first sequence in order to avoid uninformative 
and time-consuming alignments among repeats. For the pip the program plots the 
position and percent identity of each gap-free segment of the alignments. The top 
horizontal axis is automatically annotated with the positions from the repeats and 
exons. The positions of the epG islands are also computed and displayed along the top 
aXIs. 
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CHAPTER 3 - THE EFFECT OF TRANSFORMING GROWTH FACTOR ~1 
GENE POL YMORPHISMS IN AS 
This chapter presents the results of a study designed to determine whether genetic 
polymorphisms in or near the transforming growth factor ~1 (TGFB1, OMIM reference 
number 190180) locus are associated with susceptibility to, or severity of, AS. The 
theories behind association and linkage analysis and haplotype reconstruction are 
presented in chapters 1 and 2. 
3.1 INTRODUCTION 
AS exhibits a strong genetic component determining both susceptibility to and severity 
of the disease; except for HLA-B27, the genes responsible have not been definitely 
identified (Brown et al. 1997b; Hamersma et al. 2001). Non-MHC genes are estimated 
to account for at least half of the genetic variance of AS susceptibility (Brown et al. 
2000b). The male:female ratio for AS is 2.5:1 - 5:1 (Kennedy et al. 1993), but the 
gender bias is not explained by the linkage to the X chromosome (Hoyle et al. 2000). 
The gene (TGFBl) for transforming growth factor (TGF) ~1 is located on chromosome 
19q 13 .2, where suggested evidence of linkage was reported in both the whole genome 
screen previously performed by Laval et al (Laval et al. 2001) and the North American 
Spondylitis Consortium genome screen (Reveille 2002). The peak of linkage on 
chromosome 19 was observed with the marker D 19S420 (LOD score 3.58) (Laval et al. 
2001), which is located 1.8 Mb from the TGFBl gene. Strong evidence oflinkage to 
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chromosome 19 was also identified in a genome-wide scan of IBD (Rioux et al. 2000), 
a disease that is clinically associated with spondyloarthritis. 
3.1.1 TGF-~1 cytokine family 
TGF -~ 1 is a multifunctional cytokine that is capable of inducing a spectrum of cellular 
events including cell proliferation, cell cycle arrest, differentiation, matrix deposition, 
immune response and programmed cell death (Kaartinen and Warburton 2003). TGF-
~ 1 was initially identified by its ability to reversibly induce phenotypic transformation 
of fibroblast cell lines (Roberts et al. 1981). It belongs to a large family of secreted 
growth factors, called TGF-~ superfamily, which contains different TGF-~ isoforms, 
inhibins/activins, bone morphogenetic proteins and several other secreted factors. 
Mammalian species express three distinct isoforms ofTGF-~, TGF-~1, -~2 and -~3, 
encoded by unique genes located on different chromosomes (human chromosomes 
19q13, 1q41 and 14q24, respectively). Each isoform is expressed in both a tissue-
specific and a developmentally regulated fashion (Blobe et al. 2000). TGF -~ 1 is the 
predominant isofonn in most cells and tissues. TGF -~ 1 is most abundant in platelets, 
bone and spleen. It is also present in the circulation covalently bound to U2-
macroglobulin suggesting an endocrine function of this isofonn. In addition significant 
quantities ofTGF-~1 are sequestered in extracellular matrix. TGF-~2 is mostly present 
in fluids such as the aqueous and vitreous humours of the eye and amniotic fluid. 
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3.1.2 Structure and polymorphisms of TGFBl gene 
The structure of the TGFBl gene has been characterised and is presented schematically 
in figure 3.1. The TGFBl gene consists of seven exons encompassing 23.5 kb. The 
genomic region around the TGFBl gene is presented in figure 3.2. 
Figure 3.1 Position ofthe TGFBl gene on chromosome 19 and diagram of the TGFBllocus drawn 
to scale. 
The yellow boxes illustrate seven exons of the gene (numbered in blue) and the arrows point to the 
location of the five polymorphisms genotyped in this study within and in the promoter region of the 
TGFB 1 gene. The figure of chromosome 19 was obtained from the Ensembl webserver at 
www.ensembl.org. 
Chr 19 13 . 3 3. 33 
TGFBllocus 
-800 G>A 
1627 C>T 
2 3 45 6 7 
5 kb 
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Figure 3.2 Genomic region around the TGFB 1 gene. 
The fi gure was obtained from the Ensembl webserver at www.ensembl.org. 
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Three SNPs in the promoter region, one insertionldeletion in the 5' untranslated region , 
two SNPs in the signal peptide sequence, one SNP in the intron 4 and one SNP in the 
exon 5 have been identified previously (Cambien et a1. 1996; Langdahl et a1. 1997) 
(figure 3.1). Polymorphisms in the signal peptide sequence and in exon 5 are all 
nonsynonymous. Polymorphisms at positions 868 T>C and 913 G>C (reference 
sequence: ENST00000221930) in the signal protein sequence of the TGFBl gene 
change codon 10 (Leul0Pro) and codon 25 (Arg25Pro) , respectively, and the 
polymorphism in exon 5 at position 1627 C>T changes the codon 263 (Thr263Ile). 
TGF-~ 1 is made as a larger precursor of 390 amino acids , which contains an N-terminal 
signal peptide, a long pro segment called latency-associated polypeptide (LAP) and a 
II2-amino-acid C-terminal polypeptide that constitutes the mature TG F -~ 1 monomer 
(Derynck and Choy 1998). TGF -~ 1 is processed in the Golgi apparatus, where it is 
gl ycosylated, signal peptide is cleaved and dimers are formed. LAP remains associated 
non-covalently with the C-terminal fragment to form a latent molecule, which is unab le 
to bind to receptors. Most cell s secrete TGF - ~ I in the form of large latent complexes 
containing additional proteins that assoc iate with LAP. These additional proteins are 
called latent TGF-~-binding proteins (LTBPs). They are covalently linked to LAP by 
disulfide bonds (figure 3.3). Thus far four LTBP genes have been identified: LTBP 1, 
LTBP2, LTBP3 and LTBP4 on 2p22-24, 14q22-q33, l1q12 and 19q13 respectively 
(Oklu and Hesketh 2000). Recently, it has been demonstrated that fibrillin-l, the 
protein that is defective in Marfan syndrome, has a key role in regulating TGF-~ 
activation (Neptune et al. 2003). This finding supports the paradigm that structural 
matrix elements can also serve crucial regulatory roles in cytokine activation and 
signalling and perturbation of this process can contribute to disease pathogenesis. 
Mature TGF-~1 monomer is cleaved from the remaining precursor segment by a furin-
like protease (Dubois et al. 1995). Biologically active forms ofTGF-~s exist mainly as 
25 kDa homodimers. Heterodimers between TGF -~ 1 and TGF -~2 have been isolated 
(Cheifetz et al. 1987), but their biologic relevance is unclear. 
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Figure 3.3 The structure of TGF-~ latent complexes. 
Small latent TGF-~ consists of a mature TGF-~ homodimer associated non-cova lentl y with a LAP 
homodimer. The large latent TGF-~ complex contains an additional protein, L TBP, whi ch is cova lentl y 
linked to LAP by disulfide binds . The figure is modified after (Oklu and Hesketh 2000). 
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The signal peptide is involved in the translocation of newly synthesised TGF-~1 across 
the endoplasmic reticulum and consists of a positively charged N-terminal region, a 
central hydrophobic core and a polar C-terminal region (Randall and Hardy 1989). 
Changes to the amino acid composition of the peptide could affect its polarity or 
structure and lead to different rates of protein export. Leu10Pro and Arg25Pro 
polymorphisms are located in the hydrophobic core of the signal sequence. Both 
leucine and proline at position 10 are apolar, but proline induces 90° kinks in the chain 
whereas leucine allows different conformations. A change from the big polar amino 
acid arginine to the small apolar proline at position 25 could potentially affect 
intracellular trafficking or export efficiency of the preproprotein (Vemer and Schatz 
1988). Several TGFBl polymorphisms have been demonstrated to be associated with 
altered serum concentrations of TGF -~ 1, suggesting a functional consequence. 
Furthermore, several common inflammatory and autoimmune diseases have been 
associated with these TGFBl polymorphisms (Pulleyn et al. 2001; Crilly et al. 2002; 
Sugiura et al. 2002). 
Mutations in the TGFBl gene have also been associated with Camurati Engelmans 
disease, which is a rare sclerosing bone dysplasia inherited in an autosomal dominant 
manner (Janssens et al. 2000; Kinoshita et al. 2000). Four missense mutations 
Tyr81 His, Arg218Cys, Arg218His, Cys225Arg and a triple insertion of three leucines 
in the signal peptide 35insGCTGCTGCT have been identified. These variants may 
impair the ability of the propeptide to maintain the mature TGF -~ 1 in its inactive state. 
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3.1.3 TGF -~ receptors and signalling pathways 
TGF -~ exerts its effects by binding to specific high affinity transmembrane receptors. 
Three major receptors have been identified, designated type I, II and III TGF-~ 
receptors, and they are ubiquitously distributed. Type I and type II receptors are 
transmembrane serine-threonine kinases that interact with one another and facilitate 
each other's signalling (Massague 1998). Both type I and type II receptors are 
required, but are not always sufficient for signal transduction to occur. Granulocytes, 
macrophages and lymphocytes possess functional TGF -~ type I and II receptors but 
lack the type III receptor. Type III receptors, also called betaglycan and endoglin, do 
not appear to have an intrinsic signalling function but regulate TGF -~ access to the 
signalling receptors. Endoglin is a cell surface molecule expressed at high levels in 
endothelial cells. Mutations in endoglin and ALK1 (a member of the family of type I 
TGF -~ receptors) are responsible for an autosomal dominant vascular dysplasia, 
hereditary hemorrhagic telangiectasia type 1 and 2, respectively (McAllister et al. 1994; 
Johnson et al. 1996). Fibroblasts and other mesenchymal cells possess all three 
receptor types and are major targets of the biological activity ofTGF-~ in the regulation 
of extracellular matrix. 
The downstream signalling of TGF -~ is mediated through SMAD proteins. The term 
SMAD is derived from the founding members of this family, the Drosophila protein 
MAD (mothers against decapentaplegic) and the Caenorhabditis elegans protein SMA 
(small body size) (Massague 2000). SMADs are receptor-activated transcription 
factors that are phosphorylated in response to ligand binding. They are translocated to 
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the nucleus following phosphorylation. In the nucleus SMADs interact with DNA-
binding proteins to mediate transcriptional responses. 
3.1.4 Function ofTGF-~1 
The major effects ofTGF-~ include production of extracellular matrix, stimulation of 
chemotaxis, and regulation of growth and differentiation of mesenchymal cells. TGF-~ 
is chemoattractant for macrophages, neutrophils and lymphocytes. It can block the 
production of nitric oxide by macrophages, and both modulate the production of and 
antagonise the response of cells to inflammatory cytokines including TNF -u, IFNy and 
various interleukins. TGF-~1 can initiate and terminate tissue repair. Its sustained 
production leads to the development of tissue fibrosis (Border and Noble 1994). 
TGF-~1 is a potent regulator of the immune response and is generally 
immunosuppressive. It has profound suppressive effects on the growth of both T and B 
cells. It inhibits the differentiated function of mature B cells by suppressing expression 
of the immunoglobulins IgG and IgM, it has also been implicated in the IgA isotype 
switching. Mice with targeted disruption of the TGF-~1 gene display a phenotype that 
suggests the loss of a critical regulator of immune function. These mice develop a 
wasting syndrome accompanied by a multifocal, mixed inflammatory cell response and 
tissue necrosis, leading to organ failure and death (Shull et al. 1992). 
TGF-~ 1 has a major effect on the immunological aspects of several diseases including 
autoimmune disease where expression ofTGF-~l has been implicated both in 
suppression of primary disease and in mediating effects of tolerance (Prud'homme and 
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Piccirillo 2000). TGF-~ 1 can profoundly inhibit the differentiation of precursor cells 
into dendritic cells promoting tolerance and reducing the inflammatory response 
(Hackstein et al. 200 I). The autoimmune state may involve IFNy induced expression 
of MHC class II molecules in a variety of cells (Bottazzo et al. 1983). TGF -~ 1 
suppresses expression of class II MHC antigens induced by IFNy (Czarniecki et al. 
1988). Consequently, absence ofTGF-~l could lead to presentation of self antigens by 
inappropriate cells thereby eliciting an autoimmune response (Shull et al. 1992). Other 
diseases where TGF-~1 is likely to playa key role are carcinogenesis, parasitic 
infections and chronic inflammatory disease (Blobe et al. 2000). 
TGF -~ 1 can exert a multitude of effects in all aspects of inflammation. A major 
determinant of the actions of this cytokine is the micro-environment in which TGF -~ 1 
is found. Its effects are critically dependent on genetic background, cell type, state of 
cellular differentiation or activation, extracellular matrix, other growth factors and a 
plethora of additional coregulatory factors (Wahl 1999). 
3.1.5 TGF-~l in AS pathogenesis 
There are several lines of evidence suggesting that TGF -~ 1 may play an important 
functional role in AS pathology (Archer 1995). TGF -~ 1 plays a crucial role in 
inflammatory processes, extracellular matrix synthesis, bone remodelling and fibrosis 
and may be important in the biological pathways related to the expression of AS. TGF-
~ 1 is profibrotic and is possibly also responsible for late-stage fibrosis and ankylosis. 
TGF-~l acts in the formation and repair of cartilage and bone (Noda and Camilliere 
1989), which are the major targets of the immune response in AS. TGF-~1 promotes 
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the IgA switching in B cells. Total serum IgA is elevated in AS patients (Veys and yan 
Leare 1973), usually during the inflammatory phases of disease activity (Cowling et al. 
1980). 
Classically, T helper cells (Th) are functionally divided into two major subsets. Thl 
lymphocytes produce IF Ny and IL-2 and mediate cellular immune responses, whereas 
Th2 lymphocytes, which produce IL-4 and IL-l 0, are implicated in humoral responses 
and allergy. AS is associated with impaired Thl cytokine profile (Baeten et al. 2001). 
TGF -~ 1 can inhibit the production of, and response to, cytokines associated with both 
Thl and Th2 cells (Letterio and Roberts 1998). TGF-~1 has multiple suppressive 
actions on T cells, B cells and macrophages. Increased TGF-~1 production inhibits 
autoimmune and chronic inflammatory diseases (Prud'homme and Piccirillo 2000). In 
animal models systemic delivery of TGF -~ 1 or intramuscular injection of a plasmid 
expressing TGF-~1 inhibits acute and chronic arthritis (Chen and Wahl 1999). The 
results of a study of polymorphisms in this functional and positional candidate gene on 
the susceptibility to, and severity of, AS in English and Finnish populations are 
presented in this chapter. 
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3.2 SUBJECTS AND METHODS 
3.2.1 Families with AS 
Four hundred and thirty-seven individuals from the 170 Finnish families were available 
for study. They included 12 affected sibling pairs, 11 parent-case affected pairs and 
147 simplex families. Additionally, 1332 individuals from 212 parent-case trio families 
and 184 AS affected-sibling pair families recruited from the U.K. were used in the 
study. The affected-sibling pair families included altogether 421 patients with AS. The 
212 parent-case trios comprised 31 parent-case affected pairs and 181 simplex families. 
Both the English and Finnish patients and families have been included in previous 
studies (Laval et al. 2001; Crane et al. 2002; Goedecke et al. 2003). 
3.2.2 HLA-B27, TGFBl SNP and Microsatellite genotyping 
Five polymorphisms located in the promoter and coding region of the TGFBl gene and 
three microsatellite markers flanking the TGFBllocus were genotyped in families with 
AS. One thousand and seven individuals from 212 English and 170 Finnish families 
with AS were genotyped for all the five SNPs. Seven hundred sixty-two individuals 
from 184 multiplex families with AS were typed for the two polymorphisms in the 
promoter region of the TGFBl gene and three microsatellite markers. The SNPs -800 
G>A, -509 C>T, 868 T>C (commonly referred as 869 T>C), 913 G>C (commonly 
referred as 915 G>C) and 1627 C>T (reference sequence: ENST00000221930) were 
genotyped by PCR-SSP (see Appendix 3 for details of the primers and PCR conditions) 
(Lympany et al. 1998). Positive and negative controls were included in all the 
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reactions. The same positive controls were used in both the Finnish and the English 
data set and all ambiguous samples were repeated. HLA-B27 was detected by the 
method described by Bunce (Bunce et al. 1995). Families with HLA-B27 positive 
proband were included in the analysis. 
Three microsatellites spanning 6.4 cM around the TGFBllocus were genotyped: 
D 19S421, D 19S223 and D 19S217 (see Appendix 3 for details of the primers and peR 
conditions). The micro satellites were amplified under optimised peR conditions, and 
the peR products were separated and detected by capillary electrophoresis using an 
ABI Prism 3700 genotyper (Applied Biosystem, Warrington, UK). Products were then 
sized and manual inheritance checks performed using Genotyper version 1.1 (PE 
Biosystems) and Genescan version 2.1 (PE Biosystems). 
3.2.3 Statistical analysis 
Mendelian inheritance of markers was checked using the program GAS (version 2.0) 
[A. Young, unpublished]. The chi-square test with a 3 x 2 contingency table was used 
to examine whether the genotype frequencies were in HWE. P-values >0.05 were 
accepted as non-significant deviation from HWE. The program MAKEPED was used 
to produce a linkage format pedigree file that could be recognised by subsequent 
programs. The program DOWNFREQ was used to estimate the allele frequencies of 
the markers. MEGA2 (Mukhopadhyay et al. 1999) (version 2.3, 
http://watson.hgen.pitt.edulmega2.html) was used to convert data files into the formats 
required for further analysis programs. 
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Association between TGFBI polymorphisms and the disease susceptibility was studied 
with the TDT using the program TRANSMIT (version 2.5) (Clayton 1999). P-values 
were obtained by statistical simulation using 1000 replicates, using the robust variance 
option to assess association independent of linkage. NPL analysis was performed using 
the program GENEHUNTER-PLUS for qualitative data (Kong and Cox 1997) and 
MERLIN-REGRESS for quantitative data (Abecasis et al. 2002). Association was 
evaluated in a subset of families that showed positive NPL score. Association between 
TGFBI polymorphisms and the age of symptom onset, BASDAI and BASFI was 
assessed using the QTDT (Abecasis et al. 2000). Population stratification and total 
evidence of association were assessed using QTDT. 
TGFBI haplotypes were constructed using the PHASE program (Stephens et al. 2001). 
Mendelian inheritance ofhaplotypes was manually checked and only haplotypes which 
were constructed with a greater than 90% certainty were accepted for further analysis. 
These haplotypes were used as an input for QTDT in order to assess the association 
between TGFBI haplotypes and the age of symptom onset, BASDAI and BASFI. 
BASFI and BASDAI were correlated with disease duration and gender in this dataset 
and were treated as covariates in the analysis. The association between the 
polymorphisms and the presence of AAU, peripheral arthritis or IBD was studied using 
the chi -square test. For the interethnic comparison, the haplotypes were constructed 
using the program TRANSMIT (Clayton 1999). 
The pair-wise LD between the SNPs was calculated using the Lewontin's standardised 
disequilibrium coefficient D' (Lewontin 1988), calculated using the program 
HAPLOXT (Abecasis and Cookson 2000). The founder haplotypes estimated using the 
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program TRANSMIT were used as the input (Clayton 1999). The program Entropy 
was used to identify the subset of SNPs that best approximates the haplotypic diversity 
in the population [www.well.ox.ac.ukJ~rmott/SNPS]. The power of the study to detect 
association with susceptibility to AS was determined using TDT Power Calculator 
(Chen and Deng 2001). To determine whether the promoter polymorphisms -800 and-
509 lie in a regulatory region, the PipMaker program (http://bio.cse.psu.edulpipmaker/) 
was used to compare the mouse and human TGFBl sequences (Schwartz et al. 2000). 
Sequence homology could indicate evolutionary conserved regulatory regions. 
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3.3 RESULTS 
3.3.1 Clinical description of the families 
The clinical characteristics of the AS patients are described in the table 3.1. 
Table 3.1 Clinical description of the AS patients. 
This table includes only those patients from whom all the clinical data was available. In the English data 
set the clinical data was available from 86% of the 664 patients used in this study. In the Finnish data set 
the clinical data was available from 99% of the 193 patients used in this study. 
ENGLISH AS FINNISH AS 
BASFI ± SD 3.6 ± 2.7 3.7 ± 2.2 
BASDAI± SD 3.9 ± 2.1 5.2 ± 1.8 
AGE OF SYMPTOM ONSET ± SD 22.4 ± 7.6 26 ± 8.0 
DISEASE DURATION ± SD 22.0 ± 13 20± 10 
MALES (%) : FEMALES (%) 356 (63) : 212 (37) 127 (66) : 64 (34) 
AAU (%) 214 (38) 91 (48) 
IBD (%) 34 (6) 12 (6) 
3.3.2 Disease susceptibility results 
Transmitted and untransmitted marker and SNP haplotype frequencies estimated using 
the program TRANSMIT are given in tables 3.2 - 3.4. By within-family means, a 
marginal association was noted between the rare TGFBI 1627 T allele and AS in a 
Finnish population (4.2% vs. 5.3%, p=0.04) and in the combined data set (2.8% vs 
3.7%, p=0.03), but not in the English data set alone (1.7% vs. 1.9%, p=0.34). A 
marginal association was also noted between the promoter -800-509 haplotype 211 and 
AS in the English population (p=0.05), but this was neither significant in the Finnish 
population nor in the combined data set. No association was noted between any other 
SNP or marker haplotype and AS in either population. 
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Table 3.2 TGFBI marker untransmitted and transmitted founder allele frequencies and TDT p_ 
value. 
U ntransmi tted Transmitted 
founder founder 
Ethnic Alleles Alleles 
Marker Group Allele N % N % P-value 
Finnish 1 G 374 94 373 94 0.68 
-800 2 A 24 6 25 6 
English 1 G 1115 91 1128 92 0.06 
2 A 109 9 96 8 
Finnish 1 C 297 75 294 74 0.51 
-509 2 T 101 25 104 26 
English 1 C 905 74 901 74 0.65 
2 T 319 26 323 26 
Finnish 1 T 294 74 292 74 0.67 
868 2 C 102 26 104 26 
English 1 T 267 65 260 63 0.29 
2 C 143 35 150 37 
Finnish 1 G 378 95 381 96 0.26 
913 2 C 18 5 15 4 
English 1 G 375 91 377 92 0.7 
2 C 37 9 35 8 
Finnish 1 C 378 96 373 95 0.04 
1627 2 T 16 4 21 5 
English 1 C 406 98 404 98 0.34 
2 T 8 2 10 2 
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Table 3.3 TGFBJ SNP (-800, -509,868,913,1627) untransmitted and transmitted founder 
haplotype frequencies in the Finnish and English population. 
(Only haplotypes with the frequency> 1 % are shown.) 
I = wild type allele 
2 = rare allele 
ENGLISH 
Untransmitted founder Transmitted founder 
Haplotypes Haplotypes 
Haplotype N=4l4 % N=414 % p-value 
11111 221 53 227 55 0.39 
12211 99 24 104 25 0.41 
21111 35 8 28 7 0.7 
11221 28 7 32 8 0.35 
12212 8 2 9 2 0.44 
11211 9 2 6 1 0.23 
11121 7 2 4 1 0.21 
12111 4 1 2 0.5 0.27 
FINNISH 
Untransmitted founder Transmitted founder 
Haplotypes Haplotypes 
Haplotype N=388 % N=388 % p-value 
11111 243 63 246 63 0.62 
12211 72 19 74 19 0.63 
21111 22 6 24 6 0.65 
11221 12 3 9 2 0.29 
12212 12 3 15 4 0.26 
12111 12 3 9 2 0.24 
12112 4 1 2 0.5 0.2 
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Table 3.4 TGFBl SNP promoter (-800, -509) untransmitted and transmitted founder haplotype 
frequencies. 
ENGLISH 
Untransmitted founder Transmitted founder 
Haplotypes Haplotypes 
Haplotype N=1230 % N=1230 % p-value 
11 799 65 809 66 0.34 
12 322 26 325 26 0.73 
21 109 9 96 8 0.05 
FINNISH 
Untransmitted founder Transmitted founder 
Haplotypes Haplotypes 
Haplotype N=372 % N-372 % p-value 
11 257 69 253 68 0.45 
12 94 25 97 26 0.58 
21 20 5 22 6 0.53 
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3.3.3 NPL analysis and evaluation of association among the families showing linkage to 
the TGFBllocus 
The multipoint NPL analysis using GENEHUNTER-PLUS showed a weak evidence of 
linkage centromeric from the TGFBllocus (figure 3.4). The highest LOD score was 
obtained 2 cM centromeric from TGFBl gene between the markers D19S421 and 
D19S223, the peak LOD score being 1.3 (p=0.02) at distance 63 cM from the p_ 
telomere. Ninety-six families showed a positive NPL score, but no association was 
detected between AS and TGFBl -800 or -509 polymorphisms among these families. 
TGFBl1627 C>T polymorphism, which showed a weak association, was not 
genotyped in the subgroup of families with positive NPL score due to the LD between 
this SNP and the promoter polymorphisms. 
Figure 3.4 Multipoint non-parametric linkage results using the program GENEHUNTER-PLUS. 
TGFBJ gene lies 65 cM from the telomere of the p arm of chromosome 19. 
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3.3.4 Disease severity results 
Using the total evidence of association option within the QTDT program, association 
was noted between age of symptom onset and TGFBl polymorphisms in different 
populations. However this was not consistently observed in the three family 
collections. In the English parent-case trio families, association with age of onset was 
noted with TGFBl-509 (allele 2 associated with increased age of onset by 2.1 years, 
p=0.007) and 1627 (allele 2 associated with increased age of onset by 4.2 years, 
p=0.05). In this data set association was also noted between age of symptom onset and 
haplotypes of the promoter region variants -800/-509 (haplotype 1/1 associated with 
decreased age of onset by 1.8 years, p=0.02; haplotype 1/2 associated with increased 
age of onset by 2.1 years, p=0.007), and with haplotypes of the coding region variants 
868/913/1627 (haplotype 1/1/1 associated with decreased age of onset by 1.7 years, 
p=O.OI; haplotype 2/1/1 associated with increased age of onset by 1.8 years, p=0.03; 
haplotype 2/1/2 associated with increased age of onset by 4.9 years, p=0.03). The 
promoter region associations were not replicated in the English affected sibling pair 
families, and when all English families were analysed together, no significant 
association was noted for TGFBl -800, -509 or their haplotypes. Pooling English and 
Finnish families genotyped for the coding region polymorphisms, weak association was 
noted between TGFBl 913 (allele 1 associated with increased age of onset by 2.5 years, 
p=O.O I) and 1627 (allele 2 associated with increased age of onset by 3.2 years, p=0.02) 
variants. In the combined data set association was also noted between age of onset and 
haplotypes of coding region polymorphisms 868/913/1627 (haplotype 2/2/1 associated 
with decreased age of onset by 2.3 years, p=0.05; haplotype 2/1/2 associated with 
increased age of onset by 4.2 years, p=0.006). No significant association was observed 
1 1 1 
with age of symptom onset in the Finnish families, although the dataset was too small 
to provide adequate power to exclude a significant association, particularly of 
haplotypes. 
No effect of population stratification on these associations was noted in the dataset. No 
associations were noted between BASDAI or BASFI and any of the polymorphisms. 
No linkage was found between quantitative traits and the SNPs. No significant 
association between the polymorphisms and the presence of AAU, peripheral arthritis 
or IBD was noted in this study. 
3.3.5 Power of the study 
The power of this study was calculated for dominant, codominant and recessive 
inheritance models (table 3.5), assuming an AS prevalence of 0.1 % and type I error of 
0.05. For dominant and codominant models, the study had 80% power to detect 
association of loci with genotype relative risks of 1.4-3.1 depending on the SNP 
concerned. For recessive models, the power was poor for the TGFBI 913 and 1627 
polymorphisms (80% power for genotype relative risks of 10.2-26), but moderate for 
the other SNPs (80% power for genotype relative risks of 1.9-4.6). 
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Table 3.5 Power of the study. 
This study had a 0.80 power to detect an association with the following GRR th I s, e type error of 0.05 
and AS prevalence of 0.1 %. 
SNP DISEASE ORR 
-800 dominant 1.5 
codominant 1.8 
recessive 4.6 
-509 dominant 1.4 
codominant 1.5 
recessive 1.9 
868 dominant 1.6 
codominant 1.8 
receSSIve 2.2 
913 dominant 1.8 
codominant 2.5 
receSSIve 10.2 
1627 dominant 2.1 
codominant 3.1 
receSSIve 26.0 
3.3.6 LD and haplotype studies 
The founder allele frequencies between the Finnish and English data sets and the 
control individuals in two previously published British studies were compared (Awad et 
al. 1998; Syrris et al. 1998) (table 3.6). No significant differences in allele frequencies 
were noted between the English data set and the historic studies. The allele frequencies 
of TGFBI -800, 868 and 913 polymorphisms showed significant differences between 
the Finnish data set and the current English data set (p-values 3 x 10-3, 10-8 and 5 x 10-5, 
respectively). Significant differences were also noted between the Finnish data set and 
two historic British studies (table 3.6). 
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Of the 32 possible SNP-haplotypes, two main haplotypes accounted for 79% of all 
haplotypes (table 3.7), consistent with previous reports (Syrris et al. 1998; Tiret et al. 
2002). Eight haplotypes with a frequency of more than 1 % were identified. Significant 
differences were noted in haplotype frequencies between the Finnish and English 
population (chi-squared test of homogeneity = 107 [8 degrees of freedom], 
p-value <10-1°). 
Table 3.8 shows the D' and the corresponding p-values between the SNPs in the two 
populations. By inspection, there are significant differences in the LD patterns between 
the English and Finnish populations. Figure 3.5 demonstrates graphical overview of 
LD between the SNPs within and in the promoter region of TGFBI gene created using 
the program GOLD. 
Entropy values for different combinations of SNPs are given in figure 3.6. The two 
promoter SNPs and the TGFBI 868 T>C polymorphism account for 85% and 87% of 
the total diversity observed for all five SNPs in the Finnish and English populations 
respectively. 
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Table 3.6 Allele frequencies in this study and in two previously published British studies (above) 
and comparison between the studies (below). 
Allele frequencies 
Author This study This study Syrris et al. Awad et al. 
Population UK Finland UK UK 
alleles (%) alleles (%) alleles (%) alleles (%) 
-800 1 G 2388 (90) 810 (94) 450 (92) 185 (89) 
2 A 256 (10) 54 (6) 38 (8) 23 (11) 
-509 1 C 1972 (75) 652 (76) 345 (70) 158 (76) 
2 T 672 (25) 210 (24) 143 (30) 50 (24) 
868 1 T 727 (65) 660 (77) 313 (64) 139 (65) 
2 C 395 (35) 200 (23) 175 (36) 75 (35) 
913 1 G 1022 (92) 829 (96) 458 (93) 193 (90) 
2 C 94 (8) 33 (4) 30 (7) 21 (10) 
1627 1 C 1114 (98) 839 (97) 481 (98) ND 
2 T 24 (2) 25 (3) 7 (2) ND 
ND = not detenmned 
Comparison between the studies and corresponding p-values 
Two This study- This study- This study- This study- This study-
studies UK data UK data Finnish data UK data Finnish data 
This study-
compared Syrris et at. Syrris et at. Awad et al. Awad et al. 
Finnish data 
p-value p-value p-value p-value p-value 
-800 0.0026 0.22 0.33 0.60 0.024 
-509 0.57 0.08 0.05 0.72 0.99 
868 1.2xl O-~ 0.84 9.6xl0- ' 0.97 5.6xl0-4 
913 5.3xl0) 0.14 0.07 0.60 6.4x 10-4 
1627 0.33 0.48 0.13 ND ND 
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Table 3.7 Localisation of SNPs and identification of haplotypes of the TGFBI gene. 
Haplotypes with a frequency greater than 1 % are shown. [There were 2598 haplotypes in the English 
cohort and 858 haplotypes in the Finnish cohort]. 
Nucleotide: -800 -509 868 913 1627 Frequency Frequency 
Alleles: G>A C>T T>C G>C C>T N(%) N (%) 
Haplotype English Finnish 
1 G C T G C 1351 (52) 532 (62) 
2 G T C G C 650 (25) 154 (18) 
3 A C T G C 208 (8) 51 (6) 
4 G C C C C 182 (7) 26 (3) 
5 G C C G C 52 (2) 5 (0.6) 
6 G T T G C 26 (1) 34 (4) 
7 G T C G T 52 (2) 26 (3) 
8 G C T C C 26 (1) 9 (1) 
9 G T T G T 0 9 (1) 
codon codon codon 
Location: 5' 5' 10 25 263 
Amino 
acid LeuIPro ArglPro Thr/Pro 
change 
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Table 3.8 LD values between the SNPs in the Finnish and English population. 
The table shows Lewontin's standardised disequilibrium coefficient D' (p-value). AlI calculations are 
based on 1 degree of freedom. 
Ethnic 
Polymorphism Group -509 C>T 868 T>C 913 G>C 1627 C>T 
-800 G>A Finnish 0.88 (0.002) 0.88 (0.002) 0.41 (0.6) 0.39 (0.6) 
English 0.79 (0) 0.87 (0) 1 (0.007) 1 (0.2) 
-509 C>T Finnish 0.64 (0) 0.74 (0.02) 0.76 (0) 
English 0.77 (0) 0.63 (0.0008) 0.73 (0) 
868 T>C Finnish 0.58 (0) 0.46 (0) 
English 0.64 (0) 0.69 (0.0002) 
913 G>C Finnish 0.3 (0.7) 
English 1 (0.2) 
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Figure 3.5 Graphical representation of LD between the SNPs in the TGFBI gene region (above) 
and the corresponding p-values (below). 
The LD is described by Lewontin's standardized disequilibrium coefficient D ' , which measures the pair-
wise LD between the SNPs. The figure presents the graphical overview of the patterns of di sequilibrium 
in the TGFBl region and their relationship to the underlying physical map. Founder haplotype estimates 
were used as an input. The horizontal and vertical axes are scaled according to physical di stances 
between markers. For each marker pair mj and mj, the pair-wise di sequilibrium stati stics are colour coded 
(bright red and dark blue are opposite ends of the scale) and plotted at position [x, y] = [pos(mj), pos(m
J
) ] , 
where pos denotes the marker locations on the physical map. 
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Figure 3.6 Values of entropy in the Finnish and English datasets. 
The values are given for the following SNPs: 
1= 868 T>C 
2 = 868 T>C and -509 C>T 
3 = 868 T>C,-509 C>T and -800 G>A 
4 = 868 T>C, -509 C>T, -800 G>A and 913 G>C 
5 = 868 T>C, -509 C>T, -800 G>A, 913 G>C and 1627 C>T 
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3.3.7 Comparison of the human TGFBJ sequence with mouse TgfbJ 
Sequence alignment between human and mouse is demonstrated in figure 3.7 (reference 
number of the Ensembl mouse TgfbJ gene is ENSMUSG00000002603). The longest 
20 homologous segments are represented in table 3.9. All TGFBJ exons are conserved, 
and segments of sequence homology were noted in the promoter region and in the first 
intron. CpG islands were noted in the 5' region of the gene. 
Table 3.9 The longest 20 homologous portions noted by the PipMaker program. 
Segments % of homology Le~th in bp Position Position in bp* 
1 88% 423 Exon 1 800-1222 
2 83% 284 Promoter region -862-(-1145) 
3 89% 193 Exon6 21583-21775 
4 91% 190 Exon 7 22663-22852 
5 73% 190 Exon3 8951-9140 
6 73% 189 Exon2 5426-5614 
7 81% 168 Exon 5 11850-12017 
8 85% 110 Exon 1 396-505 
9 77% 106 Exon 1 252-357 
10 83% 100 Exon 1 78-177 
11 82% 98 Intron 1 1224-1321 
12 80% 92 Exon4 11627-11718 
13 84% 92 Promoter region -1917-(-3020) 
14 66% 80 Promoter region -1303-(-1382) 
15 57% 79 Intron 5 21199-21277 
16 82% 79 Promoter region -209-( -287) 
17 72% 74 Intron 1 2991-3064 
18 70% 69 Intron 1 2453-2521 
19 84% 69 Intron 1 2311-2379 
20 67% 66 Intron 1 1963-2028 
*Transcription start SIte IS denoted as O. 
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Figure 3.7 Percent identity plot (following page) of the TGFBI genomic sequences between human 
and mouse by using the PipMaker program. 
The human genomic sequences are shown on the x-axis and the percentage sequence identities (50-
100%) are shown on the y-axis. Seven TGFBJ exons are illustrated at the top of the sequences by solid 
black boxes and numbered 1-7. The arrow above the pip indicates the orientation of the TGFBJ gene. 
The location of the polymorphisms genotyped in this study is indicated. The repeats of human sequence 
are depicted as follows: (black triangles) MIRs; (light gray triangles) SINEs other than MIRs; (light gray 
boxes) LINE Is; (black boxes) LINE2; (dark gray boxes) LTRs; (dark gray triangles) other repeats; 
(white boxes) simple repeats. Short dark gray boxes are CpG islands where the ratio ofCpG/GpC 
exceeds 0.75 and short white boxes are CpG islands where the ratio ofCpG/GpC is between 0.60 and 
0.75. 
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3.4 DISCUSSION 
TGFBl is an attractive positional and functional candidate gene in AS due to its 
position under the chromosome 19 linkage peak and involvement in inflammatory 
processes, tissue fibrosis and bone remodelling. Suggestive linkage of AS to 
chromosome 19 was identified in a whole genome screen (Laval et al. 2001), the 
maximum overall LOD score detected being 3.5. A recent North American Spondylitis 
Consortium genome screen in AS also detected linkage on chromosome 19 giving 
further evidence that genes on chromosome 19 are involved in AS (Reveille 2002). A 
genome-wide screen in IBD has identified strong linkage to chromosome 19 (Rioux et 
al. 2000), which may be a relevant finding in AS pathology as subclinical ileitis is 
found in 49% of patients with AS (Leirisalo-Repo et al. 1994) and these diseases may 
share common underlying predisposing genes. This study noted a weak association 
between the rare TGFBl 1627 T allele and susceptibility to, and age of symptom onset 
of, AS. A significant association between the TGFBl -800-509 haplotype 211 and 
disease susceptibility was noted in the English population, but this was not significant 
in the Finnish population. However the lack of association of TGFBl promoter 
polymorphisms, which are in LD with the TGFBl 1627 alleles, with AS in families 
with positive NPL scores at the locus indicates that these polymorphisms do not explain 
the observed linkage of disease susceptibility to chromosome 19. It should be noted 
that the p-values reported here are not corrected for the multiple comparisons involved, 
as the number of independent comparisons would be difficult to determine. However 
the positive p-values reported would not be significant if such correction was 
employed, and these findings will require further confirmation. 
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Polymorphisms in TGFBl have been implicated in a variety of musculoskeletal 
diseases including rheumatoid arthritis (Sugiura et al. 2002), systemic sclerosis (Crilly 
et al. 2002) and osteoporosis (Langdahl et al. 1997; Yamada et al. 1998). An 
association between TGFBl 868 CC genotype and both the ossification of the posterior 
longitudinal ligament (OPLL) in the cervical spine and spinal osteophytosis has been 
reported in Japanese patients (Yamada et al. 2000; Kamiya et al. 2001). OPLL 
demonstrates ectopic ossification of the spinal ligaments very similar to that of AS 
(Mori et al. 2003). The prevalence ofOPLL in AS has been reported to be 15% and 
seems to be associated with variables identifying more severe axial disease (Ramos-
Remus et al. 1998). No association between IBD or Crohn's disease and TGFBl 
polymorphisms was found in previous studies (Garcia-Gonzalez et al. 2000; Schulte et 
al. 2001). A recent study from Scotland reported an association between TGFBl 913 
polymorphism and AS and demonstrated an association of the CC genotype with higher 
serum concentrations ofTGF-~1 (McGarry et al. 2001a). A weak association between 
age of symptom onset and this polymorphism was noted in both the combined and in 
the Finnish dataset. These findings show that this TGFBl polymorphism may playa 
role in AS, though a very weak one. This study failed to replicate the association with 
TGFBl 913 polymorphism and AS susceptibility. Marked differences in LD patterns 
were noted between the two populations. It is possible that the difference between the 
observations in the English and Finnish populations reported here and the difference 
between these results and those previously reported in a Scottish population may reflect 
differential association with a further truly associated polymorphism. 
In searching for disease genes for complex traits, it has been suggested that substantial 
advantage can be obtained by gaining access to multiple populations with divergent 
demographic histories (Varilo et al. 2003). This study of TGFBl polymorphisms was 
in a Finnish and English population, both of Caucasian origin and with well-
characterized population histories. Marked differences in allele and haplotype 
frequencies, disease associations and LD pattern were noted between these two 
populations. The results suggest that these populations have distinct population 
histories and that different TGFBl haplotypes have been traded differently by genetic 
drift. Previous studies have demonstrated that disequilibrium levels are not 
substantially greater in the general Finnish population than in the UK population (Eaves 
et al. 2000; Taillon-Miller et al. 2000). However, these two previous studies were 
limited to two chromosomal regions. LD varies considerably across the genome and 
further studies are required to confirm this observed pattern genome-wide. This is the 
first study to investigate the disequilibrium between a Finnish and English population at 
the TGFBllocus. Additionally, small LD differences, such as those observed in this 
study, especially within genes, may be relevant to the location of the causative disease-
associated variants. 
Haplotypic analysis is usually more powerful than studying individual polymorphisms 
in LD mapping, and haplotype-based methods have recently contributed to the 
identification of genes for complex diseases (Hugot et al. 2001; Ogura et al. 2001; 
Rioux et al. 2001). During the last decades haplotype-based analyses have successfully 
been used in the HLA genetics (Tuomilehto-Wolf et al. 1989; lawaheer et al. 2002). 
This study used all the common variants within the TGFBllocus to construct 
haplotypes within this region. There were two haplotypes that accounted for 79% of 
the total number ofhaplotypes in this data set. This conservation ofhaplotypes may be 
attributable to the study design which only included Caucasians, or it may suggest that 
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selective pressure acts on this functionally important locus. The occurrence of a few 
common haplotypes may also reflect the genome-wide pattern of haplotype blocks, 
where areas of conserved common haplotypes are separated by 'hot spots' of 
recombination and a breakdown ofLD. Recently, the HapMap of chromosome 19 has 
been published (Phillips et a1. 2003). Approximately one-third of this chromosome is 
contained in haplotype blocks (Phillips et a1. 2003). The TGFBI region of the HapMap 
was inspected, but no haplotype block was reported in this region. However, the 
marker density employed has a strong impact on the ability to detect small haplotype 
blocks. The marker density of the HapMap in the TGFBI region was low and the study 
may have failed to detect small haplotype blocks in this region. 
The diversity of this locus was assessed using the program Entropy. The promoter 
polymorphisms and the TGFBI 868 T>C variant account for most of diversity and a 
relatively small increase in diversity is added by the rare variants TGFBI 913 G>C and 
1627 C>T. The promoter polymorphisms and the TGFBI 868 T>C variant could be 
used as haplotype tagging SNPs (htSNP) in the TGFBI region in future association 
studies of common complex disease, where underlying disease causing variants are 
likely to be of relatively high frequency. The recently identified haplotype structure in 
the human genome has incited a lot of effort to characterize htSNPs in candidate 
regions genome-wide (Daly et a1. 2001; Johnson et a1. 2001). These htSNPs could 
reduce genotyping in future LD mapping projects. 
In vivo, TGF-~1 acts in combination with other peptide growth regulators, such as 
epidermal growth factor or its homolog, transforming growth factor alpha, platelet 
derived growth factor and basic fibroblast growth factor. The synthesis, secretion, 
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activation and tissue specific expression of TGF -~ 1 are tightly regulated processes. 
Genes in the same biochemical pathways may interact and their net effect may confer 
the phenotype. Understanding of the role ofTGF-~1 in disease pathogenesis requires 
dissection of these interactions and regulation ofTGF-~l. TGF-~ isoforms such as 
TGF-~2 or TGF-~3, and other related molecules such as TGF-~ receptors, LTBPs or 
other regulatory molecules may playa role in the pathology of AS. The genes for 
LTBP4 andfibroblast growth/actor 22 precursor are located on chromosome 19 
(l9q13.2 and 19p13.3, respectively) and are potentially interesting positional candidate 
genes for AS. The TGF-fJ type III receptor gene, betaglycan, contains several 
polymorphisms (Zippert et al. 2000) which have the potential to affect TGF-~ 
signalling. TGF -~2 mRNA has been detected in biopsy specimens from sacroiliac 
joints of patients with AS suggesting that TGF-~2 may play an active role in sacroiliitis 
(Braun et al. 1995). TGF -~2 is abundantly present in anterior chamber of the eye and 
could potentially be involved in the pathogenesis of AAU (Murray et al. 1999). It is 
also likely that as yet unknown gene-gene interactions or gene-environment interactions 
playa significant role in AS pathology. 
Genetic studies of AS are confounded by genetic heterogeneity, uncertainty of the 
underlying disease model, incomplete penetrance and epistasis. When a number of 
genes are acting multiplicatively, the individual gene effects are likely to be modest and 
large sample sizes are required to capture the small effects. Animal models suggest that 
the potency of many susceptibility alleles is strongly dependent on the genomic context, 
as a result of other susceptibility alleles and suppressive modifiers (Wanstrat and 
Wakeland 2001). In the current study the genetic homogeneity was increased by 
including only the families where the proband carried the HLA-B27 antigen in the 
analysis. A considerable number of families in two ethnically different populations 
were genotyped in order to increase the likelihood of detecting a true effect. For 
dominant and codominant models, the study had a relatively good power, and an 
association of loci with genotype relative risks of 1.4-3.1 could be detected. For 
recessive disease model and rare alleles, the power was poor. Because the TGFBl 
polymorphisms are located either within the coding region of the gene or in the 
promoter region and are likely to have functional consequences, power calculations 
were performed assuming that these polymorphisms would either be the actual disease-
causing variants or in complete LD with them. The LD pattern around TGFBl gene is 
unknown making it difficult to predict the power of this study to detect genetic 
elements around the TGFBllocus. 
Seven common SNPs and one insertion/deletion have been described within the coding 
region or in the promoter region of TGFBl gene. All the known polymorphisms in the 
TGFBl gene except the -988 C>A, +72 insertion and 713-8delC were genotyped in this 
study (Langdahl et al. 1997). The TGFBl +72 insertion was not included in the study 
as it exhibits almost complete LD with the TGFBl 913 polymorphisms (Cambien et al. 
1996). The TGFBl -988 C>A and 713-8de1C were excluded because their low 
frequency would make the current sample size inadequate to achieve required power 
(Chen and Deng 2001), and because their low frequency would make it unlikely that 
they contribute significantly to the observed linkage in AS. In an association study it is 
crucial to investigate several nearby polymorphic markers, since a disease locus may be 
in disequilibrium with some but not all the markers in its vicinity. 
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TGFBI sequence is highly conserved between different species. There is 90% 
sequence homology between human, M musculus and R. norvegius Tgfbl. There is 
also sequence homology between the TGFB isoforms, human TGFB2 has 45% and 
TGFB3 has 46% sequence homology with human TGFBI. Comparison of sequences 
from species that diverged as long as 100-300 million years ago, such as human and 
mouse, can be a powerful tool to identify gene-regulatory elements and protein-coding 
segments. Such comparisons contribute to understanding the mechanisms and history 
of genome evolution and determining the similarities and differences in gene 
organisation between the species of interest (Schwartz et al. 2000). Coding regions and 
noncoding regulatory regions are under selective pressure, and thus they are likely to be 
highly conserved between the species. Noncoding cis regulatory sequences playa 
central role in controlling gene expression and inter-species genomic sequence 
comparisons serve as a rapid and accurate means for identifying such noncoding 
regulatory elements. Functional characteristics of conserved noncoding sequences in 
the IL-4/IL-5/IL-13 cytokine cluster have demonstrated that sequence conservation is a 
good predictor of regulatory elements (Loots et al. 2000). 
The sequence homology of the TGFBI genomic sequences between human and mouse 
was assessed using the program Pipmaker. As predicted, all the exons of the TGFBI 
gene were highly conserved. Segments of sequence homology were also noted in the 
promoter region and the first intron of the TGFBI gene, suggesting that these sequences 
may playa role in the regulation of the TGFBI expression. However, no conserved 
segment was noted in the region, where the promoter SNPs (TGFBI -800 G>A and-
509 C>T) were located. Thus, this analysis does not support the role of these sequences 
in gene regulation. 
Genes that are located within a few cM of the TGFBllocus and could be positional 
candidates in AS include LTBP4 and several cytochrome P450 genes. LTBP4 lies 70.1 
kb centromerically from TGFBI gene and immunoblot analysis of fibroblast cultures 
show that it binds in a covalent complex with TGF -~ 1-LAP and associates with 
extracellular matrix (Saharinen et al. 1998). Northern blot analysis detected strong 
expression of an approximately 5-kb LTBP4 transcript in heart, a slightly lower 
expression in skeletal muscle and pancreas, moderate expression in placenta and lung 
and weak or no expression in brain, liver and kidney (Giltay et al. 1997). Cytochrome 
P450 genes in AS are discussed in chapter 6. IL-ll is another positional candidate 
gene on chromosome 19, it lies 15.7 cM telomerically from TGFBI gene. IL-ll has 
pleiotropic effects on multiple tissues and its gene expression can be stimulated by IL-
Ia, TGF-~l and TGF-~2 in respiratory epithelial and fibroblast cells (Du and Williams 
1997). 
Plasma concentrations of active and acid-activatable latent TGF -~ 1 are predominantly 
under genetic control (heritability estimate 0.54). The -509 C>T promoter 
polymorphism in the TGFBI gene has been shown to be significantly associated with 
higher concentrations ofTGF-~l, explaining 8.2% of the additive genetic variance in 
TGF-~1 concentrations (Grainger et al. 1999). Furthermore, the polymorphism at 
positions 868 T>C and 913 G>C in the signal protein sequence of the TGFB 1 gene, 
which change codon 10 (Leu10Pro) and codon 25 (Arg25Pro), respectively, have been 
reported to be related to variations in the production ofTGF-~1 (Awad et al. 1998; 
Yamada et al. 1998). However, it remains to be determined whether differences in the 
circulating concentration ofTGF-~1 among individuals with different TGFBI 
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genotypes affect the concentrations of the cytokine in the sacroiliac joints and entheses. 
The local effects ofTGF-~1 in AS require further elucidation. TGF-~1 may have a 
promising therapeutic potential for AS, and these findings do not exclude a key role for 
TGF-~l protein in pathogenesis of AS. 
3.5 CONCLUSION 
This study suggests that TGFBl polymorphisms playa minor role in AS, but do not 
explain the linkage of AS susceptibility to chromosome 19. 
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CHAPTER 4 - NOVEL HLA-DRBI GENOTYPING METHOD BASED ON 
MUL TIPLEX PRIMER EXTENSION REACTIONS 
This chapter describes the development of a novel HLA-DRB1 (HLA class II gene, 
OMIM reference number 142857) genotyping method based on multiplex primer 
extension reactions. The method was designed to perform high throughput HLA-DRB1 
genotyping. The advantages and limitations of the method are discussed. 
4.1 INTRODUCTION 
A semi-automated fluorescent method of genotyping HLA-DRB1 alleles HLA-
DRB 1 *01-16 by multiplex primer extension reactions was developed and validated. 
This method is based on the extension of a primer that anneals immediately adjacent to 
the SNP with fluorescent dideoxy-NTPs (minisequencing), followed by analysis on an 
ABI Prism 3700 capillary electrophoresis instrument. The validity of the method was 
confirmed by genotyping 261 individuals using both this method and PCR-SSP or 
sequencing and by demonstrating Mendelian inheritance of HLA-DRBl alleles in 
families. The method provides a rapid means of performing high throughput HLA-
DRB 1 genotyping using only one PCR reaction followed by three multiplex primer 
extension reactions. 
HLA class I and class II loci located in the human MHC region on chromosome 6p21.3 
encompass the most polymorphic set of genes in the human genome. With 328 alleles 
identified to date, HLA-DRB1 is the most polymorphic HLA class II locus. 
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Extraordinary allelic diversity of these genes is believed to be maintained by selective 
advantage against infectious disease associated with increased heterozygosity; one allele 
is better able to mediate resistance to one type of pathogen, whereas the other allele is 
better suited to defence against a different pathogen. HLA genes playa crucial role in 
immune responses and are thus important for tissue transplantation, autoimmune and 
inflammatory diseases. 
Various methods have been developed to type the polymorphisms in the HLA-class I 
and class II loci. These methods range from traditional serology to DNA based methods 
such as PCR restriction fragment length polymorphism (PCR-RFLP) (Uryu et al. 1990), 
PCR sequence-specific oligonucleotides (PCR-SSO) (Wordsworth et al. 1990) and PCR 
sequence-specific primers (PCR-SSP) (Bunce et al. 1995). Recently, various HLA-
DRBI sequencing based typing (PCR-SBT) methods have been developed to further 
increase the accuracy of the HLA genotyping and facilitate the identification of novel 
HLA-DRBl polymorphisms (Kotsch et al. 1999; Sayer et al. 2001). HLA-DRBl 
genotyping methods based on fluorescence-marked sequence-specific priming (Taqman 
assay) have been developed to increase automation and throughput (Tremmel et al. 
1999; Slateva et al. 2001). 
Rapid and accurate genotyping of polymorphisms is of significant scientific importance 
in studies of linkage and association with disease. Unravelling the genetic basis of 
complex diseases requires the genotyping of a large number of samples, which is 
facilitated by high throughput genotyping methods. The vast majority of 
polymorphisms in the HLA-DRBllocus are located within the second exon of the gene, 
which makes it amenable to the multiplex primer extension approach. Figure 4.1 
represent the structure of the HLA-DRB1 gene. The feasibility of the primer extension 
technique for HLA typing was demonstrated by Pastinen et al. for HLA-DQA 1 typing 
and HLA-DRB1 *02 sUbtyping (Pastinen et al. 1996). Here a high throughput 
genotyping method for the classic HLA-DRB1 alleles *01-16 based on mUltiplex primer 
extension reactions is described. This is achieved by the use of the commercially 
available ABI Prism® SNaPshot™ technology (Applied Biosystems, Foster City, CA, 
USA). SNaPshot™ is a mini sequencing method that is based on the single nucleotide 
extension of a primer that terminates immediately adjacent to the SNP using 
fluorescently labelled ddNTPs. 
Figure 4.1 The location and structure of the HLA-DRBI gene. 
HLA-DRBl gene is located on the short arm of chromosome 6 within the 6p21.3 region . It is part of the 
human MHC, or HLA region, and it is one of the most variable loci known in the human genome. HLA-
DRB 1 consists of six exons. The polymorphisms that characterise the vast majority of HLA-DRB I alleles 
are located within the second exon of the gene . The second exon is extremely polymorph ic and encodes 
part of the antigen-binding groove. The polymorphisms in the second exon tend to be restricted to 
specific regions of variability. These variable regions are interspersed between regions that are rel atively 
conserved between all HLA class II genes. The PCR amplification primers used in thi s method were 
designed in the conserved region of the gene flanking the hypervariable regions. The figures depicting 
the chromosome 6 and the structure of the HLA-DRBl gene were obtained from the Ensembl webserver 
at www.ensembl.org. 
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4.2 SUBJECTS AND METHODS 
4.2.1 Subjects and families 
Two hundred and sixty-one probands of Finnish families affected with AS were initially 
genotyped using direct sequencing and PCR-SSP (Bunce et al. 1995). The accuracy of 
the SNaPshot™ genotypes was assessed by regenotyping these probands by the 
SNaPshot™ protocol. The remaining family members [n=412] were genotyped using 
the SNaPshot™ protocol, and Mendelian inheritance of HLA-DRB1 alleles checked 
\ 
using the GAS version 2.0 software [A. Young, unpublished]. 
4.2.2 DNA amplification 
A 275 base pair (bp) fragment from exon 2 of all the DRB genes was amplified using 
the primers DRBforward 5' CCCCACAGCACGTTTC 3' and DRBreverse 5' 
GCCGATGCACTGTGAAGCTCTC 3'. Figure 4.2 represents positive reactions for the 
PCR (PCR product one). This PCR product was used to perform high-throughput 
genotyping of HLA-DRB1 alleles *01-14. 
The multiplex primer extension reactions performed using the PCR product one do not 
resolve the HLA-DRB1*02 subtypes, HLA-DRB1 *15 and *16. A separate PCR and 
primer extension reaction was designed and applied to some of the samples to perform 
HLA-DRB1 *15116 subtyping. This PCR reaction specifically amplified all HLA-
DRB1 *02 subtypes using a forward primer 5' CACGTTTCCTGTGGCAGCCTAAGA 
3' and the same generic DRBreverse primer (PCR product two) (Figure 4.3). 
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The amplification was performed in a 20 J.ll reaction mixture containing 40-100 ng 
DNA, 10 mM Tris-HCl (pH 8.3 at 25°C), 50 mM KCl, 1.5 mM MgCh, 50 J.lM of each 
dNTP, 0.25 J.lM of each primer and 1 unit ofTaq Gold DNA polymerase. The cycling 
conditions were as follows: 95°C for 10 min, 10 cycles of 94°C for 30 s, 60°C (-0.5°C 
per cycle) for 40 s, 72°C for 20 s, 30 cycles of 94°C for 30 s, 53°C for 40 s, 72°C for 20 
s and 72°C for 1 min. 
PCR products (5 J.ll) were separated on a 2% agarose gel stained with ethidium bromide, 
and visualised under ultraviolet light. The remaining PCR products were incubated 
with 1.5 units of SAP and 1 unit ofExo I at 3TC for at least one hour to degrade 
unincorporated primers and dNTPs, 75°C for 15 min to denature the enzyme and 4°C 
for 15 min. Reduced amount of dNTPs and primers were used in the PCR reaction in 
order to minimise the use of SAP and Exo I. 
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Figure 4.2 2% agarose gel image of PCR amplification of pan HLA-DRB genes (HLA-DRB1 and 
DRB2-9). 
l~ ____________________ ~y~ _______________________ ) r r 
patient samples 1-6 H20 100 bp ladder 
Figure 4.3 2% agarose gel image of PCR amplification of HLA-DRB1 * 1 5/ 16 alleles. 
Lane I - 100 bp ladder; Lanes 3, 6, 8 and 10 - HLA-DRB 1 * 15/16 positi ve samples ; Lanes 2, 4, 5, 7 and 9 
- HLA-DRB 1 * 15/16 negative samples 
Lanes 1 2 3 4 5 6 7 8 9 10 
4.3 RESULTS 
4.3.1 Primer optimisation 
The primers were designed using the IMGT/HLA Database as a reference sequence 
(Robinson et al. 2003). This is a specialist database for sequences of the genes within 
the MHC region and includes all the HLA sequences officially recognised and named 
by the WHO Nomenclature Committee for Factors of the HLA System. Oligo software 
version 4.0 was used to analyse the PCR and extension primers [www.oligo.net]. The 
melting temperatures of the primers varied between 49-69 °C and the primers did not 
contain stable secondary loops or 3' primer complementarity. SNP variants specified 
by the extension primers were carefully selected in order to avoid false positive 
extension from other HLA-DRBI alleles, other HLA-DRB genes (HLA-DRB3, B4 and 
B5) or sequence-related pseudogenes (HLA-DRB2, B6-B9). 
The extension primers were designed either on the sense or antisense DNA strand 
adjacent to the SNPs of interest. The primer extension reactions were perfonned in 
three multiplexes to avoid overlapping extension primers where SNPs are very close 
together. The length of the extension primers varied between 16 and 42 nucleotides so 
that the products could be separated by capillary electrophoresis. Between 16 and 27 
nucleotides of each primer was sequence specific, with poly A added to increase the 
primer length where appropriate. The extension primers in the SNaPshot™ multiplexes 
were determined in a way that multiple peaks of the same nucleotide of fluorescent dye 
did not appear next to each other when electrophoresed. The final development of 
primers included thirteen different extension primers that were optimised and validated 
for the full HLA-DRB1 typing (HLA-DRB1 *01-16). Table 4.1 describes the single 
nucleotide polymorphisms specified by the optimised set of extension primers. The 
sequence, length, melting temperature (T m) and localisation of these extension primers 
are listed in table 4.2. 
4.3.2 Primer extension reactions and demonstration of the method 
PCR product one was used for three subsequent multiplex SNaPshot™ reactions, PCR 
product two was used for a uniplex SNaPshot™ reaction. HLA-DRB1 alleles *01-14 
were genotyped from PCR product one. Three multiplex primer extension reactions 
were designed for these alleles in order to avoid overlapping extension primers where 
SNPs are very close together. The PCR product two was used to perform HLA-
DRB1*15 and HLA-DRB1 *16 subtyping in some of the samples. 
Figure 4.4 illustrates the positions of the extension primers and the polymorphisms 
specified by them. Figure 4.5 illustrates examples of positive primer extension 
reactions for the different extension primers. 
The primer extension reactions were performed in a 10 III reaction mixture containing 3 
III of the purified PCR product, 0.5 III of SNaPshot™ reaction mixture per SNP and 
0.18 IlM (for HLA-DRB1 *04, *07, *09) or 0.361lM of each extension primer. The 
primer extension cycling conditions were as follows: 25 cycles of 96°C for lOs, 50°C 
5 s, 60°C 30 s and 4 °c for 15 min. To prevent unincorporated fluorescent ddNTPs to 
co-migrate with the primer extension products during electrophoresis, the reactions 
were treated with 1 U SAP at 37°C for 1 hour followed by 15 min at 75°C and 15 min 
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at 4°C. Aliquots of3 J.lI ofSNaPshot™ product, 0.5 J.lI of GeneScan -120 LIZ Size 
Standard and 6.5 J.lI ofHi-Di formamide were combined in a 96-well Thermo-Fast® 
, 
Non-skirted plate (ABgene, Surrey, UK). The products were separated using POP5 
polymer and detected by capillary electrophoresis on an ABI Prism 3700 DNA 
Analyzer (Applied Biosystems, Warrington, UK). Products were then sized and 
analysed using Genotyper® version 3.5 (PE Biosystems). Genotypes were semi-
automatically assigned and checked manually by comparing with the positive control 
samples included in each plate. 
Whilst this method is simple and involves few reactions, there are some HLA-DRBl 
combinations which it does not fully resolve. Because the extension primers for HLA-
DRB1 *03 or HLA-DRB1 *08 alleles are not specific but also detect other alleles (see 
table 4.1), the method does not resolve the following heterozygote combinations of 
HLA-DRB1 alleles: HLA-DRB1*03111 or HLA-DRB1*11111; HLA-DRBl *03113 or 
HLA-DRB1*13113; HLA-DRB1*03114 or HLA-DRB1*14114, HLA-DRB1*08112 or 
HLA-DRB1 *12112. Similarly, because HLA-DRB1 *13 alleles and HLA-DRBl *01 
subtype HLA-DRB1 *0103 are specified by the same extension primer, number 5, the 
method does not distinguish the HLA-DRB1*0103113 genotype from those who are 
HLA-DRB1*0103 homozygotes. These ambiguous combinations occurred with 6.9% 
frequency in this data set. They are easily resolved by a single PCR reaction using 
PCR-SSP, specific either for HLA-DRB1*03, HLA-DRB1*08 or HLA-DRB1*0103 
depending on the ambiguity concerned (see (Bunce et al. 1995) and chapter 5). 
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Table 4.1 Description of the SNPs specified by the extension primers. 
The detennination of the al1ele can be deducted according to the specific nucleotide, which is extended by the 
extension primers. 
PRIMERS 
MULTIPLEX CODON* HLA·DRB1 SUBTYPES SPECIFIED BY THE EXTENSION PRIMERS I 
1 43/3 A: DRB1*010101-0109 No extension or G: all the other 
2 55/3 T: DRB 1 *09012-0902 No extension or C: all the other 
3 59/1 G: DRB1*100101-100102 No extension or C: all the other 
4 82/3 A:DRB1*070101-0707 G: all the other 
MULTIPLEX 
II 
A:DRB1*0103,0402,0414,0437,1102-
3,1111,1114,1116,1120-1,1136,1140-1,130101- C:DRB1*0106,0109,150101-9,1511- No 5 100/2 202,1304,1308,1315-7,1319-20,1322-4,1327- 3,1309,1424,1437 ,DRB5*01 06,0202-4 extension: 9,1331-2,1334-6,1338-41,1343,1345,1348,1351- all the other 
3,1416,1510 
G:DRB1 *030101-23,0820, 11010H 10402,1106- No 7,111202-1121,1123-1129,1131-43,130101-
extension or 6 41/2 1305,130701-1316,1318-1353,140101- C:DRB1*0814, A:DRB1*0821 T:all the 1403,140501-1409,1413-1414,1416-1427,1429-
other 1430,1432-1445 
7 87/2 A:DRB1*0308,0415, 110101-1143,1204,1411 C: all the other 
8 42/3 G:DRB1*150101-201, 150203, 1503-13, 160101- No extension or T:all the other 1608 
9 62/1 C:DRB1 *0401 01-0444 A: all the other 
No 
10 55/3 A:DRB1 *1201 01-1207 G:DRB1 *0101 01-01 09,100101-100102 
extension or 
C:all the 
other 
MULTIPLEX 
III 
11 45/1 T:DRB1*080101-080401,080403-0819,0821- C: all the other 24,120101-1208,1317,1404,1411,1415,1428,1431 
G:DRB1*0310,0706,0808,0811 ,1343,1345,140101-
12 86/2 2,1404,140701-2,1410,1416,1422,1425- No extension or T or A:all the other 
6,1428,1431-2,1435,1438-9,DRB3*0216 
DRB1*15/16 
13 76/2 T:DRB1*1501 01-6,1508-10,1512-13 A:DRB1*160101-08 
* The reference sequence used to detennine the codons was NM _ 002124. 
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Table 4.2 Description of the extension primers. 
PRIMER SEQUENCE 5'-3' * PRIMER ORIENTATION Tm-
CC) LOCATION 
NUMBER LENGTH EXON2-
MULTIPLEX 
I base 
1 GGCAGC~TAAGTTTGA 16 Sense 49.2 13-28 
2 TCAACGGIACGGAGCGGGTGCGGTA 25 Sense 69.5 40-64 
3 AAAAAAAAAAAACCTCTTGGTTATGGACGC 30 Antisense 61.3 76-93 
4 ~CGGGCGGTGACGGAGCT 40 Sense 66.5 129-145 
MULTIPLEX 
II 
5 GGACATCCTGGAAGACG 17 Sense 55.2 182-198 
6 AAAAAAGAAATGACACTCAGAC 22 Antisense 52.8 23-40 
7 AAATGACGGAGCTGGGGCGACCTGATG 27 Sense 69.5 136-159 
8 AAAAAAAAAAAAAAATGTGGCAGCCTAAGAG 32 Sense 60.5 10-25 
9 AAAAAAAAAAAAAAACCTGGACAGATACTTCTAT 37 Sense 60.6 65-83 
10 AAAAAAAAAAAAAAATTCAATGGGACGGAGCGGGTGCGGTT 42 Sense 69.4 39-64 
MULTIPLEX 
III 
11 AGTACTCTACGGGTGAGTGT 20 Sense 57.3 13-32 
12 AAAAAAAGCTGTTCCAGTGITCCGCA 26 Antisense 61.6 158-176 
DRB1*15/16 
13 ACAGCGAAGTGGGGGAGT 18 Sense 58.2 109-126 
* Mismatches introduced to destabilize stable secondary hairpin formations are in bold and underlined. Poly A 
tails are in italics. 
** T m of the primers was calculated without the poly A tail. 
* * * Location of the primers is given in nucleotides. The first nucleotide denotes the first nucleotide of the 
second ex on of the HLA-DRBI gene. (The ID of the Ensembl reference sequence used is 
OTTHUMT00006012178.) 
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Figure 4.4 Illustration of the positions of the extension primers and the polymorph isms specified by 
them. 
The figure demonstrates the multiplex reactions I, II and III performed using the PCR product one and 
uniplex reaction of HLA-DRB1 *15/16 using the PCR product two. In multiplexes I and II some poly A 
tails overlap, but the remaining allele specific part of the primer sequences do not overlap by more than 3 
bases. 
PCR PRODUCT ONE: 
MULTIPLEX I 
CODONS 43/3 55/3 5911 82/3 
1 11 1 
SNPS AlG TIC GIC AlG 
.... ~ ~ .... ~ 
PCR FRAGMENT 275 bp 
MUL TIPLEX II 
CODONS 4112 42/3 55/3 6211 87/2 100/2 
1 1 1 1 1 
SNPS GICIT GIT AlGIC CIA AlC AlC 
~ ~ ~ .... ~ 
~ 
PCR FRAGMENT 275 bp 
1-+-+ 
MULTIPLEX III 
CODONS 45/1 
1 
SNPS TIC 
• 
PCR PRODUCT TWO: 
UNIPLEX REACTION 
CODON 
SNP 
86/2 
r 
GITIA 
• 
PCR FRAGMENT 275 bp 
76/2 
TIC 
~ 
PCR FRAGMENT 267 bp 
Figure 4.5 The figure illustrates positive primer extension reactions for the different exten sion 
primers in multiplexes 1-3 and in the uniplex reaction of HLA-DRBl *15/ J6. 
MULTIPLEX I MUL TIPLEX II 
Primer no I - DRB I *0 I positive sample Primer no 5 - DRB 1* 13 positive sample 
20 22 24 26 2. 20 22 2' ,. 
PBQX3PAN EL lJO ' _ ' 6 2 ' sa 12 Green 167 .3 As famllymem bertxr .. ;2 2 fsa 72 Green 94~2 
~ ~= \ ~t= [@] ~ 
Primer no 2 - DRB I *09 positive sample Primer no 6 - DRB 1*03 /0811 11 12113 11 4 pos itive sample 
26 26 )0 32 34 22 24 26 28 )0 32 
As F amijy MemberboIl2 .. 8 f sa 48 Red 73-5 As l amily membeftlox2 o Isa 30 Blue 63-2 
~= U\ ~ '~ ,~ ~ I§] @TI 
Primer no 3 - DRB I * 10 positive sample Primer no 7 - DRBI *11 positi ve sampl e 
30 32 34 36 28 )0 32 ]A 
As FamiIy Memberbox2 .. ,7.l sa 27 Blue 58-2 PB0X3PANEL Z_A02_ '8 6 1sa 6 Green 188 3 
~:o V= 3~ 
~ ~ 
Primer no 4 - DRB 1* DRB I *07 positive sample Primer no 8 - DRB I *02 positi ve sampl e 
34 36 3. 40 42 44 46 48 
PB2PANEL 1JOG_ 137 7 Isa 47 Green 1373 
2. 30 32 34 36 36 ~ 6000 PB2PANELZ_A 10_ '74 g f sa69 Blue 174 3 4000 
2000 ~~ ~ 2~
@§ 
Primer no 9 - DRB I *04 positi ve sampl e 
34 36 38 40 
" 
As I am lly memberboJ 2 3fsa63Yeliow 81 -4 
6003 
'000 
2000 
~ 
Primer no 10 DRBI *12 positi ve sample 
" 
44 46 
'" 
Asfamllymem ber1)(»,2 8 Isa 68 Green 88-5 
[~ ' 003 
"-----
',n) 
[§J 
Primer no 10 DRBI *0 1/ 10 posit i\'e sample 
" 
.u 
" " 
, 
, 3. ->0 
"'-"'"-'"",,' . ,,", .. ~
h' 
[ ... 
[§J 
MU L TIPLEX III DRBl *JS/16 
Primer no II - DRB I *08112 positive sample Primer no 13 - DRBI *15 (red co lour ) and DRBI * 16 
(green colour) positi ve samples. 
2Q 22 
" 
2. 2. 
As l amlty mem t.e r tx)~2 S I s .. 75 Red .... 
~= 16 2Q 22 2' ,. '" OR2_2_BlO_24 1_3_0n lsa 77 Rea 24 1_3 ~ [: 100 
~ 
Primer no 12 - DRB I *14 positive sample OR2_2_01 0_249_3_078 I sa 78 Green 249_3 
~ ' ~ 1()() 
I ~" 26 26 30 32 ~ ASFBo~5- PaneI3_0 1 0 8.l sa 78 Blue 266_' 
t: 
[@ 
1-+ 
4.3.3 Validation 
In addition to confirming Mendelian inheritance of genotypes, the accuracy of the 
method was validated by genotyping 261 probands using both this method and 
sequencing or peR-SSP (Bunce et al. 1995), a method that is widely used for 
histocompatibility testing. Without any repetition of genotyping of individual samples, 
there were 17 allelic errors out of 522 alleles genotyped with SNaPshot™ (3.3%). All 
the errors were due to allele drop out resulting in erroneous scoring of a heterozygote 
person as a homozygote. Ten individuals resulted in a failed reaction after the first 
genotyping (success rate 97%). All the samples that failed and all the apparent 
homozygote samples were regenotyped with the SNaPshot™. After regenotyping, all 
the individuals were consistently genotyped both with the SNaPshot™ approach and the 
peR-SSP (success rate 100%). All the genotypes were consistent with the genotypes 
obtained by the previous peR-SSP and direct sequencing giving a zero overall error 
rate. 
Some of the consistently genotyped individuals were further used as positive controls in 
subsequent genotyping plates. A positive control of each of the classic HLA-DRB1 
allele *01-16 were included in each plate and the positive controls were used in manual 
checking of the semi-automatically assigned genotypes. A negative H20 control was 
included in each plate in order to check that the peR was not contaminated. 
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4.4 DISCUSSION 
The MHC region is of primary scientific importance in relation to autoimmunity and 
infection. The recently completed sequence map of the MHC and the identification of 
numerous novel genes within this region contributed to increased interest in high 
resolution MHC mapping studies (1999). High levels of polymorphism, linkage 
disequilibrium and gene clustering confound the precise mapping of contributory genes 
within the MHC (Allcock et al. 2002). Several complex diseases, such as rheumatoid 
arthritis and type 1 diabetes, exhibit allelic and locus heterogeneity within this region 
[Okamoto, 2002 #243; Lie, 1999 #242], which adds an additional layer of complexity to 
fine-mapping studies of the MHC region. Rapid high-throughput genotyping methods 
are required to facilitate the dissection of complex genetic associations within the MHC 
region. The method described here is cost-effective, rapid, accurate, sensitive, robust 
and amenable to high-throughput genotyping. It is based on a widely accessible 
technology. It is technically relatively easy to carry out and could be performed in most 
modem genetics laboratories. This study describes a novel approach for genotyping of 
HLA-DRB1 alleles HLA-DRB1 *01-14 from only one PCR product by multiplex primer 
extension reactions. It is especially suitable for disease association studies, where the 
amount of DNA is not sufficient for numerous PCR amplifications particularly if high 
resolution genotyping is not required. The method involves considerably fewer PCR 
reactions than PCR-SSP in particular, reducing the time required, DNA usage and 
expense. 
This method as described above does not perform HLA-DRB1 high resolution subtyping 
but there is no theoretical reason why primer extension methods could not be de\eloped 
1 .. l9 
for that application. Indeed a method for HLA-DRBI *02 sUbtyping using primer 
extension has been reported (Pastinen et al. 1996). High resolution HLA typing is of 
more importance for tissue typing prior to organ transplantation (Muro et al. 2002) and 
this method would require further development for these purposes. However, it is 
useful for screening of subjects for whom expensive and time consuming high 
resolution genotyping is not necessary. 
Oligonucleotides with a mismatched 3' -residue will not function as primers in the peR 
reaction under appropriate conditions (Newton et al. 1989). This principle can be 
extended to the extension primers in the primer extension reactions. This fact was 
exploited in the oligonucleotide design to ensure that some of the extension primers 
have a mismatched 3' -residue in the other HLA-DRB genes or the other HLA-DRBI 
alleles, so that they are not specified by the extension primer. This increases the 
specificity of the primer extension reaction but has the disadvantage is that there is no 
negative control peak and thus false negative allele scoring is possible. The primer 
extension reactions for all the homozygous samples were repeated in order to detect 
possible false negative scoring. 
Initial amplification of all the HLA-DRB genes can cause erroneous products on the 
primer extension reactions, interfere with the data analysis and cause background noise. 
Additionally, it greatly limits the possibilities of the extension primer design. 
Additional peaks were observed appearing in the data set. These peaks were generally 
shorter than 20 nucleotides and could be distinguished from the true alleles by 
comparing the size and height of the products with positive controls. The intensity of 
the fluorescence of the spurious peaks was generally considerably lower than that of the 
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true peaks. Positive controls for all the alleles were used in each plate. Scoring of the 
HLA-DRB1 genotypes was performed semi-automatically by the GenotyperK software 
and checked manually by comparing the location and the size of the peaks with the 
positive control samples with known HLA-DRB1 types. 
Different peak heights were observed in the multiplex SNaPshot™ reactions of primer 
extension signals for different polymorphisms and samples. Possible explanations 
include differential peR amplification of alleles, differential annealing of extension 
primers, differential efficiencies of the incorporation of the ddNTPs for each allele-
specific primer extension reaction and unequal emission energies of different 
fluorescent dyes (Norton et al. 2002). Linear relationship between primer concentration 
and primer extension signal strength has been reported (Norton et al. 2002). Manual 
comparison of peak heights between samples and positive controls were performed and 
peaks of at least 50% of the height of the positive control were accepted. All the 
positive control samples used were heterozygotes for HLA-DRB1. 
The existence of other HLA-DRB genes and sequence-related pseudogenes has made it a 
challenging task to develop accurate and sensitive HLA-DRB1 genotyping methods 
suitable for high throughput genotyping. The advantage of this approach is that it 
allows the use of only one peR reaction to amplify the classic HLA-DRB1 *01-14 
alleles. The disadvantage is that the peR primers used also amplify the other HLA-DRB 
genes (HLA-DRB3, B4 and B5) and sequence-related pseudogenes (HLA-DRB2 and B6-
B9). No polymorphisms specific for all the HLA-DRB1 alleles but not for any of the 
related HLA-DRB genes have been recognised, despite extensive sequencing ofintrons 
flanking ex on 2 (Kotsch et al. 1999). Therefore, HLA-DRB1 peR-SBT methods 
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typically employ several group-specific PCR primers to obtain a product specific for 
only HLA-DRBl alleles. This product can be subsequently sequenced to determine the 
exact subtype. A similar approach using group-specific HLA-DRBl PCR reactions prior 
to primer extension reactions may yield more accurate and specific HLA-DRBl 
genotyping results in the future. 
4.5 CONCLUSIONS 
In conclusion, this method has advantages over other HLA-DRBl genotyping methods 
in sample throughput and speed, but is not designed to replace traditional high 
resolution typing methods used in clinical settings. The alleles can be semi-
automatically assigned, which increases the sample throughput in comparison with 
PCR-SBT and PCR-SSO. The method is less time consuming than PCR-SBT. The 
main limitation of this method is its low resolution, which could be overcome by 
employing a group of HLA-DRBl specific PCR primers. Genotyping highly 
polymorphic HLA genes is of primary interest in MHC studies aiming to refine the 
genetic associations with the disease. Deciphering the genetic associations within the 
MHC in common complex genetic diseases requires large samples sizes to be genotyped 
in order to achieve adequate power. A novel way of performing high throughput HLA-
DRB 1 typing was demonstrated, which will facilitate future genetic studies within the 
MHC region. 
152 
CHAPTER 5 - THE EFFECT OF HLA GENES IN SUSCEPTIBILITY TO A:\D 
CLINICAL CHARACTERISTICS OF AS IN A FINNISH POPULATION 
This chapter presents the results of a study designed to investigate the influence of HLA-
DRB1 and HLA-B27 alleles and HLA-DRB1-B27 haplotypes in susceptibility to, and 
severity of, AS in a Finnish population. 
5.1 INTRODUCTION 
Previous studies have implicated several distinct HLA-DRB1 associations in AS, but 
only the association between HLA-DRB1 *01 and disease susceptibility has been 
reported by several groups. In a large British AS cohort, an association with HLA-
DRB1 *01 was noted with susceptibility to the disease (Brown et al. 1998a). A Mexican 
study also reported a significant increase of HLA-DRB1 *01 in cases with 
spondyloarthropathies (Vargas-Alarcon et al. 2002b). A small Azorean study reported 
an association between HLA-DRB1 *01 and HLA-B27 negative spondyloarthritis 
(p=0.0009) (Bruges Armas et al. 2000b), but not with HLA-B27 positive disease 
(Bruges Armas et al. 2000a). In contrast, no significant class II associations were found 
in a previous Finnish study (Westman et al. 1996). A recent Sardinian study reported an 
association between an HLA-DRB1 * 15-B27 haplotype and AS (La Nasa et al. 1993; 
Fiorillo et al. 2003). A French study noted that HLA-DRB1 *04 allele was transmitted in 
excess to cases with spondyloarthropathy, but this was not independent of linkage to 
HLA-B27 (Said-Nahal et al. 2002). HLA-DRB1 *04 is also associated with the 
development of radiographically evident sacroiliitis in patients with juvenile idiopathic 
arthritis (Flato et a1. 2002). 
Evidence that HLA-DRB1 alleles might modulate the clinical expression of AS comes 
from studies of AS complicated by AAU, peripheral arthritis or IBD, and from juvenile 
onset AS. An association between the HLA-DRB1 *08-DPB1 *0301 haplotype and 
juvenile AS was noted in a Norwegian population (Ploski et a1. 1995). In the Japanese, 
an association between HLA-DRB1 *08 and AS complicated by AAU has been reported 
(Monowarul Islam et a1. 1995). However, in this study the patients with history of 
AAU had a considerably lower mean age of onset than the remaining patients, 
suggesting that AAU is associated with an early onset disease (Ploski et a1. 1996). 
HLA-DRB1 *04 and *07 are reported to be associated with AS complicated by 
peripheral arthritis (Armstrong et a1. 1983; Aaron et a1. 1985; Miehle et a1. 1985; 
Sanmarti et a1. 1987). The HLA-DRB1 *01 subtype, HLA-DRB1 *0103, is associated 
with both isolated IBD and AS complicated by IBD (Stokkers et a1. 1999; Laval et a1. 
2000). 
Taken together these data suggest that either HLA class II genes themselves or genes on 
an HLA-B27-DRB1 haplotype act as susceptibility factors to AS. Alternatively, they 
may modify the clinical manifestations of the disease in the context of the genetic 
background of the population. The Finnish population has a rather restricted gene pool 
(Siren et a1. 1996), a property which may be useful in dissecting the relevant disease 
causing polymorphisms (Varilo et a1. 1996). The results ofa study of the HLA-DRBI 
and HLA-B27 alleles and haplotypes in susceptibility to, and severity of, AS in a 
Finnish population are presented in this chapter. 
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5.2 SUBJECTS AND METHODS 
5.2.1 AS families and controls 
AS families. Fifty-three sporadic AS cases and 620 individuals from 208 AS families 
were recruited to the study from the Rheumatism Foundation Hospital in Heinola, 
Finland. 
Control haplotypes. One thousand two hundred and fifty-four (lOS HLA-B27-positive) 
haplotypes of Finnish parents of children with insulin-dependent diabetes mellitus 
(IDDM) not transmitted to the diabetic offspring, nor found in siblings or parents with 
IDDM, were used as a control sample set (Tuomilehto-Wolf et al. 1989). 
5.2.2 HLA-DRBl genotyping 
HLA-DRBl genotyping was performed using either direct sequencing, the primer 
extension method developed in this laboratory or the peR-SSP approach (Bunce et al. 
1995). Positive and negative controls were used in all the reactions. One hundred and 
twenty-eight probands were genotyped using the direct sequencing method. This 
method was validated by regenotyping 44 samples previously genotyped by sequencing 
using the peR-SSP approach (Bunce et al. 1995). The rest of the probands [n=133] 
were genotyped using the peR-SSP approach. A novel HLA-DRBI genotyping method 
based on primer extension reactions was developed and is described in detail in chapter 
4. This method was validated by regenotyping all the probands previously genotyped 
by sequencing and peR-SSP using this method [n=261]. The primer extension method 
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was further used to genotype all the family members [n=412], Mendelian segregation of 
HLA-DRBl alleles was confirmed. The control samples were typed for the HLA-DRBl 
alleles *01 to *10 using serological methods by Eva Tuomilehto-Wolf and colleagues 
(Tuomilehto-Wolf et al. 1989). 
5.2.2.1 Sequence based method 
The sequence based method involved 8 group-specific PCR amplifications with the 
primers HLA-DRB1 *01 (5'CAGTGTCTTCTCAGGTGGCT), HLA-DRBI *15116 
(5'GGCCGCCTTGTGACCGGATG), HLA-DRBI *03/08111113114 
(5'GCCTCAGGAAGACAGAGGAG), HLA-DRB1 *04 
(5'CTTGGGATCAGAGGTAGATTTT), HLA-DRB 1 *07 
(5'CGGCGTCGCTGTCAGTGTT), HLA-DRB1 *09 
(5'CAGTTAAGGTTCCAGTGCCA), HLA-DRBI *10 
(5'CCCACAGCGTTCTTGGAGG) and HLA-DRBI *12 
(5' AGTGTCTTCTCAGGACGCCA) prepared in a 50:50 mix with a generic reverse 
primer with an M13-21 sequencing tag 
(5 'TGT AAAACGACGGCCAGTGCCGCTGCACTGTGAAGCTCTC). Amplification 
was performed in a 10-J.11 reaction mixture containing 50 ng DNA, 10 mM Tris-HCl pH 
8.3, 50 mM KCl, 1.5 mM MgCh (for HLA-DRB 1 *01 and HLA-
DRBI *03/08/11/13/14) or 2.5 mM MgCh, 25 J.1M of each dNTP, 0.25 U AmpliTaq 
Gold polymerase (Applied Biosystems, Warrington, UK) and 0.4 J.1M primers. The 
cycling conditions were as follows: 94°C for 14 min; 35 cycles of 94°C for 30 s, 55°C 
(for HLA-DRBI *15/16, HLA-DRBI *04 and HLA-DRBI *10) or 60°C for 30 sand 
72°C for 30s. PCR products were separated on a 3% agarose gel stained with ethidium 
1~6 
bromide, and visualised under ultraviolet light. PCR products were subsequently 
sequenced using M13-21 Big Dye dye-primer sequencing kit (Applied Biosystems) 
using following conditions: 15 cycles of 96°C for 10 s, 55°C for 5 s, 70°C for 1 min and 
15 cycles of 96°C for 10 s and 70°C for 1 min. The products were separated on 4.75% 
polyacrylamide gels using ABI 373 semiautomated sequencer (Applied Biosystem, 
Warrington, UK) and analysed using Sequencing Analysis version 3.0 and Factura 
version 2.0.1 (PE Applied Biosystems). PCR reactions were repeated at least once for 
all homozygous samples to distinguish the true homozygotes from PCR failures (allele 
drop out). 
5.2.2.2 HLA-DRB1 PCR-SSP genotyping 
Nineteen PCR reactions were used to genotype HLA-DRB1 alleles *01-16 and to 
subtype the HLA-DRB1 *01 alleles. All the primers used in the reactions are listed in 
table 5.1. Control primers amplifying a 796 bp fragment from the third intron of HLA-
DRB1 were included in the PCR reactions. PCR amplification was performed in a 15 JlI 
reaction mixture containing 60 ng DNA, 67 mM Tris-HC1, 16 mM (NH4)zS04, 2 mM 
MgCh, 200 JlM of each dNTP, 3.4 JlM of each allele-specific primer, 0.1 JlM of each 
control primers and 0.4 units ofBioline Taq polymerase. The following cycling 
conditions were used: 96°C for 1 min, 5 cycles of 96°C for 25 s, 70°C for 45 s, 72°C for 
45 s, 21 cycles of 96°C for 25 s, 6YC for 50 s, 72°C for 45 sand 4 cycles of 96°C for 
25s, 55°C for 1 min, 72°C for 2 min (Bunce et al. 1995). The products were resolved 
and visualised on ethidium bromide stained agarose gels. 
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Table 5.1 Primers used in the HLA-DRBI genotyping by peR-SSP. 
The lengths of the peR fragments are given in base pairs. 
Product 
Alleles recognized Orientation Primer sequences 5' - 3' Length 
DRB1 *01 01, 01021, 01022, 0104-6 Sense TTGTGGCAGCTTAAGTTTGAAT 194 
Antisense CCGCCTCTGCTCCAGGAG 
DRB1 *01 01, 0103, 0105 Sense TTGTGGCAGCTTAAGTTTGAAT 254 
Antisense CTGCACTGTGAAGCTCTCAC 
DRB1*01021,01022,0104,0106 Sense TTGTGGCAGCTTAAGTTTGAAT 254 
Antisense CTGCACTGTGAAGCTCTCCA 
DRB1*0103 Sense TTGTGGCAGCTTAAGTTTGAAT 195 
Antisense CCCGCTCGTCTTCCAGGAT 
DRB1*1501-9 Sense TCCTGTGGCAGCCTAAGAG 206 
Antisense CCACCGCGGCCCGCGC 
DRB1*1507, 1601-5, 1607-8 Sense TCCTGTGGCAGCCTAAGAG 136 
Antisense CTCCGTCACCGCCCGGT 
DRB1*0301-17,1107 Sense GTTTCTTGGAGTACTCTACGTC 211 
Antisense GTCCACCCGGCCCCGCT 
DRB1 *0401-2, 0404-5, 0408-10, 0413-16, 
0419,0421,0423,0424,0426,0428-30, Sense GTTTCTTGGAGCAGGTTAAACA 222 
0432-33, 0435-36, 1122 Antisense CTGCAGTAGGTGTCCACCG 
DRB1*0402-4, 0406, 0410-13, 0415, 0418, Sense GTTTCTTGGAGCAGGTTAAACA 259 0422,0425,0427, 0432, 0436, 1410 Antisense CTGCACTGTGAAGCTCTCCA 
DRB1 *0308, 1101-4, 1106-21, 1123-29, Sense GTTTCTTGGAGTACTCTACGTC 175 1132,1137,1139,1141 Antisense CTGGCTGTTCCAGTACTCCT 
DRB1 *1201-1202, 12032, 1205, 1206 Sense AGTACTCTACGGGTGAGTGTT 162 
Antisense CTGTTCCAGGACTCGGCGA 
DRB1*1102-3, 1111, 1114, 1116, 1120-21, 
GTTTCTTGGAGTACTCTACGTC 1141,1301-2,1304,1308,1315-6,1319- Sense 210 
20,1322-24,1327-29,1331-32,1334-36, Antisense TCCACCGCGGCCCGCTC 
1338-41,1343,1345,1416 
l~S 
Product 
Alleles recognized Orientation Primer sequences 5' • 3' Length 
DRB1*1116, 1120, 1301-2, 1308, 1316, Sense 1320,1327-29,1331-32,1334-36,1339-41, GTTCCTGGACAGATACTTCC 
1343, 1416 Antisense TCCACCGCGGCCCGCTC 152 
DRB1*0301-7, 1309, 1311, 1314-17,0820, Sense GTTTCTTGGAGTACTCTACGTC 1301-2,1305-11,1314-16,1318-20,1322-
25,1327-29,1334-37,1340-42,1344,1402- Antisense GGCTGTTCCAGTACTCGGCATC 173 
3,1406,1409,1412,1414,1417,1419-21, 
1423-24, 1427, 1429-30, 1433, 1436 
DRB1*1107, 1401, 1405, 1407-8, 1414, Sense GTTTCTTGGAGTACTCTACGTC 1418, 1423, 1426, 1433, 1435-36 223 
Antisense TCTGCAATAGGTGTCCACCT 
DRB1*0701 Sense GGTGCAGTTGCTGGAAAGACT 183 
Antisense CCCGTAGTTGTGTCTGCACAC 
DRB1*0801-13, 0815-16, 0818-19, 0822, Sense AGTACTCTACGGGTGAGTGTT 130 1404,1411,1415,1428,1431 
Antisense CTCCGTCACCGCCCGGT 
DRB1*09012 Sense GACGGAGCGGGTGCGGTA 192 
Antisense CCCGTAGTTGTGTCTGCACAC 
DRB1*10011-12 Sense CGGTTGCTGGAAAGACGCG 203 
Antisense CTGCACTGTGAAGCTCTCAC 
Control primer forward Sense TGCCAAGTGGAGCACCCAA 796 
Control primer reverse Antisense GCATCTTGCTCTGTGCAGAT 
5.2.3 HLA-B locus genotyping 
Limited HLA-B locus genotyping was performed by peR-SSP in order to assess HLA-
B27 homozygosity and heterozygosity. One peR reaction was carried out to determine 
the HLA-B27 carrier status (Bunce et al. 1995), and five peR reactions were carried out 
to determine all the other common HLA-B alleles. Primers and alleles that they specify 
are described in tables 5.2 and 5.3. The control primers used in the reactions are 
described in table 5.1. peR amplification was performed as described above (see 
section 5.2.2.2). Figure 5.1 illustrates positive reactions for HLA-B27 peR reaction (a) 
and HLA-B27 heterozygote genotyping (b). 
160 
Table 5.2 Sequences of the HLA-B locus primers used in this study. 
Primer mix 
number Orientation Primer sequences 5' - 3' Location 
62 Sense GCTACGTGGACGACACGCT HLA-B exon 2 
Antisense TCTCGGTAAGTCTGTGCCTT HLA-B exon 2 
2336 Sense ACACAGATCTGCAAGACCAAC HLA-B exon 2 
Antisense CCCCAGGTCGCAGCCG HLA-B exon 3 
2337 Sense ACACAGATCTGCAAGACCAAC HLA-B exon 2 
Antisense CCTTGCCGTCGTAGGCGTA HLA-B ex on 3 
2339 Sense ACACAGATCTGCAAGACCAAC HLA-B exon 2 
Antisense TGTCCGCCGCGGTCCAG HLA-B exon 3 
1113 Sense GCGAGGGGACCGCAGGC HLA-B intron 1 
Antisense GCGCAGGTTCCGCAGGC HLA B exon 2 
323 Sense CGCGAGTCCGAGGATGGC HLA-B exon 2 
Antisense CAGGTATCTGCGGAGCCA HLA-B exon 3 
Table 5.3 Alleles recognised by the primers. 
Primer peR 
mix fragment 
number Alleles recognized length 
62 8*2701-9 150 
2336 8*0703/8/16/27, *0801-08/10-16, *1310, *1405/6, *1501/3/5/7- 369 
12/14/15/18/19/23/24/28-31/33-35/37 -40/43/45-58/60/61/63-66/68-73, *1801/3-15/17, 
*3505/12/16/17/22/30-32/39/43/44, *3801-9, *3901-8/10-20/22-27, *4001-3/5/7-
16/18-27/29/31-33/35-40/42/43, *4102-4, *4402-6/8/9/11-14/16/17/19/21-27/29-32, 
*4801/3-7, *5004, *5106 
2337 8*0703/8/16/27, *0801-13/15/16, *1509/10/30/37/45/48/63, 421 
*3502/4/9/12/18/22/31/34/39/44, *3914, *4001/2/4-16/18/19/21-26/28-35/37/39/40/42-
44, *4101-6, *4405/25/31, *4801/3-6, *5101-12/14/16-24/26-32, *5201-5, *7801-5 
2339 8*0801-5/7/9-16, *1301-4/6-10, *1401-6, *1501-15/18-21/23-40/42-58/60-66/68-73, 469 
*1801-15/17/18, *3501-17/19-30/32-44, *3701/3-5, *3801-9, *3901-20/22-27, 
*4014/26/28, *4101-6, *4402-30/32, *4501-5, *4802, *4901-3, *5001/214, *5101-9/11-
24/26-32, *5201-5, *5301-9, *5901, *7801-5 
1113 8*0702-10/12-26/28-31, *0801/4/5/7-16, *1309, *1401-6, *1501-12114/15/18-21/25-
376 
35/37 -40/42/44-56/58/60-66/68-73, *1801-8/10-15/17/18, *2708/12/18, *3501-26/28-
44 *3901-19/22-27 *4001-12114-16/18/20-36/38-40/42-44, *4101-4/6, *4201/214, 
*4409, *4501-6, *4601/2, *4702/3, *4801-7, *5001/2/4, *5401/2, *5501-5/7-11, *5601-
6/8-10, *6701/2, *7301, *7801-5, *8101, *8201/2, *8301 
323 8*1301-4/6-10, *1501/2/4-8/11/13/15-17/20/21 /24-28/30-36/39/40/42-45/48/50/55- 643 
58/60/63/65-67/70/71/73, *4021, *4601/2, *5701-6/8/9 
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Figure 5.1 HLA-B2 7 homozygote/heterozygote geno typin g. 
a) HLA-B27 pe R reacti on, b) HLA-B2 7 heterozygote genotyping using primer mi x numb er 2336. Lane I 
- 100 bp ladder; Lanes 3 and 5 - pos iti ve reactions; Lanes 2, 4, 6, 8 and 10 - nega ti ve reac tions: Lanes 
a) 
b) Lanes: 
1 2 3 4 
100 bp Ladder 
HLA-B27 Positive 
HLA-B27 Positive 
HLA-B27 Positive 
HLA-B27 Positive 
HLA-B27 Negative 
HLA-B27 Negative 
HLA-B27 Negative 
HLA-B27 Negative 
H20 
H20 
5 6 7 8 9 10 
5.2.4 Statistical Analysis 
Haplotype reconstruction. The SIMWALK2 program (version 2.83) was used for 
haplotype reconstruction in all the AS families (Sobel and Lange 1996). Only families 
where at least two individuals were fully genotyped for HLA-DRB1 and HLA-B27 
heterozygote/homozygote were included in the analysis. In order to assess independent 
effects, only one affected invidual per family was chosen as a case for the case-control 
analysis. SIMW ALK2 provides the most likely solution for haplotype reconstruction, 
but does not assign a probability that the assignment is correct. 
The case-control study. For the case-control study the HLA-DRB1 results from the 
sequencing, the primer extension reactions and the PCR-SSP were pooled to correspond 
to the classic HLA-DRB1 specificities *01 to *10, as this was the typing resolution in 
the control population. Haplotype frequencies in AS cases and the control population 
were compared by the chi-squared analysis. The relative predispositional effect (RPE) 
method was used to evaluate the relative effects of HLA-DRB1 alleles (Payami et al. 
1989). 
LD and power calculation. The LD between HLA-B27 and HLA-DRB1 alleles was 
calculated using the Lewontin's standardised disequilibrium coefficient D' (Lewontin 
1988), calculated using the program 2BY2 (Lathrop and LaloueI1984). The proband 
and founder haplotypes estimated using the program SIMWALK2 were used as the 
input (Sobel and Lange 1996). The statistical significance of the finding was assessed 
using the chi-squared test. The power of the study was determined by the Genetic 
Power Calculator (http://statgen.iop.kcl.ac.uklgpc/) (Purcell et al. 2003). 
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Disease severity data. QTDT and analysis of covariance (ANCOV A) were used to 
calculate the significance of differences in continuous variables between different HLA 
groups. The Kolmogorov-Smimov test was used to test for deviations from the normal 
distribution prior to ANOV A analysis using SPSS software (Kinnear and Gray 2000). 
In case of non-normality of the variable and where stated, logarithmic or reciprocal 
transformation was applied in order to achieve normality. Reciprocal transformation 
was employed only if the distribution was considerably more positively skewed than 
lognormal. BASFI and BASDAI correlated with disease duration and gender in this 
data set and they were treated as covariates in QTDT and ANCOVA analyses. 2x2 
contingency table using chi-squared analysis was performed to analyse the clinical 
manifestations of the disease. All the p-values shown are 2-tailed, and p-values less 
than 0.05 were considered significant. All the p-values are uncorrected for multiple 
compansons. 
The calculation of the expected number ofHLA-B27 homozygotes. The antigen 
frequency of HLA-B27 was determined from a previously published source of Finnish 
Bone Marrow Donor Registry based on 10000 samples (Siren et al. 1996). One 
thousand and four hundred and forty-four of the 10000 individuals were HLA-B27 
positive corresponding to an antigen frequency of 14.4%. The expected frequency of 
homozygotes for HLA-B27 in healthy controls was calculated assuming HWE with 
regard to HLA-B27. Let the HLA-B27 allele frequency be a and non-HLA-B27 b such 
that a+b=l. The likelihood of being HLA-B27-antigen positive is given by: 
P (B27/B27 or B27/nonB27) 
) 
= a- + 2ab 
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2 
= a + 2a (I-a) = 0.144 
b2 = 1 - 0.144 
b = 0.925 
a =1-b= 0.0748 
The probability of being HLA-B27 homozygote in individuals known to be HLA-B27-
positive is given by: 
P (B27/B27 I B27/B27 or B27/nonB27) 
= a
2 
/ (a2 + 2ab) 
= a
2 
/ (a2 + 2a (I-a)) 
= 0.07482/0.144 
= 0.039 (3.9%) 
Familial vs. sporadic disease. All the probands and some of the other affected family 
members answered a structured questionnaire (appendix 1). AS cases, who had one or 
more first-degree relatives (father, mother, sister, brother, son, daughter) affected by 
AS, were considered to have familial disease (see questions Q65-Q66 in the appendix 
1). Cases were considered to have sporadic AS if they did not have first-degree 
relatives with AS. Every subject with familial AS were sex and age matched (within 5 
years) with 2 control cases with sporadic AS. Clinical characteristics and HLA genes 
between familial and sporadic AS cases were compared. Qualitative and quantitative 
data were analysed using the chi-squared test and ANOVA, respectively. 
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5.3 RESULTS 
5.3.1 Demographic characteristics of the data set 
In this data set, male:female ratio was 2.1: 1. One hundred and twenty-six (48%) 
subjects also had AAU, 18 (7%) IBD, 6 (2%) psoriasis and 210 (780/0) peripheral 
arthritis. The mean age at symptom onset (± S.D.) was 27 (±9) years, the mean age at 
diagnosis 35 (±10) years, the mean diagnostic delay 8 (±8) years, the mean disease 
duration 24 (±ll) years, the mean age 51 (±ll) years, mean BASDAI 5.2 (±1.9) and 
mean BASFI 3.9 (±2.3). No Mendelian inconsistencies were noted in the HLA-B locus 
or HLA-DRBllocus. Table 5.4 describes the clinical characteristics of the AS cases in 
this data set. 
The Kolmogorov-Smimov test demonstrated significant left skewing from the normal 
distribution for the age of symptom onset (p=0.001), the age of symptom onset after 
logarithm transfonnation (p=0.04) and the BASFI (p=0.001). The reciprocal 
transfonnation of the age of symptom onset, BASDAI and logarithm transformation of 
the BASFI did not result in significant skewing from the nonnal distribution, p=0.39, 
p=0.15 and p=0.57, respectively. These parameters were used in the ANCOVA and 
ANOV A analysis, respectively. 
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Table 5.4 Clinical description of the AS cases used in this study. 
All cases with AS and cases stratified according to their HLA-B27 status are presented. Some families 
included multiple AS cases. P-values refer to the statistically significant difference between HLA-B27 
positive and negative cases with AS. 
ALL CASES HLA-B27- HLA-B27-
(N=270) POSITIVE NEGATIVE P-VALUE 
CASES (N=251) CASES (N=19) 
AAU (%) 126 (48) 123 (50) 3 (16) 0.008 
IBD (%) 18 (7) 15 (6) 3 (16) NS 
PSORIASIS (%) 6 (2) 6 (2) 0 NS 
PERIPHERAL 210 (78) 197 (78) 13 (68) NS ARTHRITIS (%) 
AVERAGE 5.2 ± 1.9 5.2 ± 1.8 5.1±2.4 NS BASDAI ± S.D. 
AVERAGE 3.9 ± 2.3 3.9 ± 2.3 4.3 ± 2.3 NS BASFI± S.D. 
MALES (%): 182 (67) : 88 (33) 169 (67) : 82 (33) 13 (68) : 6 (32) NS FEMALES (%) 
AVERAGE AGE 
OF SYMPTOM 27.4 ± 8.6 26.7 ± 8.0 35.7 ± 11.2 0.0001 
ONSET± S.D. (14-55) (14-55) ( 18-54) 
(range) 
AVERAGE AGE 35.4 ± 9.9 34.8 ± 9.6 43.4 ± 10.0 0.0001 AT DIAGNOSIS (18-73) (18-73) (25-55) 
± S.D. (range) 
AVERAGE 
6.9 ± 6.8 DIAGNOSTIC 8.3 ± 8.3 8.4 ± 8.4 NS 
DELAY±S.D. (0-53) (0-53) (0-26) 
(range) 
AVERAGE 
18.3±12.0 DISEASE 23.5 ± 10.5 23.9 ± 10.2 NS 
DURATION (3-60) (3-60) (3-49) 
(range) 
AVERAGE AGE 50.8 ± ILl 50.6 ± 11.1 54.1 ± 10.1 NS 
± S.D. (range) (25-80) (25-80) (32-70) 
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5.3.2 HLA-B27 
5.3.2.1 The frequency of HLA-B27 positive haplotypes in cases and controls 
HLA-B27 antigen was detected in 251 (93%) of the 270 AS cases. Two hundred and 
twenty-one (52%) of the 421 haplotypes of AS probands reconstructed by the 
SIMWALK2 program were HLA-B27 positive, compared with 105 (8.4%) of the 1254 
control haplotypes. This increase was highly significant (X2=389, p< 10-10, OR=12, 
95% CI=9-l6). 
5.3.2.2 The expected and observed number of homo zygotes for HLA-B27 
Twenty-seven probands with AS were homozygotes for HLA-B27, 211 probands were 
heterozygotes and 19 probands were HLA-B27 negative. Assuming HWE with regard 
to HLA-B27, the expected number of HLA-B27 homozygotes of257 probands is 9 
(0.039 x 238) and the expected number ofheterozygotes is 229 (238-9). As shown in 
table 5.5, there was an over-representation of HLA-B27 homozygotes in the proband 
group (X2=9.7, p=0.002, OR=3.3, 95% CI=1.6-6.8). Table 5.6 describes the clinical 
characteristics of HLA-B27 homozygous and heterozygous AS cases. HLA-B27 
homozygosity was significantly associated with a decrease in BASDAI (mean 
BASDAI: HLA-B27 homozygotes 4.5 ± 1.6, HLA-B27 heterozygotes 5.4 ± 1.8, 
p=0.003). No other significant associations were noted between clinical characteristics 
and HLA-B27 homozygosity. 
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Table 5.5 The expected and observed number of HLA-B27 homozygotes ofthe 238 HLA-B27 
positive pro bands. 
The expected number of homo zygotes was calculated assuming HWE with regard to HLA-B27 (see 
methods section 5.2.4). 
Observed Expected 
HLA-B27 homozygote 27 (11 %) 9 (4%) 
HLA-B27 heterozygote 211 (89%) 229 (96%) 
Total 238 238 
Table 5.6 Clinical characteristics of HLA-B27 homozygous and heterozygous cases. 
ALL HLA-B27- HLA-B27- HLA-B27-
POSITIVE HOMOZYGOUS HETEROZYGOUS P-VALUE 
CASES (N=25 I ) CASES (N=31) CASES (N=220) 
AAU (%) 123 (50) 19 (61) 104 (47) NS 
IBD (%) 15 (6) 0 15 (7) NS 
PSORIASIS (%) 6 (2) 2 (6) 4 (2) NS 
PERIPHERAL 197 (78) 21 (68) 176 (80) NS ARTHRITIS (%) 
AVERAGE 5.2 ± 1.8 BASDAI ± S.D. 4.5 ± 1.6 
5.4 ± 1.8 0.003 
AVERAGE 3.9 ± 2.3 3.5 ±2.6 4.0 ± 2.3 NS BASFI ± S.D. 
AVERAGE AGE 
26.8 ± 8.1 OF SYMPTOM 26.7 ± 8.0 25.9 ± 7.3 NS 
ONSET±S.D. ( 14-55) (15-44) (14-55) 
(range) 
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5.3.2.3 Disease severity and HLA-B27 
Table 5.4 describes the cases with AS stratified according to their HLA-B27 status. One 
hundred and twenty-three (98%) of the 126 AS cases with AAU were HLA-B27-
positive, which was significantly increased compared with the 122 (88%) of the 138 AS 
cases without AAU (X2=7.05, p=0.008, OR=5.4, 95% CI=1.6-19). No significant 
differences were noted between AS associated with IBD, psoriasis or peripheral arthritis 
and the carriage of HLA-B27 in this data set. 
HLA-B27 positive cases had a significantly younger age of symptom onset. This 
association was noted using both QTDT (HLA-B27 is associated with younger age of 
symptom onset by 5.3 years, p=O) and ANOV A (mean age of symptom onset: HLA-
B27-positive 26.7 years, HLA-B27-negative 35.7 years, p=l.O x 10-4). HLA-B27 was 
also associated with younger age at diagnosis by 5.5 years (p=0). A marginal 
association was noted between BASFI and HLA-B27 using QTDT (p=0.04), but this 
was not significant in ANCOVA analysis (p=0.10). 
5.3.3 HLA-DRB1-B27 haplotypes and disease susceptibility and severity 
5.3.3.1 Case-control study - disease susceptibility 
The frequencies of HLA-DRB1-B27 haplotypes between AS cases and controls are 
presented in table 5.7. HLA-B27-positive cases and controls were compared. No 
significant associations were noted. 
Table 5.7 The number of HLA-DRBI-B27 haplotypes in AS cases and controls. 
HLA-B27 positive HLA-B27 positive OR p-va1ue AS hap10types control haplotypes 
N(%) N (%) 
DRBI *01 57 (26) 26 (25) 1.1 0.84 
DRBI *02 10 (5) 8 (8) 0.6 0.25 
DRBI *03 5 (2) 2 (2) 1.1 0.84 
DRBI *04 50 (23) 25 (24) 0.9 0.81 
DRBI *05 9 (4) 6 (6) 0.7 0.51 
DRBI *06 15 (7) 4 (4) 1.7 0.28 
DRBI *07 6 (3) 0 6.4 0.09 
DRBI *08 66 (30) 32 (30) 1.0 0.91 
DRBI *09 1 (0.5) 2 (2) 0.3 0.20 
DRBI *10 2 (1) 0 2.4 0.33 
Total 221 105 
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5.3.3.2 HLA-DRB1-B27 haplotypes and disease severity 
U sing the total evidence of association within the QTDT package, several weak 
associations were noted between quantitative traits and HLA-DRB1-B27 haplotypes. 
HLA-DRB1 *09-B27 haplotype is associated with -2.8 decrease in BASDAI, X2=5. 
p=0.03. HLA-DRB1 *04-nonB27 is associated with 0.7 increase in BASFI, X2=5, 
p=0.03. HLA-DRB1 *08-nonB27 haplotype was associated with -0.8 decrease in 
BASFI, X2=5, p=0.02. HLA-DRB1 *03-nonB27 haplotype was associated with older age 
of symptom onset by 6 years, X2=8, p=0.006. 
5.3.4 HLA-DRB1 and the clinical manifestations of the disease 
HLA-DRB1 *12 is associated with -1.5 decrease in BASFI, X2=5, p=0.03. HLA-
DRB1 *08 is associated with younger age of symptom onset by 2 years, X2=4, p=0.05. 
HLA-DRB1 *03 is associated with older age of symptom onset by 6 years, X2=11, 
p=O.OOl. HLA-DRB1 *13 is associated with older age of symptom onset by 2 years, 
X2=4, p=0.05. The disease severity scores did not correlate with the age of symptom 
onset. No significant associations between HLA-DRB1 alleles and AS complicated by 
AAU, IBD or peripheral arthritis were seen. 
1
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5.3.5 HLA-DRB1 sequencing results 
One hundred ninety-four alleles from 128 probands were sequenced. One hundred and 
forty-six alleles (75%) were unambiguously resolved to specify a certain HLA-DRBI 
subtype. Twenty-five alleles (13%) remained partially ambiguous and could specify 2 
possible subtypes. Twenty-three alleles (12%) remained ambiguous and could specify 3 
or more alleles. 
Table 5.8 specifies the HLA-DRB1 subtypes identified by direct sequencing. Thirteen 
different subtypes were identified unambiguously. The only HLA-DRB1 *01 subtype 
identified was HLA-DRB1 *0101. The predominant subtype of HLA-DRBI *04 was 
*0408, other HLA-DRB1 *04 subtypes identified were *04011, *04031 and *0404. 
HLA-DRBI *02 subtypes identified were *15011 and *16011. 
The allele frequency of HLA-DRB1 *08 (1 % by sequencing) was significantly reduced 
in comparison with a previous report, in which the HLA-DRB1 *08 allele frequency was 
9% (Siren et al. 1996). Additionally, the sequencing of the product of the group specific 
primer HLA-DRB1 *03108111113114 repeatedly resulted in ambiguous (94% of all the 
ambiguities) or failed sequence. Thus, all the samples which remained homozygote 
after sequencing (n=58) were subsequently genotyped for HLA-DRBI *03, *08, *11, 
* 13 and *14 using the peR-SSP approach (Bunce et al. 1995). 
Table 5.S HLA-DRBI subtypes identified by direct sequencing in probands. 
Ambiguous sequence is denoted xx, which could specify 3 or more possible sUbtypes. 
Classic HLA-DRBl type Subtypes identified Number of alleles (%) 
DRB1*Ol 0101 55 (28.4) 
DRBl*02 15011 23(11.9) 
16011 3 (1.5) 
l5xx 2 (1.0) 
DRBl*03 03011 7 (3.6) 
03011 or 0305 6 (3.1) 
DRBl*04 04011 17 (8.8) 
04031 2 (1.0) 
0404 7 (3.6) 
0408 20(10.3) 
0404 or 0423 5 (2.6) 
04xx 4 (2.1) 
DRBl*05 11 011 or 110 12 4 (2. 1) 
1103 or 1111 1 (0.5) 
l1xx 5 (2.5) 
1201 or 1206 7 (3.6) 
DRBl*06 1301 3 (1.6) 
1302 2 (1.0) 
13 xx 11 (5.7) 
DRBl*07 0701 4 (2.1) 
DRBl*OS 0801 or 0806 2 (1.0) 
DRBl*09 09012 1 (0.5) 
DRBl*10 1001 2 (1.0) 
lOxx 1 (0.5) 
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The allele frequencies of HLA-DRBl *04 sUbtypes were compared between the current 
and a historic study (Westman et a1. 1994a) (table 5.9). HLA-DRB1*0408 allele was 
significantly increased in AS cases of this study compared to the historic cadaveric 
donors (0.0002). Respectively, the HLA-DRBl *0401 subtype allele frequency \\as 
decreased in AS cases compared to cadaveric donors (p=0.004). The HLA-DRB1 *0404 
subtype frequency was significantly decreased in AS cases of the current study and the 
historic HLA-B27 positive individuals (p=0.04). 
Table 5.9 Comparison of HLA-DRB1*04 subtype allele frequencies between the current and 
historic study. 
Forty-six alleles were sequenced unambiguously. The partially ambiguous sequences indicating either 
HLA-DRBI *0404 or *0423 subtype were included in the HLA-DRBI *0404 group as the *0423 subtype is 
not reported to occur in the Finnish population and the exclusion of these ambiguous genotypes would 
bias the allele frequencies. P-values refer to the significant difference between the AS cases and healthy 
HLA-B2l positive individuals or random cadaveric donors. 
Current 
study Historic study 
HLA-
HLA- AS ReA B27+ Cadaveric 
DRB1*04 AS cases cases cases controls p- donors p-
sub~es (N-51) (N-14) (N-13) (N=26) value (N=50) value 
N(%) N(%) N(%) N (%) N (%) 
*0401 17 (33) 2 (14) 5 (38) 5 (19) NS 31 (62) 0.004 
*0402 0 0 0 1 (4) NS 0 NS 
*0403 2 (4) 2 (14) 0 1 (4) NS 3 (6) NS 
*0404 12 (24) 7 (50) 4 (31) 12 (46) 0.04 11 (22) NS 
*0407 0 0 0 1 (4) NS 1 (2) NS 
*0408 20 (39) 3 (21) 4 (31) 6 (23) NS 4 (8) 0.0002 
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5.3.6 Comparison of clinical features and the carriage of HLA-B27 between familial and 
sporadic cases 
Clinical characteristics of the sporadic and familial cases are described in table 5.10. 
The mean age (± S.D.) in both the familial and sporadic AS cases is 50.5 ± 10.9 years 
and male: female ratio is 1.3. No significant differences were noted in HLA-B27 status 
or clinical characteristics between familial and sporadic disease. The trend is that 
familial AS cases exhibit a younger age of symptom onset, but this was not statistically 
significant (mean age of symptom onset: familial AS 25.7 years, sporadic AS 27.7 
years, p=O.1 0). Sixty-one (97%) of the 63 familial AS cases were HLA -B2 7 positive 
compared with the 113 (94%) of the 120 sporadic AS cases. This increase was not 
statistically significant (X2=0.62, p=0.43). Eleven (18%) of the 61 HLA-B27 positive 
familial AS cases were HLA-B27 homozygote compared to the 12 (11 %) of the 111 
sporadic AS cases. This was not statistically significant (X2=1.9, p=0.17). 
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Table 5.10 Clinical description of familial and sporadic AS cases. 
The differences between the familial and sporadic cases were not statistically significant. 
FAMILIAL AS CASES SPORADIC AS CASES 
(N=68) (N=136) 
AAU (%) 34 (50) 61 (45) 
IBD (%) 6 (9) 8 (6) 
PSORIASIS (%) 2 (3) 7 (5) 
PERIPHERAL ARTHRITIS (%) 51 (75) 104 (76) 
AVERAGE BASDAI ± S.D. 5.1 ±2.0 5.3 ± 1.8 
AVERAGE BASFI ± S.D. 4.1 ± 2.6 3.8 ±2.2 
AVERAGE AGE OF SYMPTOM 25.7 ± 6.8 27.7 ± 8.4 
ONSET ± S.D. (range) (11-44) (16-56) 
AVERAGE AGE AT DIAGNOSIS 34.3 ± 8.7 35.6 ± 9.5 
± S.D. (range) (20-54) (18-63) 
A VERAGE DIAGNOSTIC 8.5 ± 6.9 8.0 ± 7.3 
DELAY ± S.D. (range) (0-35) (0-29) 
HLA-B27 POSITIVE (%) 61 (97) (N=63) 113 (94) (N=120) 
HLA-B27 HOMOZYGOTE (%) : 11 (18) : 49 (82) 12 (11) : 99 (89) HLA-B27 HETEROZYGOTE (%) 
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5.3.7 Power of the study 
The power of the case-control study is presented in table 5.11. 
Table 5.11 The power of the case-control study using 221 case haplotypes and 105 control 
haplotypes. 
The power is calculated using an AS prevalence of 0.13% and GRR of2. 
DISEASE MODEL 
Dominant Codominant Recessive 
HLA-DRBI *01 72% 47% 16% 
HLA-DRBI *02 65% 33% 7% 
HLA-DRB 1 *03 48% 21% 5% 
HLA-DRB 1 *04 72% 46% 15% 
HLA-DRB 1 *05 50% 22% 5% 
HLA-DRB 1 *06 67% 35% 7% 
HLA-DRBI *07 31% 13% 5% 
HLA-DRB 1 *08 72% 44% 13% 
HLA-DRBI *09 21% 10% 5% 
HLA-DRBI *10 14% 8% 5% 
5.3.8 LD calculations 
In the proband population LD between HLA-B27 and several HLA-DRB1 alleles was 
noted: HLA-DRB1 *01 (D' = 0.19, P = 0.05), HLA-DRB1 *02 (D'=-0.6, p=9 x 10-5), 
HLA-DRB1 *03 (D' = -0.47, P = 0.03), HLA-DRB1 *08 (D' = 0.53, P = 2 x 10-7), HLA-
DRB1 *11 (D' = -0.43, P = 0.04) and HLA-DRB1 *13 (D' = -0.42, P = 0.002) (table 
5.12). 
Table 5.12 LD values and the corresponding p-values between HLA-B27 and HLA-DRBI alleles 
calculated using the proband and founder haplotypes. 
Lewontin's standardised disequilibrium coefficient D' (p-value) is shown. 
FOUNDERS PROBANDS 
HLA-DRB1 ID'I (p-value) ID'I (p-value) 
*01 0.06 (0.22) 0.19 (0.05) 
*02 -0.38 (0.003) 
-0.55 (8.7 x 10-5) 
*03 
-0.55 (0.001) 
-0.47 (0.03) 
*04 0.07 (0.21) 0.04 (0.69) 
*07 0.005 (0.97) 0.47 (0.20) 
*08 0.41 (4.1 x 10-12) 0.53 (2.0 x 10-7) 
*09 -0.52 (0.10) -0.52 (0.27) 
*10 0.10 (0.74) 0.30 (0.62) 
*11 -0.36 (0.10) -0.43 (0.04) 
*12 -0.46 (0.18) -0.37 (0.25) 
*13 -0.40 (0.001) -0.42 (0.002) 
*14 -0.46 (0.44) 1.0 (0.34) 
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5.4 DISCUSSION 
Previous studies have demonstrated several distinct associations between HLA-DRBl 
alleles and AS susceptibility suggesting that the HLA association in AS may be 
complex and reflect the impact of combinations of alleles carried on a particular 
haplotype. Alternatively, the disease association may arise from a combination of HLA-
B27 and other HLA loci with an epistatic interaction between these loci. In this study a 
Finnish population was used to investigate the influence of HLA-B27 and HLA-DRBl 
genes and haplotypes in AS. Because of the significant LD within the MHC, HLA-B27 
positive case and control haplotypes were used to assess independent effects. 
No statistically significant difference between distinct HLA-DRB1-B27 haplotypes of 
AS cases that were adequately matched with HLA-B27 positive control haplotypes was 
noted. Due to extreme polymorphic nature of the HLA-DRBl locus and the modest 
effects ofHLA class II genes on susceptibility to AS, large-scale case-control studies 
are required to dissect these effects. The haplotypic case-control study presented in this 
chapter was underpowered. Using the AS prevalence of 0.13% (Kaipiainen-Seppanen 
et a1. 1997) and the GRR of 2, the power of this study was 5-72% depending on the 
disease model and allele frequencies. A further set of Finnish control samples with 
HLA-DRBI-B27 haplotypes will be available to increase the power of the study (lorma 
Ilonen, personal communication). 
The control haplotypes used in this study were haplotypes of Finnish parents of children 
with IDDM not transmitted to the diabetic child, nor found in siblings or parents with 
IDDM. These haplotypes are thought to be representative of the healthy Finnish 
lXO 
population as only the non-transmitted haplotypes of unaffected individuals were 
selected. Theoretically, these haplotype may include protective genes for IDDM as the 
haplotypes were never transmitted to, nor found in, diabetic individuals within the 
families. The haplotypes were obtained from a large previous study (Tuomi lehto-Wolf 
et a1. 1989); these haplotypes were used as no healthy Finnish DNA was available. 
However, a control population of healthy individuals would be preferable to the control 
population used in this study. 
Ethnically matched HLA-B27 negative control haplotypes were not available for 
analysis. Preliminary data on the English population noted a positive association 
between HLA-DRB1 *01 allele and AS on the HLA-B27 negative strand, but not on the 
HLA-B27 positive strand (Sims et a1. 2004). This suggests that HLA-DRB1 *01 or 
another gene in LD with it on the HLA-B27 negative strand are involved in 
susceptibility to AS, possibly acting in combination with HLA-B27. 
The study presented in this chapter had 80% power to exclude an association between 
HLA-DRB1 *01 allele and disease susceptibility with GRR of 2.2-4.4 on the HLA-B27 
positive strand depending on the assumed disease model (dominant, codominant or 
recessive). This preliminary data set suggests that at least in the Finnish population 
HLA-DRB1 alleles on the HLA-B27 positive strand, compared with healthy HLA-B27 
matched haplotypes, are unlikely to have a major effect on the disease susceptibility. 
Further studies using a larger sample size and analysing the effect of RLA-B27 negative 
haplotypes in the Finnish population is warranted in the future. 
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Previous studies have reported an association between HLA-DRB1 *01 and AS b t h ' 
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studies have not matched the cases and controls for HLA-B27 at the haplotypic level. 
Haplotype-based approaches have yielded successful results in the HLA region 
(Jawaheer et al. 2002; Newton et al. 2003), where the complexity of the LD and the 
density of genes make the detection of the causative variants a challenging task. The 
LD varies in a haplotype-specific manner in the HLA region; strong and extensive LD is 
found across both common and rare haplotypes (Ahmad et al. 2003). The study 
presented in this chapter fully controlled for the association of HLA-B27 by comparing 
the different HLA-DRBI alleles between HLA-B27 positive case and control haplotypes. 
However, the cases and controls were not matched for different HLA-B27 subtypes. 
The HLA-B*2705 is likely to be the most prominent subtype among both cases and 
controls. However, the possibility exist that different HLA-B27 subtypes confer 
differential strength of association with the disease. Each HLA-B27 subtype participates 
in a different HLA haplotype as suggested by different LD pattern between MICA 
alleles and HLA-B27 subtypes (Tsuchiya et al. 1998). Thus, ideally the HLA fine 
mapping studies should match the cases and controls for HLA-B27 subtypes. In the 
future large case-control studies employing healthy HLA-B27 control samples and 
matching the cases and controls completely for HLA-B27 subtypes may be better able to 
investigate the effects ofnon-HLA-B27 HLA genes on susceptibility to AS. 
Previous studies on the influence of HLA-B27 homozygosity in the development of AS 
have been contradictory. Significant excess of HLA homozygotes among the AS cases 
has been reported (Khan et al. 1978), but this has not been confirmed by others (Suarez-
Almazor and Russell 1987). The contribution of HLA-B27 homozygosity is likely to be 
. . d . t' t th's issue In other studies, modest and large samples SIzes are reqUIre to mves Iga e 1 . 
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homozygosity for HLA has been reported to be associated with susceptibility to 
autoimmune diseases (Skarsvag et al. 1992), common variable immunodeficiency (De 
La Concha et al. 1999) and an increased difficulty in clearing infections (Pollicino et al. 
1996). 
In this study, a large family-based cohort was genotyped for HLA-B27 homozygosity 
and heterozygosity. No Mendelian inconsistencies were noted in these families. In the 
PCR-SSP genotyping panel the primer mix number 1113 that was targeted to define the 
HLA-B27 heterozygotes also recognised three HLA-B27 subtypes, HLA-B2708, *12 and 
*18. Thus, the genotyping assay employed could not detect the HLA-B27 homozygotes 
who possess HLA-B2708, *12 or *18 from the HLA-B27 heterozygotes. As the 
frequency of these HLA-B27 subtypes is known to be very rare «0.5% in the UK 
population) and no Mendelian inconsistencies were observed, all the individuals who 
were positive for this reaction and for HLA-B27 were treated as HLA-B27 
heterozygotes. This is a conservative approach to investigate the potential increase of 
HLA-B27 homozygosity in AS, as it potentially decreases the number of HLA-B27 
homozygotes observed. 
HLA-B27 homozygosity was significantly increased from the expected under HWE. 
Possible explanations include: Threshold model of polygenic disease where the 
presence of increased number of susceptibility alleles increases the likelihood of 
developing the disease. Other genetic explanation could be partial dominance of HLA-
B27 in determining the phenotype of AS, although this is unlikely as HLA-B27 
homozygosity was not associated with more severe disease. HLA-B27 homozygotes 
o 0 f HL'\ 8')7 such °1S 
may have a higher likelihood to develop abnormal charactensttcs 0 . - _. l • 
homodimeric or misfolded structures. In addition HLA-B27 homozygot 
' es may express 
an increased level ofHLA-B27 molecules. The latter is supported by the observation of 
greater expression ofHLA-B27 molecules in patients with AS than in healthy controls 
(Cauli et al. 2002). It is possible that the genotyping method employed failed to detect 
some HLA-B alleles, which could subsequently increase the number of apparent 
homozygotes. This could be overcome by performing full HLA-B locus genotyping for 
all the homozygous cases. However, it was estimated that the frequency of the alleles 
that are not detected by this method is very low. This is supported by the fact that no 
Mendelian inconsistencies were detected in these families. 
A previous report has suggested that HLA-B27 homozygosity may influence the disease 
severity (Suarez-Almazor and Russell 1987). A higher frequency of involvement of 
peripheral joints has been reported among the HLA-B27 homozygotes (Khan et al. 
1978). Surprisingly, this study noted a significant decrease in BASDAI among the 
HLA-B27 homozygotes. No other disease severity indices showed significant 
differences, suggesting that HLA-B27 homozygote patients may exhibit a milder disease 
than HLA-B27 heterozygotes. This is consistent with the whole-genome disease 
severity screen, in which no linkage between the disease severity indices and the MHC 
region was observed (Brown et al. 2003). 
It has been proposed that HLA-B27 positive and HLA-B27 negative AS represent a 
heterogenous group of phenotypically similar diseases that may have different 
aetiopathogenic mechanisms. HLA-B27 positive AS is reported to be associated with 
younger disease onset (Saraux et al. 1995; Feldtkeller et al. 2003). A recent report 
suggested that HLA-B27 is also associated with earlier onset of psoriatic arthritis 
(Queiro et al. 2003). The current study showed a significant association between HLA-
B27 and a younger age of symptom onset and a younger age at diagnosis in AS patients 
confirming the previously reported associations. 
An association between HLA-DRBl *08 and juvenile AS has been reported in 
Norwegian and Mexican cases (Ploski et al. 1995; Maksymowych et al. 1997b). A weak 
association between HLA-DRBl *08 and early age at symptom onset is reported here 
(section 5.3.4), supporting these previous findings. These findings strongly suggest that 
both HLA-B27 and HLA-DRBl *08, either independently or as a haplotype, contribute to 
the genetic susceptibility of early onset disease. Significant LD between HLA-B27 and 
HLA-DRBl *08 was observed, and the association between HLA-DRBl *08 and younger 
age of symptom onset may be secondary due to strong LD. However, in this data set 
HLA-DRBl *08-B27 haplotype was not associated with the younger age of symptom 
onset. Also, the association between HLA-DRBl *08 and age of symptom onset 
remained significant even when HLA-B27 was used as a covariate in the analysis, 
suggesting that the association is likely to be independent. Large studies of HLA-B27-
negative cases may be better able to dissect whether HLA-DRBl *08 association is 
independent, although HLA-B27 negative AS may be too different to confirm the 
finding. In contrast, neither HLA-DRBl *08 nor HLA-B27 were found to be associated 
with any of the disease severity scores. Younger age of symptom onset did not correlate 
with BASDAI or BASFI, suggesting that even if disease occurs earlier in the presence 
of predisposing genes, it is not more severe. This is consistent with previous studies, 
indicating that although cases with juvenile onset of AS are more likely to develop hip 
arthritis their disease is otherwise similar in character to cases with adult onset disease , 
AS (Calin and Elswood 1988). HLA-DRBl *03 allele and HLA-DRBI *03-nonB27 
haplotype were associated with older age of symptom onset, suggesting HLA-DRBI *03, 
or another gene on the HLA-B27 negative strand, may be involved in determining a later 
age of symptom onset. Overall, these findings suggest that HLA-DRBI alleles may 
influence the age of symptom onset of AS. However, the reported p-values are not 
corrected for multiple comparisons made, and the associations reported here may 
merely be attributable to stochastic statistical fluctuations. 
AAU is more common in HLA-B27-positive than HLA-B27-negative cases with AS 
(Khan et al. 1977; Saari et al. 1978), and this is confirmed by this study. There is no 
consensus amongst previous studies concerning the association between HLA-DRBI *08 
and AAU. An association has been reported in a Japanese population (Monowarul 
Islam et al. 1995), and negative findings have been reported in Norwegian and Mexican 
studies (Ploski et al. 1995; Maksymowych et al. 1997b). A possible explanation is that 
the juvenile AS may increase AAU. However, a recent study noted that the prevalence 
of iritis correlates positively with disease duration, but not with age of symptom onset 
(Brophy and Calin 2001). The present study noted no significant association between 
HLA-DRBI *08 and AAU, and thus do not support the Japanese finding. The discrepant 
associations may be due to different ethnic background of the populations. 
Although disease severity has been shown to be primarily genetically determined 
(Hamersma et al. 2001), there is little information on the role of candidate genes in the 
severity of AS. As diverse associations between HLA-DRBI alleles and the disease 
phenotype have been reported, it is possible that the discrepant findings may be a 
consequence of an underlying association with disease severity. rather than 
susceptibility. In the present study weakly significant associations were observed with 
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HLA-DRB1 alleles and HLA-DRB1-B27 haplotypes and BASDAI and BASFI. In a 
British study, no association was found between HLA-DRB1, HLA-B27 or HLA-B60 and 
disease severity indices (Brown et al. 1998a). In a Canadian study no association 
between LMP2 polymorphisms and the disease severity scores was observed 
(Maksymowych et al. 1997a). The whole-genome linkage screen observed no linkage 
with the disease severity indices and the HLA region, consistent with the general 
observation that little overlap was noted between regions linked with susceptibility to 
AS and those linked with the clinical characteristics (Brown et al. 2003). This 
highlights the difference between these measures. Overall, these findings do not 
suggest that MHC genes have a major role in determining the severity of AS. 
In the healthy Finnish population HLA-B27 has previously been reported to be in LD 
with HLA-DRB1*01, *04 and *08 (Westman et al. 1994a). Positive LD between HLA-
B27 and HLA-DRB1 *01 and *08, and negative LD between HLA-B27 and HLA-
DRB1 *02, *03, *11 and *13 was observed. In comparison with the British population 
the overall LD pattern is similar in the Finnish population (Brown et al. 1998a). In 
contrast to a previous Finnish report (Westman et al. 1994a), this study did not 
demonstrate a significant LD between HLA-DRB1 *04 and HLA-B27. The sample size 
in the previous report was relatively small, which may explain the discrepancy. The 
difference may also be attributable to the methodology used to determine haplotypes 
and to quantify the extent ofLD. 
Comparison of HLA-DRB1 *04 subtypes demonstrated that the HLA-DRB1 *0401 and 
*0408 frequencies were significantly different between AS cases and historic random 
controls (Westman et al. 1994a). This is consistent with previous reports and confirms 
the finding that HLA-B27 associates with HLA-DRBl *0408 (Westman et a1. 1994a). In 
a previous report HLA-DRBl *0404 frequency was also increased in HLA-B27 positiye 
cases compared to random controls (Westman et a1. 1994a). This study showed no 
difference in HLA-DRBl *0404 frequency between the AS cases and historic random 
controls. These discrepant results may be attributable to the small sample sizes or bias 
in the sequencing results due to the difficulty in specifying this sUbtype from other 
subtypes. 
The clinical characteristics and the HLA-B27 status were compared between the familial 
and sporadic AS cases. No significant differences were noted in HLA-B27 status, 
BASDAI, BASFI, age of onset, age at diagnosis or prevalence of peripheral arthritis and 
AAU between familial and sporadic disease. This is consistent with a Dutch report (van 
der Paardt et a1. 2002b). One previous study suggested that familial AS is significantly 
milder than sporadic disease as assessed by the arthritis impact measurement scales 
(AIMS) (Calin et a1. 1993). This study was not able to confirm this previous finding 
using BASDAI and BASFI as clinical disease severity indices. The difference may be 
related to the disease severity indices used, the power of the study or selection of the AS 
cases. Due to small sample size several AS cases were selected from the same families 
for the familial group. These AS cases are thus not independent and could bias the 
analysis. 
One of the limitations of this study is the lack of markers genotyped, which hinders the 
reliable reconstruction of the haplotypes and the definition of the causative variants. As 
the MHC is completely sequenced and polymorphisms within it are abundant (1999), it 
may be feasible to employ a dense map of SNPs to determine the primary associations. 
The extent of LD in the human MHC region is longer in physical distance (but not in 
genetic distance) than elsewhere in the genome making it a challenging task to identify 
the primary associations (Walsh et al. 2003). A haplotype map of the human MHC may 
facilitate this endeavour and make the mapping of the causative variants quicker and 
more cost-effective in the future (Walsh et al. 2003). 
5.5 CONCLUSIONS 
This study supports the concept that the genetic basis of AS is heterogenous, and genes 
within the human MHC are involved in determining both the disease susceptibility and 
the age of disease onset. Homozygosity for HLA-B27 was noted to be significantly 
increased among the cases with AS. A significant association was noted between age of 
symptom onset and both HLA-B27 and HLA-DRBl *08. No statistically significant 
difference between distinct HLA-DRB1-B27 haplotypes of AS cases that were 
adequately matched with HLA-B27 positive control haplotypes was noted. Further 
studies assessing the effect of HLA-B27 negative haplotypes and using a larger number 
of control haplotypes may be better able to clarify the role of HLA-DRBl alleles in AS 
susceptibility. 
CHAPTER 6 - THE EFFECT OF POLYMORPHISMS OF THE CYP2D6 GE:\E 
IN AS IN A FINNISH POPULATION 
This chapter presents the results of a study designed to investigate whether the 
previously observed association between the Cytochrome P450 2D6 (CYP2D6, 
debrisoquine 4-hydroxylase, OMIM reference number 124030) gene and AS can be 
demonstrated in a Finnish population. A within-family association study of the main 
poor metaboliser (PM) allele of the CYP2D6 gene (CYP2D6*4, OMIM reference 
number 124030.0001) was performed. 
6.1 INTRODUCTION 
The association between homozygosity for inactive CYP2D6 alleles and AS has been 
reported by two previous independent studies (Beyeler et al. 1996; Brown et al. 2000a). 
The CYP2D6 gene was the first non-MHC locus that was associated with AS. The 
finding was supported by within-family association methods demonstrating a moderate 
over-transmission of CYP2D6*4 alleles in patients with AS (p=0.01) and by linkage 
studies showing a LOD score of 1 (Laval et al. 2001). The strength of association by 
case-control methods was strong (p=0.0007), but the relative risk of 2.1 only moderate 
and hence the influence of this gene on overall risk appears small. It has been 
hypothesized that altered metabolism of a natural toxin or antigen by the CYP2D6 gene 
may increase susceptibility to AS (Brown et al. 2000a). The aim of this study was to 
evaluate the effect of CYP2D6*4 allele in 170 Finnish families with AS. 
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6.1.1 Cytochrome P450 genes 
Cytochrome P450 (CYP) enzymes are a superfamily of microsomal metabolising 
enzymes. They are involved in the oxidative metabolism of both endogenous and 
exogenous molecules. They represent the first line of defence against environmental 
chemicals and are present in all higher organisms. Physiological substrates include 
steroids, fatty acids, prostaglandins, leukotrienes and biogenic amines. Exogenous 
compounds include plant toxins, drugs and carcinogens (Johansson et al. 1993). 
Metabolism of drugs usually converts them to metabolites that are more water soluble 
and thus more easily excreted by the kidney. It can also convert prodrugs into 
therapeutically active compounds, and it may even give rise to the formation oftoxic 
metabolites (Weinshilboum 2003). CYP enzymes are the most important of the 
enzymes that catalyse phase I metabolism, which involves the activation of drugs and 
carcinogens into more toxic electrophilic intermediates. Phase II drug-metabolising 
enzymes (such as N-acetyltransferases and glutathione S-transferases) conjugate the 
intermediates to water-soluble derivatives to complete the detoxification cycle. 
Approximately 40% of human CYP-dependent drug metabolism is carried out by 
polymorphic enzymes, which can result in abolished, quantitatively or qualitatively 
altered, or enhanced metabolism (Ingelman-Sundberg et al. 1999). 
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6.1.2 CYP2D6 polymorphisms 
The CYP2D6 gene is part ofa cluster of three CYP2D genes on 22gl3.I. A definite 
pseudogene CYP2D8P and a presumed pseudogene CYP2D7 are located 5' of the 
CYP2D610cus (Kimura et al. 1989). To date, 77 allelic variants of CYP2D6 have been 
identified and characterised (see www.imm.ki.se/cypalleles). Defective alleles can be 
the result of gene deletions, gene conversions with related pseudo genes and single base 
mutations causing frameshift, missense, nonsense or splice-site mutations. Many of 
these polymorphisms are functionally significant, often resulting in altered activity or 
complete absence of enzyme. 
About 5-10% of Caucasians are so-called poor metabolisers (PM) of debrisoguine, 
completely lacking CYP2D6 activity because of inactivating mutations in both alleles of 
the CYP2D6 gene. The PM phenotype causes an impaired ability to metabolise the 
antihypertensive probe drug debrisoquine and other drugs specific for this drug-
metabolising enzyme (Ingelman-Sundberg et al. 1999). Individuals showing impaired 
activity (intermediate metabolisers) and subjects showing particularly high levels of 
activity (ultrarapid metabolisers) have been described. The presence of multiple copies 
of the CYP2D6 gene has been demonstrated to associate with the ultrarapid metaboliser 
phenotype (Johansson et al. 1993). Subjects with wild-type CYP2D6 genotype and the 
normal range of activity are called extensive metabolisers. 
Five PM-associated alleles (CYP2D6*3, *4, *6, *7, *8) and CYP2D6 deletion allele *5 
are responsible for the PM phenotype in approximately 99% of Caucasian indiyiduals 
(Stuven et al. 1996). The most common PM mutation is CYP2D6*4 allele that contains 
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a splice site mutation ENST00000320841: c.508-3G>A transition at the junction of the 
intron 4/exon 5. This mutation shifts the position of the 3-prime splice site and results 
in loss of the first base (G) in exon 5 (Gough et al. 1990). The mutation leads to a stop 
codon 40 bases further on, giving a truncated transcript and causing absence of the 
CYP2D6 protein (Kagimoto et al. 1990). The most likely process whereby the 
transcript is degraded is a form of RNA surveillance known as nonsense-mediated 
mRNA decay. CYP2D6*4 mutation represents more than 75% of PM alleles (Broly et 
al. 1991; Daly et al. 1991). The second most common PM -associated mutation is the 
gene deletion, CYP2D6*5, accounting for 14% of the inactive mutations (Broly et al. 
1991 ). 
Medical interest in CYP2D6 polymorphisms arises because CYP2D6 is responsible for 
oxidative metabolism of over 30 clinically used drugs and environmental chemicals, 
including neuroleptics, tricyclic antidepressants, antiarrhythmics and morphine 
derivatives. Codeine has been demonstrated to be ineffective analgesic in poor 
metabolisers as morphine is not activated by CYP2D6 (Poulsen et al. 1996). 
Phenotyping methods use marker substrates specific for CYP2D6 enzyme, such as 
debrisoquine, metoprolol, dextromethorphan and sparteine, to determine the metabolic 
status of subjects. 
The distribution of variant alleles for CYP2D6 gene differs markedly between ethnic 
groups (Table 6.2). CYP2D6*4 frequencies are approximately 4% in black populations 
and < 1 % in Asians (Nebert 1997). A higher frequency of duplicated or multiduplicated 
CYP2D6 genes, indicative of ultra rapid metabolism, has been observed in the Ethiopian 
population compared to Caucasians (Aklillu et al. 1996). 
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The origin of the high degree of interspecies and intraspecies variability of drug 
metabolising enzymes is unknown. It may be the result of continuous molecularlv 
driven coevolution of plants producing phytoalexins and animals responding with new 
version of enzymes to detoxify these chemicals (Gonzalez and Nebert 1990). The 
carriers of the polymorphisms may also have a selective advantage such as improved 
rates of pre-or postnatal development or growth, or resistance to bacterial or viral 
infections (Nebert 1997). 
Genetic differences in the metabolic activation of endogenous compounds or of 
xenobiotics such as chemical carcinogens have been proposed to increase susceptibility 
to cancer and other diseases (Lemos et al. 1999). Associations between CYP2D6 
polymorphisms and disease have been extensively studied. Conflicting associations 
have been reported between CYP2D6 polymorphisms and systemic lupus 
erythematosus, lung cancer and Parkinson's disease (Baer et al. 1986; Christensen et al. 
1998; Rostami-Hodjegan et al. 1998; Kortunay et al. 1999). The power of most of these 
association studies has not been reported. 
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6.2 SUBJECTS AND METHODS 
6.2.1 Subjects 
At the time of conducting this study 437 individuals from 170 Finnish families were 
available. The structure of families is in common with chapter three. 
6.2.2. Genotyping 
The genotyping of CYP2D6*4 polymorphism was performed using PCR-RFLP as 
previously described (Brown et al. 2000a). Briefly, a 421 bp fragment was amplified using 
the primers 5' -GGTGTTCCTCGCGCGCTATG -3' and 5'-
CTCGGTCTCTCGCTCCGCAC -3'. A restriction digest was performed using the enzyme 
BstNI. This enzyme cuts at a polymorphic site at position 1934 in wild type but not mutant 
alleles. To distinguish between reactions where the restriction digest has failed and 
homozygous mutant samples, a non-polymorphic BstNI restriction site at position 1772 was 
also included in a PCR fragment of 421 bp. Thus CYP2D6*4 homozygotes produce two 
fragments of lengths 77 and 344 bp, whereas non-CYP2D6*4 homozygotes produce three 
fragments of lengths 77, 161 and 183 bp. Amplifications were carried out in 10 pI reactions 
consisting of 50 ng DNA, 25 ng each primer, 200 pM each dNTP, 2.0 mM MgCb, 1 pI 
10xNH4 buffer (Bioline, London, UK) and 0.2 units Taq polymerase (Bioline, London, 
UK). The cycling conditions used were 32 cycles of denaturation at 94°C for 1 min. 
annealing 60°C for 1 min and extension 72°C for 1 min. Digests, in a total volume of 20 J.ll, 
contained 10 pI ofPCR product, 2 pI ofNE buffer 2 (New England Biolabs, Beverly. \1,'\. 
USA), 0.2 }ll bovine serum albumin, 10 units ofBstNI and dH20 were incubated for at least 
16 hours at 60°C. 
6.2.3 Statistics 
Within-family association was assessed using a generalisation of the TDT (Clayton 1999). 
Power calculations were performed as described (Chen and Deng 2001). 
6.3 RESULTS 
6.3.1 Allele frequencies 
Genotype and allele frequencies were in HWE. The founder allele frequency of 
CYP2D6*4 was 12% in Finns, shown in table 6.1 with allele frequencies published for 
other ethnic groups (Ingelrnan-Sundberg et al. 1999). 
Table 6.1 Major variant alleles of the CYP2D6 gene. 
The figure is modified after (Ingelman-Sundberg et at. 1999). 
CYP2D6 Enzyme 
variant Mutation function Metabolism Allele frequencies (%) 
Finns 
(this Other Ethiopians and 
study) Caucasians Asians Africans Saudi Arabians 
Defective Inactive 
*4 splicing enzyme None 12 12-21 2 1-4 
*S Gene deletion No enzyme None ND 2-7 6 4 \-3 
Gene 
duplication or Higher 
*2xN multiduplication enzyme levels Increased ND \-S 0-2 2 10-\6 
Pro34Ser, Unstable 
SI 6 3-9 *10 Ser486Thr enzyme Reduced ND \-2 
Thr107Ile, Altered 
Arg296Cys, substrate 
ND 34 3-9 *17 Ser486Thr affinity Reduced ND 0 
NO, not determined 
6.3.2 CYP2D6*4 in disease susceptibility 
The results ofTDT analysis using the program TRANSMIT are presented in table 6.2. 
No differences between transmitted and untransmitted allele frequencies were found. 
Table 6.2 CYP2D61934 G/A allele untransmitted founder and proband allele frequencies. 
Untransmitted founder Probands 
Allele N % N % P-value 
1 G 352 89 351 89 0.69 
2 A 44 11 45 11 
6.3.3 Power calculations 
Assuming no missing parental genotypes, a population prevalence of AS of 0.1 % and 
recessive disease model, this study had 800/0 power at the p-value of 0.05 to detect an 
effect of GRR of 7. Using these same parameters and assuming a locus specific effect 
of GRR of 2, this study has 9% power, and for 80% power 4405 families would be 
required. 
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6.4 DISCUSSION 
No association between CYP2D6*4 alleles and AS could be demonstrated. Replication 
of genetic data is essential in order to reliably confirm a true association. Failure to 
replicate a previously reported association may be the result oflack of power, 
differences in LD patterns between different populations or a false positive initial 
finding. Previous reports observed an association between homozygosity for 
CYP2D6*4 and AS, but not between heterozygosity for CYP2D6*4 indicating that this 
is a recessive locus in AS or in LD with another recessive locus (Brown et a1. 2000a). 
TDT has poor power to detect an association for a recessive trait. The low prevalence 
of PM genotype in a Finnish population further reduces statistical power. This study 
had only 9% power to detect an association assuming a locus specific GRR of 2. Our 
power calculations were performed using the TDT power calculator, which allows no 
missing parents in the calculations. In our case, 58 families had no parents available 
and 39 families had only 1 parent available. Therefore, the calculated power is an 
overestimate of the actual power. The study cannot exclude a true association of small 
locus-specific effect. A larger patient group is required in order to draw definite 
conclusions. 
It is strongly recommended that all the genetic studies report not only the type I error, 
but also the type II error of the study, that is the estimated power to detect the genetic 
effect being investigated (Dahlman et a1. 2002). Due to positive publication bias and 
large variance in test statistics, estimates of the size of the locus-specific effect in the 
initial study tend to be grossly inflated. Thus, the power calculations for a replication 
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study cannot simply be based on the first estimate of the locus-specific effect (Goring et 
al. 2001; Dahlman et al. 2002). 
Large sample sizes are required to have adequate power to identify the non-B27 genetic 
effects being studied in AS. Using the allele frequency of 0.12, a population prevalence 
of AS of 0.1 % and a recessive disease model, the sample size required to have 80% 
power at a p-value of 0.05 would be 4405 parent-case trios to detect an effect size of 
GRR of2. The recruitment ofa patient cohort of this magnitude for a relatively rare 
disease such as AS is beyond the scope of most centres. Genotyping 4405 parent-case 
trios is a major undertaking. It has been demonstrated that small changes in 
susceptibility allele frequencies may have large effects on power (Ardlie et al. 2002b). 
In case of unknown allele frequencies in the locus of interest, it may be worthwhile to 
genotype a small subset of samples first and perfonn power calculations on the basis of 
these frequencies prior to a further study. 
A within-family association method was used to detect a possible association. This has 
the advantage that the cases and controls are readily matched and spurious associations 
caused by population stratification are avoided. The disadvantage of TDT test is that it 
only counts heterozygous parents in the analysis. If the disease allele is rare, as is the 
case in this study, it reduces the number of heterozygous parents with the mutant allele. 
TDT requires the genotyping of three individuals (parent-case trios) in each unit 
compared to two individuals per unit in a case-control study. The recruitment of 
individuals for a well-matched, large case-control study may be more feasible than a 
large number of parent-case trios. Alternatively, very large family collections are 
required, and perhaps international collaborations may facilitate their recruitment. 
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The genotyping method used for this study does not differentiate the CYP2D6*4 
homozygotes from the CYP2D6*415 heterozygotes. This differentiation would require a 
further peR reaction (Brown et al. 2000a). As both CYP2D6*4 and CYP2D6*5 alleles 
are associated with the PM phenotype and the allele frequency of CYP2D6*4 in the 
Finnish population is low, CYP2D6*4 homozygotes and the CYP2D6*415 heterozygotes 
were not differentiated in this study. 
The founder allele frequency of CYP2D6*4 was 12%. This is below the level for the 
British (19%) (Brown et al. 2000a), but considerably higher than that in Asians and 
Africans (1-4%) (Ingelman-Sundberg et al. 1999). The relatively low allele frequency 
in the Finns compared to the British population may be due to inward gene flow into the 
Finnish community from the east (Kittles et al. 1998). 
It may be worthwhile to study other genes encoding metabolising enzymes in AS. A 
recent German study demonstrated an association between CYP 1 A 1 *1 A allele and 
psoriasis, a disease that is clinically related to AS (Richter-Hintz et al. 2003). This 
allele is associated with lower oxidation ofxenobiotics, possibly leading to 
accumulation ofxenobiotics and conceivably a higher chance of aberrant antigen 
formation. The same study also noted that heterozygosity for CYP2C19*lA *2A was 
protective for psoriatic arthritis, but the sample size for this sub-analysis was very small 
(Richter-Hintz et al. 2003). 
The CYP2D6 genetic polymorphisms are responsible for pronounced interindividual 
differences in plasma concentrations and in drug action and side-effects after 
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administration of the same dose. CYP2D6 poor metabolisers lack the catalytic function 
of this enzyme and, hence, the plasma concentrations of drugs specific for this enzyme 
may lead to toxic plasma concentrations and side effects. It has been suggested that 
genotyping could be used in the clinical setting to customise drug dose (Ingelman-
Sundberg et al. 1999). However, most drugs are metabolised by several different 
enzymes transported by other proteins and eventually interact with one or more targets. 
Therefore, even if inheritance influences the effect of a drug, the relatively simple one-
to-one relation observed for CYP2D6 may not be obvious. This may explain the 
relatively few examples of clinical tests based on pharmacogenetics (Weinshilboum 
2003). 
The environmental trigger in AS is unknown, but is likely to be Ubiquitous. 
Theoretically xenobiotics could elicit or exacerbate AS. Drugs and other chemicals are 
capable to induce allergic or autoimmune reactions (Griem et al. 1998). One possible 
mechanism is that self-peptides or MHC determinants are chemically modified. Some 
metals are believed to induce autoimmune reactions secondary to the creation of new 
high affinity sites for MHC determinants on selfpeptides. Alternatively, hapten-
specific T lymphocytes may help B lymphocytes that are able to recognise haptenated 
self-protein (Kimber and Dearman 2002). Examples of autoimmune diseases caused by 
xenobiotics include Stevens-Johnson syndrome and dihydralazine-induced systemic 
lupus erythematosus (Brown et al. 2000a). These diseases are clearly different diseases 
to AS, but demonstrate that impaired xenobiotic metabolism can induce autoimmune 
disease in humans. 
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It has been proposed that altered metabolism of a natural toxin by the CYP2D6 gene 
could increase susceptibility to AS (Brown et al. 2000a). This hypothesis illustrates 
how the interaction between an environmental trigger and inter-individual genetic 
predisposition may confer susceptibility to disease. It is of note that the metabolism of 
xenobiotics may involve several enzymes and interactions with other proteins. 
Xenobiotics may interact directly with certain cytokines altering their activity (Brooks 
et al. 2001), illustrating the potentially complex network of interactions involved in their 
actions and metabolism. 
6.S CONCLUSIONS 
This study failed to demonstrate a significant association between CYP2D6*4 
polymorphism and AS, but the low power of the study cannot exclude the presence of a 
true positive association. As exemplified by this study large sample sizes are required 
to detect small effects. The underlying disease model and the disease associated allele 
frequency are critical factors influencing the test power. Power calculations are 
essential for the correct interpretation of negative results. The abundance of available 
information on the existence and function of polymorph isms and the development of 
high-throughput genotyping means, allow the design of large-scale studies having 
sufficient power to detect at least common dominant or codominant disease loci. Such 
studies on different genes for xenobiotics metabolising enzymes could possibly lead to 
new insights into the AS aetiology in the future. 
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CHAPTER 7 - DISCUSSION AND FUTURE DIRECTIO~S 
7.1 BACKGROUND 
AS is a complex genetic disease in which allele and locus heterogeneity play important 
roles. HLA-B27 is necessary but not sufficient to explain the total variance of the 
heritability of the disease; other genes are likely to significantly contribute to the disease 
pathogenesis. The maximization of sample homogeneity is particularly important for 
the successful outcome of linkage and association studies in AS. This thesis 
investigates genetic determinants of AS mainly in a homogenous Finnish population. 
The current Finnish population of approximately 5 million arose from a limited number 
of founders about 2000-2500 years ago (de la Chapelle 1993). Since this initial 
founding, the population has undergone several bottlenecks and genetic drift has shaped 
the allele frequencies. The Finnish population has proven to be very useful in the 
mapping of susceptibility loci of rare monogenic disorders (Hastbacka et al. 1994). It 
has been demonstrated that several disease mutations characterised in Finland show a 
founder effect. Internal population isolates in the northern Finland reveal greater LD 
than the older populations (Laan and Paabo 1997; Varilo et al. 2003). In contrast, the 
general Finnish population does not exhibit larger regions of LD than more outbred 
populations (Eaves et al. 2000; Taillon-Miller et al. 2000), suggesting that LD mapping 
projects employing the Finnish population could not reduce the required marker density. 
The Finnish population may exhibit a limited number of disease genes in initial 
founders and less genetic heterogeneity. The population is especially suitable for casc-
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control studies because the known and homogenous genetic background of all 
individuals reduces the effect of population stratification. Furthennore, isolated 
populations may be more homogeneous in the environment which has the potential to 
decrease the genetic complexity underlying polygenic diseases. Some linkage-based 
projects aimed at identifying susceptibility genes in common diseases have been 
conducted using the Finnish population (Asumalahti et al. 2000; Watanabe et al. 2000; 
Laitinen et al. 2001). In the light of limited experimental evidence, it remains to be 
determined whether Finland is more suitable than more outbred population for disease 
gene mapping of complex diseases. 
Significant differences in the allele and haplotype frequencies between the Finnish 
population and the British population were noted in the CYP2D610cus, TGFBllocus 
and HLA region suggesting divergent population histories of these two populations. 
The extent of observed LD in these regions was not substantially greater in the Finnish 
population than in the English population, consistent with previous reports (Eaves et al. 
2000; Taillon-Miller et al. 2000). 
This thesis investigates three candidate regions in AS: TGFBllocus on chromosome 19, 
CYP2D610cus on chromosome 22 and the HLA region on chromosome 6. Previously 
all of these regions have been linked with AS by linkage studies (Rubin et al. 1994; 
Brown et al. 1998b; Laval et al. 2001). 
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7.2 SUMMARY OF THE RESULTS 
The first project investigates a positional and functional candidate gene, TGFBl, in 
susceptibility to, and severity of, AS in a Finnish and British population. A weak 
association between the TGFBl1627 C>T polymorphism and AS was noted in the 
Finnish population (p=0.04), but this was not significant in the English population alone 
(p=0.34). A marginal association between the TGFBI promoter SNP (-800-509) 
haplotype 2/1 was noted in the English population (p=0.05), but this was not significant 
in the Finnish data set (p=0.53). These discrepant associations may reflect genuine 
locus and allele heterogeneity between the Finnish and English populations, different 
LD patterns with a further truly associated variant, phenotype differences between the 
populations or different environmental backgrounds. Alternatively, the differences may 
be related to the stochastic statistical fluctuations and the multiple comparisons made. 
No association was noted among the families which showed a positive NPL score at this 
locus, suggesting that these polymorphisms do not explain the linkage of AS 
susceptibility to chromosome 19. 
The second experimental chapter of this thesis describes a novel HLA-DRBI genotyping 
method based on the primer extension reactions. This method was developed to allow 
rapid and cost-effective screening of a large number of AS cases and their family 
members. The primary limitation of this method is its low resolution, which could be 
improved by employing a group of HLA-DRBI specific peR primers. 
The third experimental chapter of this thesis describes the effect of HLA genes and 
haplotypes in susceptibility to, and severity of, AS in the Finnish population. HLA-B27 
positive case and control haplotypes were employed to adequately control for the strong 
association between HLA-B27 and AS, and a significant LD between HLA-B27 and 
HLA-DRBl alleles. As demonstrated in table 5.12, several distinct HLA-DRB1 alleles 
exhibit significant LD with HLA-B27, and thus it is essential to use HLA-B27 matched 
controls. Previous studies have reported positive associations with HLA-DRB1 *01 
allele and AS (Brown et al. 1998a; Vargas-Alarcon et al. 2002b), but these studies have 
not controlled for the effect of HLA-B27 at the haplotypic level. No statistically 
significant difference between distinct HLA-DRB1-B27 haplotypes of AS cases that 
were adequately matched with HLA-B27 positive control haplotypes was noted. A 
further control group will be available for future analysis to increase the power of the 
study (Jorma Ilonen, personal communication). Homozygosity for HLA-B27 was over-
represented in cases with AS when compared to the expected number of HLA-B27 
homozygotes predicted by Hardy-Weinberg. Significant associations between both 
HLA-B27 and HLA-DRBl *08 and a younger age of symptom onset was found 
suggesting that genes within the MHC are involved in determining the age of symptom 
onset. 
The fourth experimental chapter of this thesis investigates the influence of CYP2D6*4 
poor metaboliser allele in AS. Due to the low allele frequency of the poor metaboliser 
alleles in the Finnish population, the power of the within-family association by TDT 
was poor. No association was found, but due to lack of power this study could not 
exclude true positive association with the disease either. 
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7.3 FUTURE DIRECTIONS IN THE GENETICS OF COMPLEX DISEASES 
The scope of complex disease gene mapping has been markedly changed by the vast 
increase in the number of known and putative new genes resulting from the Human 
Genome Project (Lander et al. 2001), the identification of many polymorphisms 
(Sachidanandam et al. 2001) and the development of new high-throughput methods for 
large-scale genotyping (Syvanen 2001). It has also set a new challenge of how best to 
use the wealth of information. These developments promise great advances in medical 
genetics. As a result of weak linkage signals, positional cloning has limited use in the 
identification of complex disease variants conferring low relative risks for individual 
loci. Attention has therefore turned to association or LD studies in the expectation that 
this approach may be more effective (Risch and Merikangas 1996). 
In theory, association studies can be conducted genome-wide. However no consensus 
has emerged yet on the number of SNPs that may be required, the selection of study 
design or the methodology of statistical analysis. Even low-end estimates of the number 
of SNPs required for a whole genome association study are in the range of 50000 -
100000 (Collins et al. 1999; Boehnke 2000). Two strategies have been proposed for 
genome-wide association studies namely map-based gene discovery and sequence-based 
gene discovery (Peltonen and McKusick 2001). Sequence-based approaches test 
functional variants in known genes across the genome and a map-based method 
systematically tests a dense map of anonymous polymorphisms across the genome. For 
D The the map-based study, it is critical to define the exact pattern of genome-wide L . 
primary limitation of this approach is the lack of complete disequilibrium with any 
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tested candidate allele, which can substantially reduce power (Muller-Myhsok and Abel 
1997). As genome-wide LD maps and gene- and population-specific data become 
available, it may be possible to evaluate potential haplotypes and to select most useful 
SNP markers. The human population is predicted to possess millions of SNPs, making 
it necessary to prioritise the choice of marker SNPs. Prior knowledge of the location of 
the SNPs, the LD pattern around the SNP and the allele frequencies of the SNPs allows 
for sophisticated study designs maximising the likelihood of successful outcome. The 
development of improved genotyping methods, possibly those based on a DNA pooling 
approach (Amheim et al. 1985; Sasaki et al. 2001; Matyas et al. 2002; Werner et al. 
2002), is required before genome-wide association studies are achievable at acceptable 
genotyping costs and effort. The investigation of the genetic basis of complex disorders 
has also set new challenges for statistical analysis and interpretation of the results. 
Statistical tools that can deal with large numbers of genotypes, complex disease 
inheritance and multiple phenotypes are required. Identification of effective gene 
mapping strategies is of primary importance for the future of complex disorders. 
Haplotype mapping focusing on different human populations (Daly et al. 2001; Gabriel 
et al. 2002) and systematic profiling of protein expression (Agaton et al. 2003) may 
facilitate the identification of novel genes and pathways involved in complex disease. 
The identification of causative genes of complex disorders has proven to be challenging. 
Linkage and association studies have frequently produced conflicting results in 
ethnically distinct populations. However, recent advances in the genetics of complex 
diseases support an optimistic view of future prospects. Examples of recent success in 
the field of complex disease genetics include the identification of associations between 
NOD2 variants and Crohn's disease (Hugot et al. 2001; Ogura et al. 2001), and betwccn 
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ADAM33 gene and asthma and bronchial hyperresponsiveness (Van Eerdewegh et al. 
2002). Variation in the calpain-l 0 gene was initially linked and associated with type 2 
diabetes mellitus susceptibility in a population of Mexican Americans (Horikawa et a1. 
2000). Subsequent association and linkage studies of the variants in this locus in other 
populations produced conflicting results (Evans et a1. 2001; Fingerlin et a1. 2002; Orho-
Melander et a1. 2002). However, a recent meta-analysis and a large association study 
confirm the role for calpain-l 0 variation in type 2 diabetes susceptibility (Weedon et al. 
2003). It also demonstrates that meta-analyses of published genetic associations, 
combined with large replication studies, are a powerful approach to detect causative 
variants in common disease (Weedon et a1. 2003). 
Demonstrating the definitive proof of specific genetic causation in complex disease is 
elusive. A recent review suggests guidelines for steps to be taken to address the 
possible confounders of association before polymorphisms may be called 'causative' 
(Page et a1. 2003). All known sources of bias should be eliminated before causative 
association is claimed. Once a haplotype associated with increased susceptibility to a 
disease has been identified, all SNPs that define the haplotype are candidates for 
causality. Gene expression analysis and complementary studies using animal models 
can aid the detection of the causal variant. 
Genetic information may allow customising drug selection and dose based on each 
person's genetic profile. Such individualised treatment plans may avoid side effects, 
increase the specificity and efficiency of the treatments and potentially lead to 
pharmaco-economic gain. The identification of causative variants in genes for complex 
diseases allows the rational development of drugs to target the genes. protein path\\'3y~ 
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and networks demonstrated to be involved in primary disease path . (C II· ogenesIs 0 InS et 
al. 2003). Unravelling of the biological function of the disease associated genetic 
variants and development of novel specific pharmacological treatments based on these 
findings, is a key challenge in the postgenomic era. 
7.4 DIRECTIONS FOR FUTURE WORK IN THE GENETICS OF AS 
A key objective for future efforts in the genetics of AS will be the transition from 
linkage analysis and modelling into identification of susceptibility genes and analysis of 
the pathways and mechanisms of AS. Large patient collections, the development of 
powerful analytical methods and high throughput SNP genotyping technologies will 
facilitate this endeavour. The recently established AS consortium 
(www.well.ox.ac.uklbrownlGASC.shtml) aims to promote collaborative research and 
makes a large patient collection available to establish future collaborative projects. 
Future meta-analyses of linkage projects undertaken by various groups is likely to have 
the high statistical power required to refine areas of linkage in AS. 
Recent advances in the genetics of AS include the identification of an association in the 
susceptibility locus of the IL-l genetic cluster (McGarry et al. 2001 b; van der Paardt et 
al. 2002a; Maksymowych et al. 2003). Genetic fine mapping studies are required to 
refine the definite causative variants involved in this locus. Further studies are 
necessary to establish the functional importance of these variants. Given the 
preliminary results that treatment with recombinant human IL-I Ra is effective in some 
patients with AS (Haibel et al. 2003), it may be possible that polymorphisms in this 
locus influence the outcome of this treatment. The involvement of cytokines in the 
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pathogenesis of AS is likely to be multifaceted and a variety of cytok· d k· 
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receptor polymorphisms may interact with one another. Elucidation of the interaction 
of cytokine genes may provide insights into this poorly understood disease. 
The development of novel research methods, such as the microarray technology, may 
shed light on the disease mechanisms involved in AS. The transcript pattern of affected 
and unaffected tissues can be compared by microarray technology, this could facilitate 
the identification of novel candidate genes in AS. The technology can identify genes 
that are dysregulated because of the susceptibility allele. Microarray analysis has the 
ability to assess the expression of a plethora of genes simultaneously. A significant 
weakness of micro arrays is that they are prone to great experimental variability. 
However, the technology is relatively new, experimental procedures should improve 
and result in greater reliability in the future. Another disadvantage of microarrays in AS 
includes the difficulty of obtaining samples of the affected tissues, such as the spine, 
sacroiliac joints and enthesis. Peripheral blood, which is easy to obtain, may not be 
involved in the disease process, and peripheral blood cells may not exhibit disease-
specific changes in gene expression. Recent microarray analysis demonstrated 
enhanced expression of monocyte chemotractant protein 1, proteasome subunit C2 and 
immunoglobulin heavy chain binding protein (BiP) in synovial fluid mononuclear cells 
of SpA patients, providing clues to the genes involved in synovial disease in SpA (Gu et 
al. 2002a). As BiP is a chaperone protein resident inside the ER, increases in BiP 
suggests that ER stress response due to accumulation ofmisfolded HLA-B27 may be 
involved in SpA (Ou et al. 2002b). 
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Two major types of micro arrays have been developed: DNA and protein arrays. DNA 
microarrays allow the comparison of expression of mRNA between the affected and 
unaffected tissue. However, there is disparity between the relative expression leyels of 
mRNA and their corresponding proteins. In addition, due to alternative splicing of 
mRNA and post-translational processes the number of functional proteins is known to 
exceed the number of its genes. Protein micro arrays may increase the understanding of 
protein expression in AS and allow the profiling of relevant protein interactions. 
However, due to the diverse physical properties of proteins, the development of protein 
arrays is complicated and currently in its infancy. Data integration of DNA and protein 
microarrays, histology and genetics could facilitate the elucidation of disease pathways 
in AS and contribute to the stratification of individual patients into subgroups with an 
optimal response to specific therapeutic interventions. 
The phenotype of a complex disease may encompass a wide range of clinical symptoms 
and subtypes. Thus, it is essential that standardised, validated ascertainment criteria are 
used in patient recruitment. The modified New York diagnostic criteria were used in 
this study (van der Linden et al. 1984a). However, the disease diagnosis arises from 
clinical traditions, and there are many phenotypic features in AS that cut across 
diagnostic categories such as sacroiliitis. AS patients vary in severity of symptoms and 
age of onset which results in heterogeneity in the phenotypic expression. This 
heterogeneity is likely to increase the number of loci involved and hamper the 
identification of disease genes. One approach is to subdivide the phenotype of AS into 
smaller and more homogeneous entities, which in turn may help in the identification of 
disease genes. This approach could involve for example the investigation of AS patient 
. . . h of symptom onset An example WIth associated IBD or AS patIents WIt a younger age . 
of this kind of success was the initial finding oflinkage for the breast cancer (BReAl) 
gene. Genetic analysis of breast cancer families with early-onset disease yielded a 
significant linkage peak on chromosome 17q21, which allowed the identification of 
BRCAI gene (Hall et al. 1990). Another commonly used approach is to use large 
multiply affected kindreds in which the affected individuals are likely to share more 
disease alleles (Tomfohrde et al. 1994). Such studies could facilitate genetic linkage 
studies in AS. 
A number of linkage and association studies published to date are underpowered. Well-
designed and large genetic studies are required to identify the non-HLA-B27 genetic 
effects in AS. Collaborative projects may help to identify sufficiently large patient 
groups required for genetic analysis. The disadvantage of multi-centre studies is the 
potential for heterogeneity in the ascertainment and the phenotype definition of patients. 
Furthermore, the inclusion of samples from different ethnic popUlations may increase 
the heterogeneity of multi-centre studies as diverse populations may exhibit different 
LD patterns and disease associations. Ideally, a positive association and linkage signal 
is confirmed in several ethnically distinct populations and by several independent 
groups. Homogeneous populations such as the Finnish population may help us to 
define the genetic complexities of AS pathogenesis. 
7.5 CONCLUDING REMARKS 
This thesis is consistent with the concept that AS represents a disease with a complex 
genetic aetiology. A novel HLA-DRBl method was developed and emplyed in a large 
number of AS families to evaluate the contribution of HLA-DRBI alleles in AS. 
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Association between the MHC region and AS appears to be heterogenous, and genes 
within the MHC are involved both in disease susceptibility and the age of symptom 
onset. HLA-B27 homozygosity increases susceptibility to AS. TGFBl gene 
polymorphisms do not appear to have a major impact in AS and they do not explain the 
observed linkage to chromosome 19. 
The molecular mechanisms of disease pathogenesis of AS remain to be adequately 
defined. AS is a highly heritable disease and a large proportion of the genetic variance 
of the disease is not yet known. Unravelling these genetic variants could yield insights 
into the pathogenic mechanisms, allow the refinement of the molecular diagnosis of the 
disease and eventually open new avenues for tailored therapies. 
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APPENDIXl 
Questionnaire for Ankylosing Spondylitis I Selkiirankareumakysely 
MAIN 
I 
I 
INDIVID char(3) 
PTID** char(9) 
SSN** 
BDATE 
I TEL 2** 
TEL 3** 
Ql 
Q2YEAR ) 
Q2AGE 
char(4) 
proband 
1-999= other relatives 
internal use 
I-character Social Security 
1. Mikii on koulutuksenne? .. 
1 = kansankoulu 
- ammattikoulu 
3= opistotutkinto 
korkeakoulu 
Mil/oin selkiirankareumanne 
alkovait? Vuonna: 
99= don't know 
Mil/oin selkiirankareumanne 
proband 
001-999= other relatives 
internal use 
II-character Social 
don't know 
.a. When did your 
ankylosing spondylitis 
:4S) begin? year: 
9999= don't know 
a.i. age: 
don't know 
b. When was the 
242 
oireet alkovait? Vuonna: ~iagnOSiS of AS made? 
9999= don't know ear: 
9999 don't know 
Q3AGE char(2) K3 . ... ikiiisenii 1. b. i. age: 
99= don't know 
I 
99 don't know i 
K4. Oletteko ollut 1.e. Have you ever seen a 
reumatautien. .. : rheumatologist: Q4 char(1) 1= yes 1= yes 
2= no 2= no 
I 9= don't know 9- don't know 
K5. Mikiili vastasitte KYLLA: ... 1. e. i. If YES, on average, I 
vastaanotolla how many visits do you I 
Q5 char(2) selkiirankareumanne takia? make to your ' 
kertaa rheumatologist per year 
99= don't know because of your AS? 99- don't know 
. -
K6. Onko seliistiinne koskaan l.d. Have vall ever had 
[ptettu rontgenkuvaa? IX-rays taken of your 
Q6 char(l) 1= yes back? I 
2= no 1= yes I 
9= don't know 2=no 19= don't know 
char(10) K7. Mikiili vastasitte KYLLA', niin 
I.e. If YES, please say 
Q7DATE mainitkaa aika ja paika missii when and where the most dd.mm.yyyy 
viimesin. .. recent ones were taken. Year: 
Q7PLACE** char(100) K7.paika I. e. i. Where (place): 
K8. Oletteko tiillii hetkellii 3.a.;' Are you currently 
.. ..? tyossa . ... employed? 
Q8 char(1) 1= yes 1= yes 
2= no 2= no 
9= don't know 9= don't know 
3.b.IfYES, how much 
K9. Mikii vastauksenne on time off work have you 
KYLLA', niin kuinka pitkiiiin. .. had per year because of 
1 = en ollenkaan J;our AS: 
Q9 char(l) 2= vahemman kuin 1 viikko 
1= none 
3= 1-4 viikkoa 2= less than 1 week 
4= 1-3 kuukautta 3= 1-4 weeks 
5= yli 3 kuukautta 4= 1-3 months 
9= don't know 5= more than 3 months 
9= don't know 
KIO. Mikiili vastauksenne oi El, 13.c. If NO, are .'vou: 
niin oletteko ! 1 = unemployed & 
QI0 char(1) 1 = tyoton / hakemassa tyota intending to work 
2= elakkeella ,2= retired 
9= don't know 9= don't know 
I 
- - ----- -.,....---~-. --~-- --------
I 
. ! 
Qll Ichar(2) IKII. los olette ... vuotiaana 13.d.l. IJ RETIRED. at 
2 .. B 
Q12 char(2) 
Q13 char(l) 
Q14 1 char(l) 
Q142 char(l) 
Q143 char(1) 
Q144 char(l) 
char(1 ) 
char(1) 
char(1 ) 
99 don't know what age did VOli retire? I 
99 don't kn~w 
. ...... .. 3.d.i.i. What is the usual 
Kl!. Mz~ka zkazsena ... vuotiaana ,age of retirement for 
99- don t know ~our occupation? 
f99- don't know 
Kl3. Oletteko tyottomana -
elakkeella: 
1 = pelkastaan 
selkarankareumanne takia 
2= osittain selkarankareumanne 
takia 
3= muunkuin 
selkarankareumanne takia 
9= don't know 
K14. Mitka ovat mielestanne 
P AASIALLISET 
selkarankareumoireenne? 
K14.1. vasymys 
0= no 
1= yes 
K14.2. selkakipu (niska / selka / 
lonkka)K14. Mitka ovat 
mielestanne P MSIALLISET 
selkarankareumoireenne? 
0= no 
1= yes 
K14.3. jaykkyys 
0= no 
1= yes 
K14.4. nivelkipu / turvotus 
0= no 
~~ yes 
K14.5. kosketus / paineluarat 
alueet 
0= no 
1=yes 
K14.6. ei pysty erittelemaan 
0= no 
1= yes 
K14.7a. muu, tarkentakaa 
0= no 
1= yes 
3.e. Are you 
UNEMPLOYED / 
RETIRED: 
1 = Solely because of 
your AS? 
2= Partly because of your 
AS? 
3= For reasons other than 
your AS? 
9- don't know 
4. In your opinion, 
which is the main 
symptom of your AS? 
(please tick one) 
4.1. Fatigue: 
0= no 
1= yes 
4.2. Spinal pain (neck / 
back / hip): 
0= no 
1= yes 
4.3. Stiffness: 
0= no 
1= yes 
4.4. Joint pain / swelling: 
0= no 
1= yes 
4.5. Areas tender to 
touch / pressure: 
0= no 
1= yes 
4.6. Cannot distinguish 
one main symptom: 
0= no 
1= yes 
4.7a. Other (please 
specify:) 
0= no 
1= ves 
. Q14_7TXT char(50) KI4.7b. tarkentakaa 4.7b. Specification 
KI5. Onko Teilla ollut 5.a. Do YOli get iritis 
varikalvontulehdus .. (uveitis)? Q15 char(l) 1= yes 1= yes 
2= no (go to K23) 12= no (go to 6.a) 
9= don't know 19= don't know 
KI6. Mikali vastasitte KYLLA.' 5.a.i.1jYES, who made , 
kuka sen totesi? the diagnosis? 
1 = yleislaakari I=GP 
Q16 char(l) i 2= reumatautien erikoislaakari 2= Rheumatologist 
3= silmalaakari 3= Eye specialist 
4= joku muu kuin laakari 4= No doctor 
8= irrelevant (QI5=2) 8= irrelevant (5.a=2) 
9= don't know 9= don't know 
. -" .-- --
KI7. Onko Teilla ollut silman 5.b. Have you had any 
varikalvontulehdukseen. .. treatment for it? 
Q17 char(l) 1= yes 1= yes 2= no 2= no 
8= irrelevant (Q 15=2) 8= irrelevant (5.a=2) 
9= don't know 9= don't know 
KI8. Mikali vastasitte KYLLA', 5.b.i.1jYES, please Q18 char(200) nUn mainitkaa tarkemmin 
minkalaisen hoidon olette saanut specify 
KI9. Kuinka monta kertaa Teilla S.c. Approximatelly how 
on ollut silman many attacks have you 
Q19 char(2) varikalvontulehdus? ... kertaa had overall? 
88= irrelevant (QI5=2) 88= irrelevant (5.a=2) 
99= missing 99= missing 
K20. Kuinka monta kertaa Teilla S.d. Approximatelly how 
on yleensa silman many attacks do you 
Q20 char(2) varikalvontulehdus ... kertaa have per year? 
88= irrelevant (QI5=2) 88= irrelevant (5.a=2) 
99= missing 99= missing 
K2I. Milloin Teilla oli silman 
5.e. When was your last 
attack? 
char(lO) varikalvontulehdus viimeksi? 88.88.8888= irrelevant Q21DATE dd.mm.yyyy 88.88.8888= irrelevant (QI5=2) (5.a=2) 
99.99.9999= missing 99.99.9999= missing 
, 
K22. Onko silman 5./ Has the uveitis 
varikalvontulehdus aiheuttanut resulted in persistent 
~ysyvan ... deterioration of vision 
Q22 char(l) 1= yes 1= yes 
2= no 2= no r 
8= irrelevant (QI5=2) 8= irrelevant (5.a=2) 
9= don't know 9= don't know 
K23. Onko Teilla psoriasi 6.a. Do you get 
Q23 char(l) (ihottuma) ? !psoriasis :) 
1- yes 1= yes 
2 no (go to K27) 2= no (go to 7.a) , 
9= don't know 9- don't know 
K24. Mikiili vastasitte KYLLA' 6.a.i. If YES, who made , 
nUn mainitkaa kuka teki .. the diagnosis? 
1 = yleislaakari l=GP 
Q24 char(l) 2= reumatautien erikoislaakari 2= Rheumatologist 
3= ihotautilaakari 3= Eye specialist 
4= joku muu kuin laakari 4= No doctor 
8= irrelevant (Q23=2) 8= irrelevant (6.a=2) 
9= don't know 9- don't know 
K25. Onko Teillii ollut jokin hoito 6.b. Have you had any 
ipsoriaasikseene? tratment for it? 
Q25 char(1) 1= yes 1= yes 2= no 2= no 
8= irrelevant (Q23=2) 8= irrelevant (6.a=2) 
9= don't know 9= don't know 
" ". 
K26. Mikiili vastasitte KYLLA', 6.b.i. If YES, please Q26 char(200) nUn mainitkaa tarkemmin 
hoidosta? specify 
K27. Onko Teillii todettu Crohnin 7.a. Have you ever been 
sairaus? diagnosed as having 
Q27 char(1) 1= yes Crohn's disease? 1= yes 2= no 
9= don't know 2= no 9= don't know 
K28. Mikiili vastasitte KYLLA', 7.a.i. If YES, who made 
kuka teki diagnoosin? the diagnosis? 
1 = yleislaakari I=GP 
Q28 char(l) 2= reumatautien erikoislaakari 2= Rheumatologist 
3= vatsatautien erikois1aakari 3= Eye specialist 
4= joku muu kuin laakari 4= No doctor 
, 
9= don't know 9= don't know 
K29. Onko Teillii todettu 
7.b. Have you ever been 
ihaavainen paksusuolen tulehdus? 
diagnosed as having 
Ulcerative colitis? 
Q29 char(l) '1= yes 1= yes 
"2= no 2= no 
9= don't know 9= don't know 
K30. Mikiili vastasitte KYLLi, 7.b.i. If YES, who made 
kuka teki diagnoosin? the diagnosis? 
1 = yleislaakari l=GP 
Q30 char(l) 2= reumatautien erikoisHiakari 2= Rheumatologist 
3= vatsatautien erikoislaakari 3= Eye specialist 
4= joku muu kuin laakari 4= No doctor 
9= don't know 9= don't know 
K31. Mitkii ovat mielestiinne 8. Have you had during I 
PAASIALLISET past year unexplained 
selkiirankareumoireenne? (i.e. not due to an 
, 
I 
accident or injury) pain I 
or swelling on any of 
I 
K31.1. kosi 
the following joints? 
8.1. Hand I Q31_1 char(1) 0= no 0= no I 
1= yes 1- yes 
! 
K31.2. kyynarpaa 18.2. Elbow 
Q31_2 char(l) 0= no 0= no 
1= yes 1- yes 
K31.3. olkapaa 8.3. Shoulder 
Q31_3 char(1) 0= no 0= no 
1= yes 1- yes ! 
K31.4. lonkka 8.4. HIP I I Q31_4 char(1) 0= no 0= no I 
1= yes 1- yes 
K31.5. polvi 8.5. Knee 
Q31_5 char(1) 0= no 0= no 
1 =.= yes 1= yes , , 
K31.6. nilkka 8.6. Ankle 
Q31_6 char(l) 0= no 0= no 
1= yes 1= yes 
K31. 7. jalkatera 8.7. Foot 
Q31 7 char(1) 0= no 0= no 
1= yes 1= yes 
K31.8. kantapaa 8.8. Heel 
Q31_8 char(l) 0= no 0= no 
1= yes 1= yes 
9.a. Have you ever had 
surgery for your joint or 
K32. Onko Teilla koskaan tehty 
spine as a result of your 
lAS? leikkausta niveliinne tai... 
Q32 char(1) 1= yes 
1= yes 
2= no 
2= no 9= don't know 
9= don't know Note: infonnation on 
surgeries is table 
sun!eries 
lO.a. For how many 
K34. Kuinka mointa tuntia hours per week on an 
keskimaarin viikossa osallistutte average have ."·Oll taken 
urheiluun. .. ipart in sports, AS 
1 = 10 tai useampia tunteja exerCIses or 
Q34 char(1) 2= 5-9 tuntia hydrotherapy during the 
3= 2-4 tuntia last three months? 
4= 1 tunti 1 = 10 and more hours 
5= 0 tuntia 2= 5-9 hours 
I 9= don't know i3= 2-4 hours I 
14= 1 hour 
---
----
247 
i -. 
I 
I 
15=0 hours 
I 9 don't know 
10.h. Place a vertical 
K35 .... joka mark on the scale below 
liikuntaharjoituksillanne on to indicate the 
oireittenne lievitykseen effectiveness which rOllr 
0= Ei mit~Hin exercise has on relieving 
1= 1 [Your symptoms: 
2=2 0= None 
3= 3 1= 1 
Q35 char(2) 4=4 
2=2 
5= 5 3= 3 
:6=6 4=4 
7=7 5= 5 
I 
I 
8= 8 6=6 
i 
9=9 7=7 
10= 10 8= 8 
11= Hyvin tehokas 9=9 
99= don't know 10= 10 11 = Very effective 
99- don't know 
l1.a. Place a vertical 
K36 . ... sairaudellanne on ollut mark on the scale below 
vointiinne VIIMEISEN VIIKON to indicate the effect your 
~IKANA disease has had on your 
0= Ei mitiHin well-being over the last 
1= 1 hour week: 
2= 2 hours 
0= None 
3= 3 hours 
1= 1 hour 
4= 4 hours 
2= 2 hours 
Q36 char(2) 3= 3 hours 
,5= 5 hours 
6= 6 hours 
4= 4 hours 
7= 7 hours 
5= 5 hours 
6= 6 hours 
8= 8 hours 
9= 9 hours 
-7= 7 hours 
8= 8 hours 
10= 10 hours 
11 = Huonoin mahdollinen 
9= 9 hours 
10= 10 hours 
99= don't know 11 = Worst possible 
99= don't know 
K37 . .. , sairaudellanne on ollut 11.h. Place a vertical 
vointiinne VIIMEISEN KUUDEN mark on the scale below 
(6) kuukauden aikana to indicate the effect your 
0= Ei mitaan disease has had on ,'our 
Q37 char(2) 1= 1 hour ·well-being over the six 
2= 2 hours months: 
3= 3 hours 0= None 
4= 4 hours 1= 1 hour 
5= 5 hours 2= 2 hours 
-- ---.-~~---~-> 
, 
24X 
6 6 hours 3- 3 hours 
7= 7 hours 4= 4 hours 
8= 8 hours :5= 5 hours 
9= 9 hours 16= 6 hours 
10= 10 hours 7= 7 hours 
11 = Huonoin mahdollinen 8= 8 hours 
99= don't know 9= 9 hours i 
10= 10 hours 
I 
I 
11 = Worst possible I 
99 don't know 
12.a. Are YOli currently 
taken any medication for 
K38 . ... talla hetkellajokin your AS? 
laakitys selkarankareuman takia? 1= yes 
Q38 char(l) l=yes 2= no 
2= no 9= don't know 
9= don't know Note: information on 
medication is given in 
table medications 
13. Please place a mark 
on each line below to 
indicate your answer to 
each question, relating 
I 
to the PAST WEEK 
K41. Kuinka arvioitte 13.1. How you would 
kokemaanne uupumuksen / describe the overall/eve/ 
vasymyksen kokonaistasoa? of fatigue / tiredness you 
0= Ei vaikutusta have experienced? 
1= 1 
0= None 
2=2 
1= 1 
3= 3 
2=2 
4=4 
3= 3 
Q41 char(2) 5= 5 4=4 I 
6=6 
5= 5 I 
6=6 
I 
7= 7 7=7 
8= 8 8= 8 
9=9 9=9 
10= 10 
11 = H yvin vaikea 
10= 10 
11 = Very severe 
99= don't know 99= don't know 
K42. Kuinka arvioitte 13.2. How \'Oll would 
selkarankareumastanne describe the overall/evel 
aiheutuvan niska-, se/ka- tai ... (~f AS neck, back or hip 
Q42 char(2) 0= Ei ollenkaan 
Ipain YOli have had? 
1= 1 0= None 
2=2 1= 1 
3= 3 2= 2 
4=4 3= 3 
Q43 char(2) 
Q44 : char(2) 
Q45 char(2) 
i5 5 
6=6 
I 
'7=7 
, 
:8= 8 
'9=9 
10= 10 
lll= Hyvin paljon 
. 99= don't know 
4=4 
5=5 
6=6 
7=7 
8=8 
9=9 
10= 10 
11 = Very severe 
99 don't know 
, 13.3. How you would 
: K43. Onko muualla kuin niskassa describe the overall level 
selassa tai lonkassa oleva ' of pain / swelling in 
nivelten kipu\turvotus... ioints other than neck, 
'0= Ei ollenkaan back or hips you have 
! 1= 1 had? 
,2=2 0= None 
3= 3 1= 1 
04=4 2=2 
15= 5 3= 3 
6=6 4=4 
7= 7 5= 5 
.8= 8 6= 6 
19= 9 7= 7 
I 
10= 10 8= 8 
.9=9 11= Hyvin paljon 
99= don't know 
, 
10= 10 
11 = Very severe 
99- don't know 
: K44. Kuinka arvioitte milla 
;13.4. How you would 
,describe the overall level 
! tahansa kehon alueella olevan 
kosketus- tai '" 
0= Ei vaikutusta 
1= 1 
2=2 
3=3 
14=4 
5=5 
!6=6 
7=7 
8=8 
9=9 
10= 10 
11 = Hyvin paljon 
,99= don't know 
K45. Kuinka arvioitte selan 
, 
aamujaykkyyden vaikuttaneen 
I 
of discomfort you have 
; had from any areas 
: tender to touch or 
preassure? 
0= None 
1= 1 
2=2 
3= 3 
4=4 
·5= 5 
;6=6 
7=7 
8=8 
9=9 
10= 10 
11 = Very severe 
99= don't know 
13.5. How you would 
describe the overall level 
250 
vointiinne paivan aikana? 
10- E' 'kut of morning stiffness you , - I val usta have had from the time 
I 1= 1 you wake up? 
I 2=2 0= None 
3= 3 11= 1 I 
4=4 2= 2 
5= 5 3=3 
6=6 4=4 
7=7 5= 5 
8= 8 6=6 
9=9 7= 7 
10= 10 8= 8 
11 = Hyvin paljon 9=9 
t 99= don't know 10= 10 
I 
I 
11 = Very severe 
99= don't know 
! 13.6. How long does I 
K46. Kuinka kauan selkanne tyour morning stiffness 
aamujaykkyys kestaa? last from the time you 
1= 0 min. wake up? 
2= 10 min. 1= 0 min. 
Q46 char(l) 3= 20 min. 2= 10 min. 4= 30 min. 3= 20 min. 
5=40 min. 4= 30 min. 
6= 50 min. 5= 40 min. 
7= >= 1 tai useampi tunti 6= 50 min. 
9= don't know 7= >= 1 or more hours 
9= don't know 
14. Please place a mark 
on each line below to 
indicate your level of 
ability with each of the 
following activities 
during the PAST 
WEEK 
K47. Sukkien tai sukkahousujen 14.1. Putting on your 
pukeminen paalle ilman apua tai socks or tights without 
apuvalineita? help or aids (e.g. sock 
0= Helppoa aid): 
1= 1 0= Easy 
2=2 1= 1 
3= 3 2=2 Q47 char(2) 4=4 3= 3 
5= 5 4=4 
6= 6 5= 5 
7=7 6= 6 ! 
8= 8 7= 7 
9=9 8= 8 , , 
9= 9 I 10= 10 ~ 
. 
11 Mahdotonta 10= 10 
99= don't know 11 = Impossible 
99- don't know I 
K48. Kumartuminen vyotiirostii 14.2. Bending forward I 
eteenpiiin nostaaksenne kyniin I{rom the waist to pick lip ! 
! lattialta ilman ... a pen from thefloor ! 
0= Helppoa without an aid: i 
1= 1 0= Easy 
2=2 1= 1 
3= 3 2=2 
Q48 char(2) 4=4 
3= 3 
5= 5 4=4 
6=6 5= 5 
7=7 6=6 
8= 8 7= 7 
9=9 8= 8 
10= 10 9= 9 
11 = Mahdotonta 10= 10 
99= don't know 11 = Impossible 99= don't know 
K49. Kurkottaminen korkealle 14.3. Reaching up to a 
hyllylle ilman apua tai high shelf without help or 
apuviilineitii ? aids (e.g. helping hand): 
0= Helppoa 0= Easy 
1= 1 1= 1 
2=2 2= 2 
3= 3 3= 3 
Q49 char(2) 4=4 4=4 5= 5 5= 5 i 
6=6 6=6 ! I I 
7=7 7= 7 
8= 8 8= 8 
9=9 9=9 
10= 10 10= 10 
11 = Mahdotonta 11= Impossible 
99= don't know 99= don't know 
K50. Nouseminen ylos 14.4. Getting up out of an 
kiisinojattomasta tuolista armless dining room 
kiiyttiimiittii kiisiii tai muuta chair without using your 
apua? hands or any other help: 
0= Helppoa 0= Easy 
1= 1 1= 1 
Q50 char(2) 2=2 2=2 
3= 3 3= 3 
4=4 4=4 
5= 5 5= 5 
6=6 6=6 
7= 7 7= 7 
i 
8= 8 8= 8 
9 9 9=9 
10= 10 10= 10 
11 = Mahdotonta 11 = Impossible 
99= don't know 99= don't know - -- _. . - .,,--
, '" 
K51. Nouseminen ylos 14.5. Getting up off the 
selinmakuulta lattalta ilman I,floor without help from 
apua? lying on your back: 
0= Helppoa 0= Easy 
1= 1 1= 1 
2=2 2=2 
3= 3 3=3 
Q51 'char(2) 4=4 4=4 5= 5 5= 5 , 
6=6 6=6 
7=7 7=7 
8= 8 8=8 
:9=9 9=9 
i 10= 10 10= 10 
; 11 = Mahdotonta 11 = Impossible 
: 99= don't know 99= don't know 
-<- ----- -- ,- -
14.6. Standing 
K52. Seisominen ilman tukea 10 unsupported for 10 
minuuttia vaikeuksitta? minutes without 
0= Helppoa discomfort: 
1= 1 0= Easy 
2=2 '1= 1 
, 
3=3 2=2 
4=4 3= 3 
Q52 char(2) 5= 5 4=4 l 
i 6=6 5= 5 i 
7=7 6=6 
18= 8 7=7 
: 
9=9 8=8 
10= 10 9=9 
11 = Mahdotonta 10= 10 
99= don't know 11 = Impossible 
99= don't know 
,- ' 
--
K53. Kiipeiimiiinen 12-15 askelta 14.7. Climbing 12-15 
kiiyttiimiittii kaidetta tai steps without using a 
kiivelyapuviilinettii ? handrail or walking aid. 
0= Helppoa One/oot on each step: 
1= 1 0= Easy 
2=2 1= 1 Q53 char(2) 3=3 2=2 
4=4 3=3 
5=5 4=4 
6=6 5= 5 
7=7 6=6 
8-8 7=7 
253 
9 9 8-8 
i 10= 10 9=9 
I 11 = Mahdotonta 10= 10 
: 99= don't know 11 = Impossible , 
----
99 don't know 
i 
:14.8. Looking over your 
, K54. Katsominen yli olan 
· kiiiintiimiittii kehoanne? shoulder without turning 
,,0= Helppoa [Your body: 
'1= 1 ,0= Easy , 
2=2 1= 1 
, 3=3 2=2 
4=4 3=3 
Q54 !char(2) 5=5 .4=4 
6=6 5= 5 
:7=7 6=6 I 
I 8= 8 7=7 
19=9 8= 8 
10= 10 :9=9 
, , 11 = Mahdotonta 10= 10 
, 99= don't know • 11 = Impossible 99- don't know 
.. ,-.-.- - --... " ~ 
, 
, 
I 14.9. Doing physically 
, 
!K55. Ruumiillisesti rasittavien demanding activities 
· tehtiivien tekeminen? 1 (e.g. physiotherapy 
, 'exercises, gardening or 0= Helppoa 
1= 1 sports): 
2=2 0= Easy 
3=3 1= 1 
i4=4 
2=2 
Q55 Ichar(2) :5=5 3=3 4=4 
6=6 
'7=7 
5= 5 
I 
18=8 
6=6 
i i 7=7 
'9=9 8=8 
10= 10 
, 
, 11 = Mahdotonta '9=9 
99= don't know 
10= 10 
11 = Impossible 
I 99= don't know 
- ---- - , 
K56. Piiivittiiisten toimintojen 14.10. Doing afull day's 
, 
! tekeminen, joko kotona tai tiissii? , activities whether it be at 
i 
:0= Helppoa home or at work: 
, 1= 1 0= Easy 
! 
,2=2 1= 1 
Q56 :char(2) 
'3=3 2=2 ! 
I 3= 3 
I 
4=4 
5=5 4=4 
6=6 5= 5 
7=7 6=6 
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8 8 7=7 
9=9 8=8 
.10= 10 9=9 
, 11 = Mahdotonta 10= 10 
99= don't know 11 = Impossible 
... 99 don't know 
K57. Oletteko kaksonen? 15.a. Are you a twin? 
Q57 char(l) ,1= yes 1= yes 
2= no 2= no 
-- - - ---
-- -"~ 
- .- ---
9= don't know 9 don't know 
- ---" --._-
- -
----- -
K58. Mikiili vastasitte Kyllii, 
15.a.i. If YES, are you: oletteko 
Q58 ·char(l) 1 = identtinen kaksonen 1 = identical twin 
2= ei-identtinen kaksonen 2= non-identical twin 
9= don't know 9= don't know 
-
. ,"-
-
.. 
j K59. Onko muita kaksosia 15.h. Are there any 
, 
suvussanne? (other) twins in your 
Q59 char(l) .1= yes ifamily? 
2= no 1= yes 
9= don't know 2= no 9- don't know 
.. 
K60. Mikiili vastasitte Kyllii, nUn 15.h.i. If YES, please 
Q60 :char(200) miiiiritelkiiii heidiin state their relationship to 
sukulaisuussuhteenne Teihin: you: 
16. Do you have any 
, K61. Onko Teillii veljiii tai brothers or sisters? 
! sisaruksia? 
1= yes 
i Q61 'char(l) i 1= yes 2= no 9= don't know 
2= no 
·9= don't know 
Note: infonnation on 
brothers and sisters is in 
table relatives 
-- - --
" -_. -- -~ .. --
.17. Do you have any 
children? 
:K63. Onko Teillii lapsia? 1= yes 
Q63 ·char(l) 1= yes 
2= no 
2= no 9= don't know 
9= don't know Note: infonnation on 
childrens is in table 
relatives 
. - .-- 18.a. To your knowledge. 
K65. Onko Teidiin tietiiiiksenne do any members of your 
kenelliikiiiin sukulaisistanne ... Iramily have ankylosing 
Q65 char(l) 1= yes spondylitis? 
2= no 1= yes 
9= don't know 2= no 
9= don't know 
Q66 char(200) K66. Mikiili vastasitte Kyllii. nUn 18.a.i. If YES. please 
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1 
I 
I 
I 
i 
--
mainitkaa kenella sukulaisella state which relative(s): 
I 
Note: infonnation on 
I relatives with AS is in 
I itable relati\ es srr 
iChar(50) PLACE** Place offilling this Questionnaire Place offilling this 
I Questionnaire 
DATE FILL char(10) Date offilling this Questionnaire iDate offilling this dd.mm.yyyy !Questionnaire 
Merkinta, onko allekirjoitus: lv/ark if signed 
1= yes lPersonally: 
SIGNED char(1) 2= no 1= yes 
3= puolesta 2= no 
3= on behalf of 9= don't know 
9= don't know 
Table RELATIVES 
K62-K64.VeljHi, sisaruksia, lapsia, vanhemmat 
16., 17. Brothers, sisters, children, parents 
Variable I Format r' Kuvaus I" D . ti' ,;~~~~ escrIp on.4~
RECID** integer Record ID, for internal use Record ID, for internal use 
CENTERID char(2) Center ID: 01-99 Center ID: 01-99 
FAMILYID char(4) F amity ID: 0001-9999 Family ID: 0001-9999 
- " 
IndividualID: IndividualID: 
INDIVID char(3) 000= proband 000= proband 
001-999= other relatives 001-999= other relatives 
PTID** char(9) for internal use for internal use 
REL ID char(7) Ifor internal use Ifor internal use 
Relation: Relation: I 
1= brother 1= brother 
2= sister 2= sister 
3= child 3= child 
4= father 4= father 
5= mother 5= mother 
RELATION char(2) 6= father's father 6= father's father 
7= father's mother 7= father's mother 
8= mother's father 8= mother's father 
9= mother's mother 9= mother's mother 
10= other 10= other 
99= don't know 99= don't know 
L NAME** char(30) Last name Last name 
F NAME** char(50) First names(s) First names(s) 
Sex: Sex: 
1= male 1= male 
SEX char(1) 2= female 2= female 
9- don't know 9= don't know 
I 
IAlive status: 
ALIVE char(1) 1= alive 2= dead 
9= don't know 
Participation: 
PARTIC char(l ) 1 = Osallistuu 2= ei -osallistuu 
9= don't know 
DBIRTH char(10) Date of birth dd.mm.yyyy 
ADDRESS** 50 Address, street 
\ CITY** 130 IAddress, city 
iZIPCODE** 16 IAddress, postal code 
I TEL 1** 120 ITelephone - 1 
I TEL 2** 120 ITelephone - 2 
Table RELATIVES SRR 
Tietoja sukulaisista, joilla on selkarankareuma 
18.a.i. Other relatives with ankylosing spondylitis 
IAlive status: 
1= alive 
2= dead 
9= don't know 
Participation: 
1 = Osallistuu 
2= ei-osallistuu 
9= don't know 
I 
Date of birth 
Address, street 
IAddress, city 
\Address, postal code 
iTelephone - 1 
\Telephone - 2 
Kuvaus Description 
I 
Variable-;·. ',> Format 
RECID**" 'Iinteger 
CENTERID char(2) 
IRecord ID, for internal use\R;cord ID, for internal use 
Center ID: 01-99 Center ID: 01-99 I, 
I FA MIL YID Ichar( 4) IFamily ID: 0001-9999 IFamily ID: 0001-9999 
IndividualID: IndividualID: 
INDIVID char(3) 000= proband 000= proband 
001-999= other relatives 001-999= other relatives 
PTID** char(9) for internal use for internal use 
REL ID** char(7) for internal use for internal use 
Relation: Relation: 
1= brother 1= brother 
2= sister 2= sister 
3= child 3= child 
4= father 4= father 
5= mother 5= mother 
RELATION char(2) 6= father's father 6= father's father 
7= father's mother 7= father's mother 
8= mother's father 8= mother's father 
9= mother's mother 9= mother's mother 
10= other 10= other 
I 
99= don't know 99= don't know 
L NAME** char(30) Last name Last name 
F NAME** char(50) First names(s) First names(s) .- . 
, 
iChar(J) [sex: [sex 
\ 
SEX 1= male 1- male 
I 
2~7 
I 
2- female :2= female 
9= don't know ,9= don't know 
IAlive status: (Alive status: 
ALIVE char(l) 1= alive 1= alive 2= dead 2= dead 
9= don't know 9= don't know 
Participation: Participation: 
PARTIC char(l) 1 = Osallistuu 1 = Osallistuu 2= ei -osallistuu 2= ei-osallistuu 
I 9= don't know 9= don't know 
DBIRTH** char(10) Date of birth Date of birth dd.mm.yyyy 
lADDRESS** 150 IAddress street , IAddress street , I 
I 
CITY** 30 Address, city Address, city I 
ZIPCODE** 6 Address, postal code Address, postal code 
TEL 1** 20 Telephone - 1 Telephone - 1 
TEL 2** 20 Telephone - 2 Telephone - 2 I 
~-------
Table SURGERIES 
K33. Mikiili vastasitte KYLLA, kertokaa leikkaustyyppi ja leikkausvuosi 
9b. Have you ever had surgery for your joints or spine as a result of your AS? If 
YES, please specify the type of surgey and give year(s) 
Variable Format ~"f~~ Kuvaus -. Description 
RECID** integer Record ID, for internal use Record ID, for internal use 
CENTERID char(2) Center ID: 01-99 Center ID: 01-99 
FAMILYID char(4) Family ID: 0001-9999 Family ID: 0001-9999 
IndividualID: IndividualID: 
INDIVID char(3) 000= proband 000= proband 
001-999= other relatives 001-999= other relatives 
PTID** char(10) for internal use for internal use 
char(4) Year when surgery was 
Year when surgery was 
YEAR Iverformed Iverformed 
TYPE char(50 Type of surgery Type of surgery 
Table MEDICATIONS 
K39. Mikiili vastasitte KYLLA, i1moittakaa liiiikkeen nimi, annos ja montako 
kertaa piiiviissii otatte annoksen 
12.a. Are you currently taken any medication for your AS? If YES, please give the 
name and dosage that is on the bottle or package. 
] Variable I Format I . ____ K_u_v_au_s ___ --+ ____ D_e_s_cr_i~p_ti_o _ n__ 
I RECID** linteger IRecord ID, for internal use IRecord ID, for internal use 
'ICENTERID!char(2) I Center ID: 01-99 !Center ID: 01-99 
I FAMIL YID Ichar( 4) IF arnily ID: 0001-9999 IF amily ID: 0001-9999 
IndividualID: IndividualID: 
INDIVID char(3) 000= proband 000= proband 
001-999= other relatives 001-999= other relatives 
PTID** char(9) for internal use for internal use 
NAME char(30) N arne of medication Name of medication 
DOSE char(50) Dose Dose 
YEAR char(4) Year Year 
K40. Ympyroikaa alla olevassa 12.c. Place a vertical mark on 
asteikossa se numero, joka the line below to indicate the 
Iparhaiten osoitta laakityksen 
effectiveness of the medication 
tehokkuutta helpottamaan in relieving your symptoms: 
oireitanne: 0= No effect 
0= Ei vaikutusta 1= 1 
1= 1 2=2 
2=2 3= 3 
char(2) 3=3 4=4 EFFECTIV 4=4 5= 5 
5= 5 6=6 
6=6 7= 7 
7=7 8= 8 
8= 8 9=9 
9= 9 10= 10 
10= 10 11 = Very effective 
11= Hyvin tehokas 99= don't know 
i 99 don't know , 
.-----. 
I 
, 
I 
Lysis Buffer 
109.4 g of Sucrose 
1000 ml of distilled water 
1 ml of 1M Tris-HCI (PH 7.8) 
1.2 ml 4.9M MgCh 
10 m1 of Triton X-IOO 
APPENDIX 2 
6M Guanidinium hydrochloride GuHCl 
286.59 g solid guanidinium hydrochloride 
500 ml distilled water 
Autoclave at 121°C for 20 mins 
7.5M Ammonium Acetate 
57.81 g solid NH4Ac 
100 ml distilled water 
Autoclave at 121°C for 20 mins 
100/0 Sodium Dodecyl Sulphate (SDS) 
109 SDS power 
100 ml distilled water 
20 mg/ml Proteinase K 
1 g Proteinase K 
50 ml distilled water 
lxTE buffer 
O.OIM Tris-HCl 
O.lM EDTA 
pH = 8.0 
1 x TBE solution 
O.IM Tris 
0.09M Boric Acid 
O.OOIM EDTA 
pH = 8.0 
~61 
APPENDIX 3 
Alleles I haplotypes I 
microsatellites Product MgCb 
recognised Orientation Primer Sequences 5' • 3' length (bp) concentration 
TGFB1 -800 G to -509 C Sense AGGGACTCTGCCTCCAACG 291 2.5mM 
Antisense GGGCAACAGGACACCTGAG 
TGFB1 -800 G to -509 T Sense AGGGACTCTGCCTCCAACG 291 2.5 mM 
Antisense GGGCAACAGGACACCTGAA 
TGFB1 -800 A to -509 C Sense AGGGACTCTGCCTCCAACA 291 2.5mM 
Antisense GGGCAACAGGACACCTGAG 
TGFB1 -800 A to -509 T Sense AGGGACTCTGCCTCCAACA 291 2.5mM 
Antisense GGGCAACAGGACACCTGAA 
TGFB1 868 T Sense CCCCAGACCTCGGGCGC 416 1.5 mM 
Antisense GCAGCGGTAGCAGCAGCA 
TGFB1 868 C Sense CCCCAGACCTCGGGCGC 416 1.5 mM 
Antisense GCAGCGGTAGCAGCAGCG 
TGFB1 913 G Sense CCCCAGACCTCGGGCGC 428 1.25 mM 
Antisense TAGTCCCGCGGCCGGCC 
TGFB1 913 C Sense CCCCAGACCTCGGGCGC 428 1.25 mM 
Antisense TAGTCCCGCGGCCGGCG 
TGFB1 1627 C Sense GCTTCCCTCTCGCCACTC 200 2.25 mM 
Antisense GGGCCCTCTCCAGCGGGG 
TGFB11627 T Sense GCTTCCCTCTCGCCACTC 200 2.25 mM 
Antisense GGGCCCTCTCCAGCGGGA 
019S217 Sense GGGGTTGA TTGAAGTTGGTT 219-233 2mM 
Antisense CAAGACCCATACCCATGA 
019S223 Sense CAAAATCGAGGTGCATAGAA 228-246 2mM 
Antisense ACCATGACTGGCTAATTGTG 
019S421 Sense AGCCCTTGCTGGTTTATG 188-220 2mM 
Antisense GAGCCTGTGGTGGAGC 
The cycling conditions for the TGFBI SNPs were as follows: 96°C for 1 min, 5 cycles 
of 96°C for 25 s, 70°C for 45 s, 72°C for 45 s, 21 cycles of 96°C for 25 s, 65°C for 50 
s, 72°C for 45 sand 4 cycles of 96°C for 25 s, 55°C for 1 min, 72°C for 2 min. 
The cycling conditions for the TGFBI microsatellites were as follows: 32 cycles of 
denaturation at 94°C for 1 min, annealing 54°C (D 19217 and D 19223) or 500C 
(DI9421) for 1 min and extension 72°C for 1 min. 
